

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 953 641 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
03.11.1999 Bulletin 1999/44

(51) Int Cl.⁶: **C12N 15/30**, C07K 14/44,
C07K 16/20, C12N 5/16,
A61K 39/002

(21) Application number: **99301746.6**

(22) Date of filing: **09.03.1999**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **26.03.1998 US 79389**
15.12.1998 US 112282

(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(72) Inventors:
• **Brake, David Alan**
East Lyme, Connecticut 06333 (US)

- **Madura (nee Coleman), Rebecca Anne**
Westerly, Rhode Island 02891 (US)
- **Durtschi, Becky Ann**
Ledyard, Connecticut 06339 (US)
- **Krishnan, Balakrishnan Rajendra**
East Lyme, Connecticut 06333 (US)
- **Yoder, Susan Christine**
Salem, Connecticut 06340 (US)

(74) Representative:
Simpson, Alison Elizabeth Fraser et al
Urquhart-Dykes & Lord,
91 Wimpole Street
London W1M 8AH (GB)

(54) Polynucleotide molecules encoding neospora proteins

(57) The present invention provides isolated polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1 and MAG1 proteins from *Neospora caninum*, as well as recombinant vectors, transformed host cells, and recombinantly-expressed proteins. The present invention further provides

a polynucleotide molecule comprising the nucleotide sequence of the bidirectional *GRA1/MAG1* promoter of *N. caninum*. The present invention further provides genetic constructs based on the polynucleotide molecules of the present invention that are useful in preparing modified strains of *Neospora* cells for use in vaccines against neosporosis.

EP 0 953 641 A2

Description

1. FIELD OF THE INVENTION

5 [0001] The present invention is in the field of animal health, and is directed to vaccine compositions and diagnostics for disease. More particularly, the present invention relates to polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1, and MAG1 proteins from *Neospora*, which polynucleotide molecules and proteins are useful in the production of vaccines against neosporosis, and as diagnostic reagents.

10 2. BACKGROUND OF THE INVENTION

[0002] *Neospora* is a pathogenic protozoan parasite of animals that has been recognized as a major cause of abortion, neonatal death, congenital infection, and encephalitic disease in mammals. Dubey and Lindsay, 1996, Vet. Parasitol. 67:1-59; Dubey and Lindsay, 1993, Parasitology Today, 9:452-458. *Neospora caninum* infects dogs, and congenitally infects pups, often leading to paralysis. Tachyzoites of *N. caninum* have been isolated from naturally infected pups. Lindsay and Dubey, 1989, J. Parasitol. 75:163-165. *Neospora* is a major cause of abortion in dairy and beef cattle. Cases of *Neospora*-related disease, i.e., neosporosis, have also been reported in goats, sheep and horses.

15 [0003] Although *N. caninum* is superficially similar to the pathogen, *Toxoplasma gondii*, *N. caninum* and *T. gondii* have been distinguished from each other both antigenically and ultrastructurally. Dubey and Lindsay, 1993, above. In addition, *Neospora*-like protozoan parasites isolated from the brains of aborted bovine fetuses and continuously cultured *in vitro* were shown to be antigenically and ultrastructurally distinct from both *T. gondii* and *Hammondia hammondi*, and were most similar to *N. caninum*. Conrad *et al.*, 1993, Parasitology 106:239-249. Furthermore, analysis of nuclear small subunit ribosomal RNA genes revealed no nucleotide differences between strains of *Neospora* isolated from cattle and dogs, but showed consistent differences between *Neospora* and *T. gondii*. Marsh *et al.*, 1995, J. Parasitol. 25 81:530-535.

[0004] The etiologic role of a bovine isolate of *Neospora* in bovine abortion and congenital disease has been confirmed. Barr *et al.*, 1994, J. Vet. Diag. Invest. 6:207-215. A rodent model of central nervous system neosporosis has been developed using inbred BALB/c mice infected with *N. caninum*. Lindsay *et al.*, 1995, J. Parasitol. 81:313-315. In addition, models to study transplacental transmission of *N. caninum* in pregnant outbred and inbred mice have been described by Cole *et al.*, 1995, J. Parasitol. 81:730-732, and by Long *et al.*, 1996, J. Parasitol. 82:608-611, respectively. An experimental *N. caninum* pygmy goat model that closely resembles naturally acquired *Neospora*-induced cattle abortion has been demonstrated. Lindsay *et al.*, 1995, Am. J. Vet. Res. 56:1176-1180. An experimental *N. caninum* sheep model that closely resembles naturally acquired *Neospora*-induced cattle abortion has also been demonstrated. Buxton *et al.*, 1997, J. Comp. Path. 117:1-16.

35 [0005] In *T. gondii*, electron dense granules comprising an excretory-secretory group of antigens are present in the cytoplasm of tachyzoites. These antigens have been designated as GRA proteins. The GRA1 protein of *T. gondii* has been reported to have a molecular weight ranging from about 22-27 kDa, and the GRA2 protein of *T. gondii* has been reported to have a molecular weight of about 28 kDa. Sam-Yellowe, 1996, Parasitol. Today 12:308-315. Similar electron dense granules are present in the cytoplasm of *N. caninum* tachyzoites (Bjerkas *et al.*, 1994, Clin. Diag. Lab. Immunol. 40 1:214-221; Hemphill *et al.*, 1998, Intl. J. Parasitol. 28:429-438).

[0006] *T. gondii* cells are also known to comprise a group of major surface antigens that have been designated as SAG. The SAG1 protein of *T. gondii* is reported to have a molecular weight of about 30 kDa. Kasper *et al.*, 1983, J. Immunol. 130:2407-2412. Monoclonal antibodies directed against *T. gondii* SAG1 protein significantly blocked the ability of *T. gondii* tachyzoites to invade bovine kidney cells under tissue culture conditions. Grimwood and Smith, 1996, Intl. J. Parasitol. 26: 169-173. Because *T. gondii* SAG1 appears to play a role in the invasion process, it has been hypothesized that SAG1 may be necessary to support the virulence phenotype. Windeck and Gross, 1996, Parasitol. Res. 82:715-719. Consistent with this hypothesis is the observation that mice immunized with *T. gondii* SAG1 protein and then challenged with *T. gondii* had reduced toxoplasma cyst formation in their brains than did control mice. Debard *et al.*, 1996, Infect. Immun., 64:2158-2166. *T. gondii* SAG1 may be functionally related to a similar molecule in *N. caninum* designated as NC-p36 described by Hemphill *et al.*, 1997, Parasitol. 115:371-380.

50 [0007] Micronemes are intracellular organelles located at the apical end of tachyzoites of both *T. gondii* and *Neospora*, and may play a role in host cell recognition and attachment to the host cell surface during invasion. Formaux *et al.*, 1996, Curr. Top. Microbiol. Immunol. 219:55-58. At least 4 different microneme-associated (MIC) proteins have been identified in *T. gondii*. The MIC1 protein of *T. gondii* is about 60 kDa, binds to the surface of host cells, and has been reported to have partial homology to thrombospondin-related adhesive protein (TRAP) from *Plasmodium falciparum* which binds to human hepatocytes. Robson *et al.* 1995 EMBO J. 14:3883-3894.

55 [0008] The conversion of parasites from tachyzoites to bradyzoites is critical for chronic infection and persistence of *T. gondii*. A gene expressing an immunodominant, bradyzoite-specific 65 kD antigen, designated as MAG1, has been

identified in *T. gondii*. Parmley *et al.*, 1994, Mol. Biochem. Parasitol. 66:283-296. *MAG1* has been reported to be specifically expressed in bradyzoite cysts, but not in the tachyzoite stage. This specificity of expression may indicate the involvement of *MAG1* in the conversion between tachyzoite and bradyzoite stages of the life cycle of the parasite. Bohne *et al.*, 1996, Curr. Topics Microbiol. Immunol. 219:81-91.

[0009] Identification in *Neospora* of protein homologs of *T. gondii* GRA1, GRA2, SAG1, MIC1, and MAG1 proteins, and the nucleotide sequence of polynucleotide molecules encoding said *Neospora* proteins, will serve to facilitate the development of vaccines against neosporosis, as well as diagnostic reagents

3. SUMMARY OF THE INVENTION

[0010] The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the GRA1 protein from *N. caninum*. In a preferred embodiment, the GRA1 protein has the amino acid sequence of SEQ ID NO:2. In a further preferred embodiment, the isolated GRA1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:1 from about nt 205 to about nt 777, the nucleotide sequence of the open reading frame (ORF) of the GRA1 gene, which is presented in SEQ ID NO:3 from about nt 605 to about nt 1304, and the nucleotide sequence of the GRA1-encoding ORF of plasmid pRC77 (ATCC 209685). In a non-limiting embodiment, the isolated GRA1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:1 and SEQ ID NO:3. The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is homologous to the nucleotide sequence of a GRA1-encoding polynucleotide molecule of the present invention. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is homologous to the GRA1 protein of *N. caninum*. The present invention further provides a polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned *GRA1*-related polynucleotide molecules.

[0011] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the GRA2 protein from *N. caninum*. In a preferred embodiment, the GRA2 protein has the amino acid sequence of SEQ ID NO:5. In a further preferred embodiment, the isolated GRA2-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of the ORF of SEQ ID NO:4, which is from about nt 25 to about nt 660, and the nucleotide sequence of the GRA2-encoding ORF of plasmid pRC5 (ATCC 209686). In a non-limiting embodiment, the isolated GRA2-encoding polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:4. The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is homologous to the nucleotide sequence of a GRA2-encoding polynucleotide molecule of the present invention. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is homologous to the GRA2 protein of *N. caninum*. The present invention further provides a polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned *GRA2*-related polynucleotide molecules.

[0012] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the SAG1 protein from *N. caninum*. In a preferred embodiment, the SAG1 protein has the amino acid sequence of SEQ ID NO:7. In a further preferred embodiment, the isolated SAG1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of the ORF of SEQ ID NO:6, which is from about nt 130 to about nt 1089, and the nucleotide sequence of the SAG1-encoding ORF of plasmid pRC102 (ATCC 209687). In a non-limiting embodiment, the isolated SAG1-encoding polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:6. The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is homologous to the nucleotide sequence of a SAG1-encoding polynucleotide molecule of the present invention. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is homologous to the SAG1 protein of *N. caninum*. The present invention further provides a polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned *SAG1*-related polynucleotide molecules.

[0013] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the MIC1 protein from *N. caninum*. In a preferred embodiment, the MIC1 protein has the amino acid sequence of SEQ ID NO:9. In a further preferred embodiment, the isolated MIC1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of the ORF of SEQ ID NO:8 from about nt 138 to about nt 1520, the nucleotide sequence of the ORF of the *MIC1* gene, which is presented as SEQ ID NO:10, and the nucleotide sequence of the MIC1-encoding ORF of plasmid pRC340 (ATCC 209688). In a non-limiting embodiment, the isolated MIC1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:8, and the nucleotide sequence of SEQ ID NO:10. The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is homologous to the nucleotide sequence of a MIC1-encoding polynucleotide mol-

ecule of the present invention. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is homologous to the MIC1 protein of *N. caninum*. The present invention further provides a polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned *MIC1*-related polynucleotide molecules.

5 **[0014]** The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the MAG1 protein from *N. caninum*. The MAG1 protein has a putative amino acid sequence shown in SEQ ID NO:13. In a preferred embodiment, the isolated MAG1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence presented in SEQ ID NO:11 from about nt 1305 to about nt 2786, a cDNA molecule prepared therefrom, such as a cDNA molecule having
10 the ORF of SEQ ID NO:12 from about nt 122 to about nt 1381, and the nucleotide sequence of the MAG1-encoding ORF present in plasmid bd304 (ATCC 203413). The present invention further provides a polynucleotide molecule having a nucleotide sequence of any ORF present in SEQ ID NO:11. In a non-limiting embodiment, the isolated MAG1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:11 and SEQ ID NO:12. The present invention further provides an isolated polynucleotide
15 molecule having a nucleotide sequence that is homologous to the nucleotide sequence of a MAG1-encoding polynucleotide molecule of the present invention. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is homologous to the MAG1 protein of *N. caninum*. The present invention further provides a polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned *MAG1*-related polynucleotide molecules.

20 **[0015]** The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the promoters of the *N. caninum GRA1* and *MAG1* genes, which is presented in SEQ ID NO:11 from about nt 127 to about nt 703, and includes its complementary sequence.

[0016] The present invention further provides oligonucleotide molecules that hybridize to any of the polynucleotide molecules of the present invention, or that hybridize to a polynucleotide molecule having a nucleotide sequence that
25 is the complement of any of the polynucleotide molecules of the present invention.

[0017] The present invention further provides compositions and methods for cloning and expressing any of the polynucleotide molecules of the present invention, including recombinant cloning vectors, recombinant expression vectors, transformed host cells comprising any of said vectors, and novel strains or cell lines derived therefrom. More particularly, the present invention provides a recombinant vector comprising a polynucleotide molecule having a nucleotide sequence encoding the *GRA1*, *GRA2*, *SAG1*, *MIC1* or *MAG1* protein of *N. caninum*. In specific, though non-limiting,
30 embodiments, the present invention provides plasmid pRC77 (ATCC 209685) encoding *GRA1*; plasmid pRC5 (ATCC 209686) encoding *GRA2*; plasmid pRC102 (ATCC 209687) encoding *SAG1*; plasmid pRC340 (ATCC 209688) encoding *MIC1*; and plasmid bd304 (ATCC 203413) comprising the *MAG1* gene sequence and the *MAG1/GRA1* bidirectional promoter region.

35 **[0018]** The present invention further provides a substantially purified or isolated *N. caninum* polypeptide selected from the group consisting of *GRA1*, *GRA2*, *SAG1*, *MIC1* and *MAG1* proteins. In a preferred embodiment, the *N. caninum GRA1* protein has the amino acid sequence of SEQ ID NO:2. In another preferred embodiment, the *N. caninum GRA2* protein has the amino acid sequence of SEQ ID NO:5. In another preferred embodiment, the *N. caninum SAG1* protein has the amino acid sequence of SEQ ID NO:7. In another preferred embodiment, the *N. caninum MIC1* protein has
40 the amino acid sequence of SEQ ID NO:9. In another preferred embodiment, the *N. caninum MAG1* protein has the amino acid sequence of SEQ ID NO:13. The present invention further provides substantially purified or isolated polypeptides that are homologous to any of the aforementioned *N. caninum* proteins. The present invention further provides polypeptides which are fusion proteins comprising any of the aforementioned polypeptides fused to a carrier or fusion partner, as known in the art. The present invention further provides polypeptides consisting of a substantial portion of
45 any of the aforementioned polypeptides. The polypeptides of the present invention are useful both in vaccine compositions to protect mammals against neosporosis and as diagnostic reagents.

[0019] The present invention further provides a method of preparing any of the aforementioned polypeptides, comprising culturing host cells transformed with a recombinant expression vector, said vector comprising a polynucleotide molecule comprising a nucleotide sequence encoding any of the aforementioned polypeptides, wherein the nucleotide
50 sequence is in operative association with one or more regulatory elements, under conditions conducive to the expression of the polypeptide, and recovering the expressed polypeptide from the cell culture.

[0020] The present invention further provides antibodies specifically directed against a *N. caninum GRA1*, *GRA2*, *SAG1*, *MIC1* or *MAG1* protein.

55 **[0021]** The present invention further provides genetic constructs for use in mutating a *Neospora GRA1*, *GRA2*, *SAG1*, *MIC1* or *MAG1* gene to produce modified *Neospora* cells. Such modified *Neospora* cells are useful in vaccine compositions to protect mammals against neosporosis. In a preferred though non-limiting embodiment, a genetic construct of the present invention comprises a polynucleotide molecule comprising a nucleotide sequence that is otherwise the same as a nucleotide sequence encoding a *GRA1*, *GRA2*, *SAG1*, *MIC1* or *MAG1* protein from *N. caninum*, or a sub-

stantial portion thereof, but that further comprises one or more mutations *i.e.*, one or more nucleotide deletions, insertions and/or substitutions, that can serve to mutate the gene. Once transformed into cells of *Neospora*, the polynucleotide molecule of the genet construct is specifically targeted, *e.g.*, by homologous recombination, to the particular *Neospora* gene, and either deletes or replaces the gene or a portion thereof, or inserts into the gene. As a result of this recombination event, the *Neospora* gene is mutated. The resulting mutated gene is preferably partially or fully disabled in that it encodes either a partially defective or fully defective protein, or fails to encode a protein. The present invention further provides *Neospora* cells which have been modified by one or more of said gene mutations and methods of preparing modified *Neospora* cells using a genetic construct of the present invention.

[0022] The present invention further provides a vaccine against neosporosis, comprising an immunologically effective amount of a polypeptide of the present invention, or an immunologically effective amount of a polynucleotide molecule of the present invention, or an immunologically effective amount of modified *Neospora* cells of the present invention; and a veterinarily acceptable carrier. In a preferred embodiment, the vaccine of the present invention comprises modified live cells of *N. caninum* that express a *GRA1*⁻, *GRA2*⁻, *SAG1*⁻, *MIC1*⁻ or *MAG1*⁻ phenotype, or a combination of said phenotypes. In a non-limiting embodiment, the vaccine is a combination vaccine for protecting a mammal against neosporosis and, optionally, one or more other diseases or pathological conditions that can afflict the mammal, which combination vaccine comprises an immunologically effective amount of a first component comprising a polypeptide, polynucleotide molecule, or modified *Neospora* cells of the present invention, an immunologically effective amount of a second component that is different from the first component, and that is capable of inducing, or contributing to the induction of, a protective response against a disease or pathological condition that can afflict the mammal; and a veterinarily acceptable carrier.

[0023] The present invention further provides a method of preparing a vaccine against neosporosis, comprising combining an immunologically effective amount of a *N. caninum* polypeptide of the present invention, or an immunologically effective amount of a polynucleotide molecule of the present invention, or an immunologically effective amount of modified *Neospora* cells of the present invention, with a veterinarily acceptable carrier, in a form suitable for administration to a mammal.

[0024] The present invention further provides a method of vaccinating a mammal against neosporosis, comprising administering to the mammal an immunologically effective amount of a vaccine of the present invention.

[0025] The present invention further provides a kit for vaccinating a mammal against neosporosis, comprising a first container having an immunologically effective amount of a polypeptide of the present invention, or an immunologically effective amount of a polynucleotide molecule of the present invention, or an immunologically effective amount of modified *Neospora* cells of the present invention; and a second container having a veterinarily acceptable carrier or diluent.

4. DETAILED DESCRIPTION OF THE INVENTION

4.1. Polynucleotide Molecules

[0026] An isolated polynucleotide molecule of the present invention can have a nucleotide sequence derived from any species or strain of *Neospora*, but is preferably from a pathogenic species of *Neospora* such as *N. caninum*. A non-limiting example of a strain of *N. caninum* from which a polynucleotide molecule of the present invention can be isolated or derived is strain NC-1, which is available in host MARC-145 monkey kidney cells under Accession No. CRL-12231 from the American Type Culture Collection (ATCC), located at 12301 Parklawn Drive, Rockville, MD 20852, USA. Strain NC-1 is also described in Dubey *et al.*, 1988, J. Am. Vet. Med. Assoc. 193:1259-63, which publication is incorporated herein by reference. Alternatively, pathogenic strains or species of *Neospora* for use in practicing the present invention can be isolated from organs, tissues or body fluids of infected animals using standard isolation techniques such as those described in the publications reviewed above.

[0027] As used herein, the terms "polynucleotide molecule," "polynucleotide sequence," "coding sequence," "open-reading frame (ORF)," and the like, are intended to refer to both DNA and RNA molecules, which can either be single-stranded or double-stranded, and that can include one or more prokaryotic sequences, cDNA sequences, genomic DNA sequences including exons and introns, and chemically synthesized DNA and RNA sequences, and both sense and corresponding anti-sense strands. As used herein, the term "ORF" refers to the minimal nucleotide sequence required to encode a particular *Neospora* protein, *i.e.*, either a *GRA1*, *GRA2*, *SAG1*, *MIC1* or *MAG1* protein, without any intervening termination codons.

[0028] Production and manipulation of the polynucleotide molecules and oligonucleotide molecules disclosed herein are within the skill in the art and can be carried out according to recombinant techniques described, among other places, in Maniatis *et al.*, 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel *et al.*, 1989, Current Protocols In Molecular Biology, Greene Publishing Associates & Wiley Interscience, NY; Sambrook *et al.*, 1989, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Labo-

ratory Press, Cold Spring Harbor, NY; Innis *et al.* (eds), 1995, PCR Strategies, Academic Press, Inc., San Diego; and Erlich (ed), 1992, PCR Technology, Oxford University Press, New York, all of which are incorporated herein by reference.

5 4.1.1. GRA1-Related Polynucleotide Molecules

[0029] References herein below to the nucleotide sequences shown in SEQ ID NOS:1 and 3, and to substantial portions thereof, are intended to also refer to the corresponding nucleotide sequences and substantial portions thereof, respectively, as present in plasmid pRC77 (ATCC 209685), unless otherwise indicated. In addition, references herein below to the amino acid sequences shown in SEQ ID NO:2, and to substantial portions and peptide fragments thereof, are intended to also refer to the corresponding amino acid sequences, and substantial portions and peptide fragments thereof, respectively, encoded by the corresponding GRA1-encoding nucleotide sequence present in plasmid pRC77 (ATCC 209685), unless otherwise indicated.

[0030] The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the GRA1 protein from *N. caninum*. In a preferred embodiment, the GRA1 protein has the amino acid sequence of SEQ ID NO:2. In a further preferred embodiment, the isolated GRA1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:1 from about nt 205 to about nt 777, the nucleotide sequence of the open reading frame (ORF) of the *GRA1* gene, which is presented in SEQ ID NO:3 from about nt 605 to about nt 1304, and the nucleotide sequence of the GRA1-encoding ORF of plasmid pRC77 (ATCC 209685). In a non-limiting embodiment, the isolated GRA1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:1 and SEQ ID NO:3. The GRA1 gene presented in SEQ ID NO:3 comprises an ORF from nt 605 to nt 855 and from nt 983 to nt 1304 with an intervening intron extending from nt 856 to nt 982. In addition, putative promoter motifs have been identified within 150 bp 5' of the mRNA start site that are similar to those found in *T. gondii* GRA genes (see Section 5.3, below).

[0031] The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is homologous to the nucleotide sequence of a GRA1-encoding polynucleotide molecule of the present invention. The term "homologous" when used to refer to a GRA1-related polynucleotide molecule means a polynucleotide molecule having a nucleotide sequence: (a) that encodes the same protein as one of the aforementioned GRA1-encoding polynucleotide molecules of the present invention, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *N. caninum* GRA1 protein, under moderately stringent conditions, *i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (see Ausubel *et al.* (eds.), 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3), and that is useful in practicing the present invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *N. caninum* GRA1 protein under highly stringent conditions, *i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel *et al.*, 1989, above), and is useful in practicing the present invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of a nucleotide sequence selected from the group consisting of the ORF of SEQ ID NO:1, which is from about nt 205 to about nt 777, and the ORF of the *GRA1* gene, which is presented in SEQ ID NO:3 from about nt 605 to about nt 1304, and which is useful in practicing the present invention.

[0032] As used herein, a polynucleotide molecule is "useful in practicing the present invention" where the polynucleotide molecule can be used to amplify a *Neospora*-specific polynucleotide molecule using standard amplification techniques, or as a diagnostic reagent to detect the presence of a *Neospora*-specific polynucleotide in a fluid or tissue sample from a *Neospora*-infected animal.

[0033] Polynucleotide molecules of the present invention having nucleotide sequences that are homologous to the nucleotide sequence of a GRA1-encoding polynucleotide molecule of the present invention do not include polynucleotide molecules having the native nucleotide sequence of *T. gondii* encoding a *T. gondii* GRA protein, and further have no more than about 90%, and preferably no more than about 80%, sequence identity to such a *T. gondii* polynucleotide molecule, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, National Center for Biotechnology Information).

[0034] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is homologous to the *N. caninum* GRA1 protein. As used herein to refer to polypeptides that are homologous to the *N. caninum* GRA1 protein, the term "homologous" refers to a polypeptide otherwise having the amino acid sequence of the *N. caninum* GRA1 protein, but in which one or more amino acid residues have been

conservatively substituted with a different amino acid residue, where the resulting polypeptide is useful in practicing the present invention. Conservative amino acid substitutions are well-known in the art. Rules for making such substitutions include those described by Dayhof. M.D. 1978, Nat. Biomed. Res. Found., Washington, D.C., Vol. 5, Sup. 3, among others. More specifically, conservative amino acid substitutions are those that generally take place within a family of amino acids that are related in acidity, polarity, or bulkiness of their side chains. Genetically encoded amino acids are generally divided into four groups: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan and tyrosine are also jointly classified as aromatic amino acids. One or more replacements within any particular group, e.g., of a leucine with an isoleucine or valine, or of an aspartate with a glutamate, or of a threonine with a serine, or of any other amino acid residue with a structurally related amino acid residue, e.g., an amino acid residue with similar acidity, polarity, bulkiness of side chain, or with similarity in some combination thereof, will generally have an insignificant effect on the function or immunogenicity of the polypeptide.

[0035] As used herein, a polypeptide is "useful in practicing the present invention" where the polypeptide can be used as a diagnostic reagent to detect the presence of *Neospora*-specific antibodies in a blood or serum sample from an animal that is currently infected, or that has been infected, with *Neospora*.

[0036] The present invention further provides a polynucleotide molecule consisting of a substantial portion of any of the aforementioned *Neospora GRA1*-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a *GRA1*-related polynucleotide molecule means a polynucleotide molecule consisting of less than the complete nucleotide sequence of the *GRA1*-related polynucleotide molecule, but comprising at least about 5%, and more preferably at least about 10%, of the nucleotide sequence of the *GRA1*-related polynucleotide molecule, and that is useful in practicing the present invention, as usefulness is defined above for polynucleotide molecules.

[0037] In addition to the nucleotide sequences of any of the aforementioned *GRA1*-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences selected from those that naturally flank the *GRA1* ORF or gene *in situ* in *N. caninum*, and include the nucleotide sequences shown in SEQ ID NO:1 from about nt 1 to about nt 204 and from about nt 778 to about nt 1265, or as shown in SEQ ID NO:3 from about nt 1 to about nt 604, and from about nt 1305 to about nt 1774, or substantial portions thereof.

4.1.2. GRA2-Related Polynucleotide Molecules

[0038] References herein below to the nucleotide sequence shown in SEQ ID NO:4, and to substantial portions thereof, are intended to also refer to the corresponding nucleotide sequence and substantial portions thereof, respectively, as present in plasmid pRC5 (ATCC 209686), unless otherwise indicated. In addition, references herein below to the amino acid sequence shown in SEQ ID NO:5, and to substantial portions and peptide fragments thereof, are intended to also refer to the corresponding amino acid sequence, and substantial portions and peptide fragments thereof, respectively, encoded by the corresponding *GRA2*-encoding nucleotide sequence present in plasmid pRC5 (ATCC 209686), unless otherwise indicated.

[0039] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the *GRA2* protein from *N. caninum*. In a preferred embodiment, the *GRA2* protein has the amino acid sequence of SEQ ID NO:5. In a further preferred embodiment, the isolated *GRA2*-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of the ORF of SEQ ID NO:4, which is from about nt 25 to about nt 660, and the nucleotide sequence of the *GRA2*-encoding ORF of plasmid pRC5 (ATCC 209686). In a non-limiting embodiment, the isolated *GRA2*-encoding polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:4.

[0040] The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is homologous to the nucleotide sequence of a *GRA2*-encoding polynucleotide molecule of the present invention. The term "homologous" when used to refer to a *GRA2*-related polynucleotide molecule means a polynucleotide molecule having a nucleotide sequence (a) that encodes the same protein as one of the aforementioned *GRA2*-encoding polynucleotide molecules of the present invention, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *N. caninum GRA2* protein, under moderately stringent conditions. *i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel *et al.*, 1989, above), and that is useful in practicing the present invention, as usefulness is defined above for polynucleotide molecules. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *N. caninum GRA2* protein under highly stringent conditions, *i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C

(Ausubel *et al.*, 1989, above), and is useful in practicing the present invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of the nucleotide sequence of the ORF of SEQ ID NO: 4, which is from about nt 25 to about nt 660, and is useful in practicing the present invention.

[0041] Polynucleotide molecules of the present invention having nucleotide sequences that are homologous to the nucleotide sequence of a GRA2-encoding polynucleotide molecule of the present invention do not include polynucleotide molecules having the native nucleotide sequence of *T. gondii* encoding a *T. gondii* GRA protein, and further have no more than about 90%, and preferably no more than about 80%, sequence identity to such a *T. gondii* polynucleotide molecule, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, NCBI).

[0042] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is homologous to the *N. caninum* GRA2 protein. As used herein to refer to polypeptides that are homologous to the *N. caninum* GRA2 protein, the term "homologous" refers to a polypeptide otherwise having the amino acid sequence of the *N. caninum* GRA2 protein, but in which one or more amino acid residues have been conservatively substituted with a different amino acid residue, as defined above, where the resulting polypeptide is useful in practicing the present invention, as usefulness is defined above for polypeptides.

[0043] The present invention further provides a polynucleotide molecule consisting of a substantial portion of any of the aforementioned *Neospora* GRA2-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a GRA2-related polynucleotide molecule means a polynucleotide molecule consisting of less than the complete nucleotide sequence of the GRA2-related polynucleotide molecule, but comprising at least about 5%, and more preferably at least about 10%, of the nucleotide sequence of the GRA2-related polynucleotide molecule, and that is useful in practicing the present invention, as usefulness is defined above for polynucleotide molecules.

[0044] In addition to the nucleotide sequences of any of the aforementioned GRA2-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences that naturally flank the GRA2 gene or ORF *in situ* in *N. caninum*, and include the flanking nucleotide sequences shown in SEQ ID NO:4 from about nt 1 to about nt 24, and from about nt 661 to about nt 1031, or substantial portions thereof.

4.1.3. SAG1-Related Polynucleotide Molecules

[0045] References herein below to the nucleotide sequence shown in SEQ ID NO:6, and to substantial portions thereof, are intended to also refer to the corresponding nucleotide sequence and substantial portions thereof, respectively, as present in plasmid pRC102 (ATCC 209687), unless otherwise indicated. In addition, references herein below to the amino acid sequence shown in SEQ ID NO:7, and to substantial portions and peptide fragments thereof, are intended to also refer to the corresponding amino acid sequence, and substantial portions and peptide fragments thereof, respectively, encoded by the corresponding SAG1-encoding nucleotide sequence present in plasmid pRC102 (ATCC 209687), unless otherwise indicated.

[0046] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the SAG1 protein from *N. caninum*. In a preferred embodiment, the SAG1 protein has the amino acid sequence of SEQ ID NO:7. In a further preferred embodiment, the isolated SAG1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of the ORF of SEQ ID NO:6, which is from about nt 130 to about nt 1089, and the nucleotide sequence of the SAG1-encoding ORF of plasmid pRC102 (ATCC 209687). In a non-limiting embodiment, the isolated SAG1-encoding polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:6.

[0047] The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is homologous to the nucleotide sequence of a SAG1-encoding polynucleotide molecule of the present invention. The term "homologous" when used to refer to a SAG1-related polynucleotide molecule means a polynucleotide molecule having a nucleotide sequence: (a) that encodes the same protein as one of the aforementioned SAG1-encoding polynucleotide molecules of the present invention, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *N. caninum* SAG1 protein, under moderately stringent conditions, *i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel *et al.*, 1989, above), and that is useful in practicing the present invention, as usefulness is defined above for polynucleotide molecules. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *N. caninum* SAG1 protein under highly stringent conditions, *i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel *et al.*, 1989, above), and is useful in practicing the present invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucle-

otide molecule consisting of the nucleotide sequence of the ORF of SEQ ID NO:6, which is from about nt 130 to about nt 1089, and is useful in practicing the present invention.

[0048] Polynucleotide molecules of the present invention having nucleotide sequences that are homologous to the nucleotide sequence of a SAG1-encoding polynucleotide molecule of the present invention do not include polynucleotide molecules having the native nucleotide sequence of *T. gondii* encoding a *T. gondii* SAG1 protein, and further have no more than about 90%, and preferably no more than about 80%, sequence identity to such a *T. gondii* polynucleotide molecule, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, NCBI).

[0049] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is homologous to the *N. caninum* SAG1 protein. As used herein to refer to polypeptides that are homologous to the *N. caninum* SAG1 protein, the term "homologous" refers to a polypeptide otherwise having the amino acid sequence of the *N. caninum* SAG1 protein, but in which one or more amino acid residues have been conservatively substituted with a different amino acid residue, as defined above, where the resulting polypeptide is useful in practicing the present invention, as usefulness is defined above for polypeptides.

[0050] The present invention further provides a polynucleotide molecule consisting of a substantial portion of any of the aforementioned *Neospora* SAG1-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a SAG1-related polynucleotide molecule means a polynucleotide molecule consisting of less than the complete nucleotide sequence of the SAG1-related polynucleotide molecule, but comprising at least about 5%, and more preferably at least about 10%, of the nucleotide sequence of the SAG1-related polynucleotide molecule, and that is useful in practicing the present invention, as usefulness is defined above for polynucleotide molecules.

[0051] In addition to the nucleotide sequences of any of the aforementioned SAG1-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences that naturally flank the SAG1 gene or ORF *in situ* in *N. caninum*, and include the flanking nucleotide sequences shown in SEQ ID NO:6 from about nt 1 to about nt 129 and from about nt 1090 to about nt 1263, or substantial portions thereof.

4.1.4. MIC1-Related Polynucleotide Molecules

[0052] References herein below to the nucleotide sequences shown in SEQ ID NOS:8 and 10, and to substantial portions thereof, are intended to also refer to the corresponding nucleotide sequences and substantial portions thereof, respectively, as present in plasmid pRC340 (ATCC 209688), unless otherwise indicated. In addition, references herein below to the amino acid sequences shown in SEQ ID NO:9, and to substantial portions and peptide fragments thereof, are intended to also refer to the corresponding amino acid sequences, and substantial portions and peptide fragments thereof, respectively, encoded by the corresponding MIC1-encoding nucleotide sequence present in plasmid pRC340 (ATCC 209688), unless otherwise indicated.

[0053] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the MIC1 protein from *N. caninum*. In a preferred embodiment, the MIC1 protein has the amino acid sequence of SEQ ID NO:9. In a further preferred embodiment, the isolated MIC1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of the ORF of SEQ ID NO:8, which is from about nt 138 to about nt 1520, the nucleotide sequence of the ORF of the *MIC1* gene, which is presented as SEQ ID NO:10, and the nucleotide sequence of the MIC1-encoding ORF of plasmid pRC340 (ATCC 209688). In a non-limiting embodiment, the isolated MIC1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:8 and SEQ ID NO:10.

[0054] The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is homologous to the nucleotide sequence of a MIC1-encoding polynucleotide molecule of the present invention. The term "homologous" when used to refer to a MIC1-related polynucleotide molecule means a polynucleotide molecule having a nucleotide sequence: (a) that encodes the same protein as one of the aforementioned MIC1-encoding polynucleotide molecules of the present invention, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *N. caninum* MIC1 protein, under moderately stringent conditions, *i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel *et al.*, 1989, above), and that is useful in practicing the present invention, as usefulness is defined above for polynucleotide molecules. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *N. caninum* MIC1 protein under highly stringent conditions, *i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel *et al.*, 1989, above), and is useful in practicing the present invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucle-

otide molecule consisting of a nucleotide sequence selected from the group consisting of the ORF of SEQ ID NO:8 from about nt 138 to about nt 1520, and the ORF of the *MIC1* gene, which is presented as SEQ ID NO:10, and is useful in practicing the present invention.

[0055] Polynucleotide molecules of the present invention having nucleotide sequences that are homologous to the nucleotide sequence of a *MIC1*-encoding polynucleotide molecule of the present invention do not include polynucleotide molecules having the native nucleotide sequence of *T. gondii* encoding a *T. gondii* *MIC1* protein, and further have no more than about 90%, and preferably no more than about 80%, sequence identity to such a *T. gondii* polynucleotide molecule, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, NCBI).

[0056] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is homologous to the *N. caninum* *MIC1* protein. As used herein to refer to polypeptides that are homologous to the *N. caninum* *MIC1* protein, the term "homologous" refers to a polypeptide otherwise having the amino acid sequence of the *N. caninum* *MIC1* protein, but in which one or more amino acid residues have been conservatively substituted with a different amino acid residue, as defined above, where the resulting polypeptide is useful in practicing the present invention, as usefulness is defined above for polypeptides.

[0057] The present invention further provides a polynucleotide molecule consisting of a substantial portion of any of the aforementioned *Neospora* *MIC1*-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a *MIC1*-related polynucleotide molecule means a polynucleotide molecule consisting of less than the complete nucleotide sequence of the *MIC1*-related polynucleotide molecule, but comprising at least about 5%, and more preferably at least about 10%, of the nucleotide sequence of the *MIC1*-related polynucleotide molecule, and that is useful in practicing the present invention, as usefulness is defined above for polynucleotide molecules.

[0058] In addition to the nucleotide sequences of any of the aforementioned *MIC1*-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences that naturally flank the *MIC1* ORF or gene *in situ* in *N. caninum*, and include the nucleotide sequences as shown in SEQ ID NO:8 from about nt 1 to about 137, and from about nt 1521 to about nt 2069, or substantial portions thereof.

4.1.5. MAG1-Related Polynucleotide Molecules

[0059] References herein below to the nucleotide sequence shown in SEQ ID NO:11, and to substantial portions thereof, are intended to also refer to the corresponding nucleotide sequences and substantial portions thereof, respectively, as present in plasmid bd304 (ATCC 203413), unless otherwise indicated. In addition, references herein below to the amino acid sequence shown in SEQ ID NO:13, and to substantial portions and peptide fragments thereof, are intended to also refer to the corresponding amino acid sequence, and substantial portions and peptide fragments thereof, respectively, encoded by the corresponding MAG1-encoding nucleotide sequence present in plasmid bd304 (ATCC 203413), unless otherwise indicated.

[0060] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the MAG1 protein from *N. caninum*. In a preferred embodiment, the MAG1 protein has the amino acid sequence of SEQ ID NO:13. In a further preferred embodiment, the isolated MAG1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence presented in SEQ ID NO:11 from about nt 1305 to about nt 2786, a cDNA molecule prepared therefrom, such as a cDNA molecule having the ORF of SEQ ID NO:12 from about nt 122 to about nt 1381, and the nucleotide sequence of the MAG1-encoding ORF present in plasmid bd304 (ATCC 203413). The present invention further provides a polynucleotide molecule having a nucleotide sequence of any ORF present in SEQ ID NO:11. In a non-limiting embodiment, the isolated MAG1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:11 and a cDNA deduced therefrom based on the putative exon/intron boundaries.

[0061] The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is homologous to the nucleotide sequence of a MAG1-encoding polynucleotide molecule of the present invention. The term "homologous" when used to refer to a MAG1-related polynucleotide molecule means a polynucleotide molecule having a nucleotide sequence: (a) that encodes the same protein as one of the aforementioned MAG1-encoding polynucleotide molecules of the present invention, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *N. caninum* MAG1 protein, under moderately stringent conditions, *i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel *et al.*, 1989, above), and that is useful in practicing the present invention, as usefulness is defined above for polynucleotide molecules. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *N. caninum* MAG1 protein under highly stringent conditions, *i.e.*, hybridization

to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1×SSC/0.1% SDS at 68°C (Ausubel *et al.*, 1989, above), and is useful in practicing the present invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of a nucleotide sequence selected from the group consisting of the nucleotide sequence of the ORF of the *MAG1* gene, which is presented in SEQ ID NO:11 from about nt 1305 to about nt 2786 and a cDNA molecule prepared therefrom based on the putative exon/intron boundaries, such as a cDNA molecule having the ORF of SEQ ID NO:12 from about nt 122 to about nt 1381, and is useful in practicing the present invention.

[0062] Polynucleotide molecules of the present invention having nucleotide sequences that are homologous to the nucleotide sequence of a *MAG1*-encoding polynucleotide molecule of the present invention do not include polynucleotide molecules having the native nucleotide sequence of *T. gondii* encoding a *T. gondii* *MAG1* protein, and further have no more than about 90%, and preferably no more than about 80%, sequence identity to such a *T. gondii* polynucleotide molecule, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, NCBI).

[0063] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is homologous to the *N. caninum* *MAG1* protein. As used herein to refer to polypeptides that are homologous to the *N. caninum* *MAG1* protein, the term "homologous" refers to a polypeptide otherwise having the amino acid sequence of the *N. caninum* *MAG1* protein, but in which one or more amino acid residues have been conservatively substituted with a different amino acid residue, as defined above, where the resulting polypeptide is useful in practicing the present invention, as usefulness is defined above for polypeptides.

[0064] The present invention further provides a polynucleotide molecule consisting of a substantial portion of any of the aforementioned *Neospora* *MAG1*-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a *MAG1*-related polynucleotide molecule means a polynucleotide molecule consisting of less than the complete nucleotide sequence of the *MAG1*-related polynucleotide molecule, but comprising at least about 5%, and more preferably at least about 10%, of the nucleotide sequence of the *MAG1*-related polynucleotide molecule, and that is useful in practicing the present invention, as usefulness is defined above for polynucleotide molecules. For example, a substantial portion of the polynucleotide molecule of SEQ ID NO:11 can comprise putative exon 1 from about nt 704 to about nt 820, or putative exon 2 from about nt 1301 to about nt 1399, or putative exon 3 from about nt 1510 to about nt 1808, or putative exon 4 from about nt 1921 to about nt 3297.

[0065] In addition to the nucleotide sequences of any of the aforementioned *MAG1*-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences that naturally flank the *MAG1* gene or ORF *in situ* in *N. caninum*, and include the nucleotide sequences as shown in SEQ ID NO:11 from about nt 1 to about nt 1304, and from about nt 2787 to about nt 4242, or that naturally flank the ORF of a cDNA molecule prepared therefrom based on the putative exon/intron boundaries, and include flanking sequences of the ORF of a cDNA molecule having the ORF of SEQ ID NO:12, from about nt 1 to about nt 121, and from about nt 1382 to about nt 1892, or substantial portions thereof.

4.2. *Gra1/Mag1* Promoter Region

[0066] The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the *N. caninum* *GRA1* and *MAG1* gene promoters. During the conduct of the experimental work disclosed herein, it was determined that the *N. caninum* *GRA1* and *MAG1* genes disclosed herein are naturally arranged *in situ* in a head-to-head orientation with an intervening nucleotide sequence of about 577 nt in length. This intervening nucleotide sequence, which is presented in SEQ ID NO:11 from nt 127 to nt 703, represents a putative bidirectional promoter region comprising the promoters of both the *N. caninum* *GRA1* and *MAG1* genes.

[0067] The *GRA1/MAG1* bidirectional promoter region of the present invention is useful for a variety of purposes including for controlling the recombinant expression of either the *GRA1* or *MAG1* genes, or both genes, or of one or more other genes or coding sequences, in host cells of *N. caninum* or in host cells of any other species of *Neospora* or other member of the Apicomplexa, or in any other appropriate host cell. Such other genes or coding sequences can either be native or heterologous to the recombinant host cell. The promoter sequence can be fused to the particular gene or coding sequence using standard recombinant techniques as known in the art so that the promoter sequence is in operative association therewith, as "operative association" is defined below. By using the promoter, recombinant expression systems can be constructed and used to screen for compounds and transcriptional factors that can modulate the expression of the *GRA1* and *MAG1* genes of *Neospora* or other members of the Apicomplexa. In addition, such promoter constructs can be used to express heterologous polypeptides in *Neospora* or other members of the Apicomplexa.

4.3. Oligonucleotide Molecules

[0068] The present invention further provides oligonucleotide molecules that hybridize to any one of the aforemen-

tioned polynucleotide molecules of the present invention, or that hybridize to a polynucleotide molecule having a nucleotide sequence that is the complement of any one of the aforementioned polynucleotide molecules of the present invention. Such oligonucleotide molecules are preferably at least about 10 nucleotides in length, and more preferably from about 15 to about 30 nucleotides in length, and hybridize to one or more of the aforementioned polynucleotide molecules under highly stringent conditions, *i.e.*, washing in 6xSSC/0.5% sodium pyrophosphate at about 37°C for ~14-base oligos, at about 48°C for ~17-base oligos, at about 55°C for ~20-base oligos, and at about 60°C for ~23-base oligos. Other hybridization conditions for longer oligonucleotide molecules of the present invention can be determined by the skilled artisan using standard techniques. In a preferred embodiment, an oligonucleotide molecule of the present invention is complementary to a portion of at least one of the aforementioned polynucleotide molecules of the present invention.

[0069] Specific though non-limiting embodiments of oligonucleotide molecules useful in practicing the present invention include oligonucleotide molecules selected from the group consisting of SEQ ID NOS:14-26 and 28-34, and the complements thereof.

[0070] The oligonucleotide molecules of the present invention are useful for a variety of purposes, including as primers in amplification of a *Neospora*-specific polynucleotide molecule for use, *e.g.*, in differential disease diagnosis, or to encode or act as antisense molecules useful in gene regulation. Regarding diagnostics, suitably designed primers can be used to detect the presence of *Neospora*-specific polynucleotide molecules in a sample of animal tissue or fluid, such as brain tissue, lung tissue, placental tissue, blood, cerebrospinal fluid, mucous, urine, amniotic fluid, etc. The production of a specific amplification product can support a diagnosis of *Neospora* infection, while lack of an amplified product can point to a lack of infection. Methods for conducting amplifications, such as the polymerase chain reaction (PCR), are described, among other places, in Innis *et al.* (eds), 1995, above; and Erlich (ed), 1992, above. Other amplification techniques known in the art, *e.g.*, the ligase chain reaction, can alternatively be used. The sequences of the polynucleotide molecules disclosed herein can also be used to design primers for use in isolating homologous genes from other species or strains of *Neospora* or other members of the Apicomplexa.

4.4. Recombinant Expression Systems

4.4.1. Cloning And Expression Vectors

[0071] The present invention further provides compositions for cloning and expressing any of the polynucleotide molecules of the present invention, including cloning vectors, expression vectors, transformed host cells comprising any of said vectors, and novel strains or cell lines derived therefrom. In a preferred embodiment, the present invention provides a recombinant vector comprising a polynucleotide molecule having a nucleotide sequence encoding the GRA1, GRA2, SAG1, MIC1 or MAG1 protein of *N. caninum*. In specific though non-limiting embodiments, the present invention provides plasmid pRC77 (ATCC 209685), which encodes the *N. caninum* GRA1 protein; plasmid pRC5 (ATCC 209686), which encodes the *N. caninum* GRA2 protein; plasmid pRC102 (ATCC 209687), which encodes the *N. caninum* SAG1 protein; plasmid pRC340 (ATCC 209688), which encodes the *N. caninum* MIC1 protein; and plasmid bd304 (ATCC 203413), which encodes the *N. caninum* MAG1 protein, and which also comprises the bidirectional promoter region described above.

[0072] Recombinant vectors of the present invention, particularly expression vectors, are preferably constructed so that the coding sequence for the polynucleotide molecule of the invention is in operative association with one or more regulatory elements necessary for transcription and translation of the coding sequence to produce a polypeptide. As used herein, the term "regulatory element" includes but is not limited to nucleotide sequences that encode inducible and non-inducible promoters, enhancers, operators and other elements known in the art that serve to drive and/or regulate expression of polynucleotide coding sequences. Also, as used herein, the coding sequence is in "operative association" with one or more regulatory elements where the regulatory elements effectively regulate and allow for the transcription of the coding sequence or the translation of its mRNA, or both.

[0073] Methods are well-known in the art for constructing recombinant vectors containing particular coding sequences in operative association with appropriate regulatory elements, and these can be used to practice the present invention. These methods include *in vitro* recombinant techniques, synthetic techniques, and *in vivo* genetic recombination. See, *e.g.*, the techniques described in Maniatis *et al.*, 1989, above; Ausubel *et al.*, 1989, above; Sambrook *et al.*, 1989, above; Innis *et al.*, 1995, above; and Erlich, 1992, above.

[0074] A variety of expression vectors are known in the art which can be utilized to express the *GRA1*, *GRA2*, *SAG1*, *MIC1*, and *MAG1* coding sequences of the present invention, including recombinant bacteriophage DNA, plasmid DNA, and cosmid DNA expression vectors containing the particular coding sequences. Typical prokaryotic expression vector plasmids that can be engineered to contain a polynucleotide molecule of the present invention include pUC8, pUC9, pBR322 and pBR329 (Biorad Laboratories, Richmond, CA), pPL and pKK223 (Pharmacia, Piscataway, NJ), pQE50 (Qiagen, Chatsworth, CA), and pGEM-T EASY (Promega, Madison, WI), among many others. Typical eukaryotic ex-

pression vectors that can be engineered to contain a polynucleotide molecule of the present invention include an ecdysone-inducible mammalian expression system (Invitrogen, Carlsbad, CA), cytomegalovirus promoter-enhancer-based systems (Promega, Madison, WI; Stratagene, La Jolla, CA; Invitrogen), and baculovirus-based expression systems (Promega), among others.

5 [0075] The regulatory elements of these and other vectors can vary in their strength and specificities. Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements can be used. For instance, when cloning in mammalian cell systems, promoters isolated from the genome of mammalian cells, e.g., mouse metallothionein promoter, or from viruses that grow in these cells, e.g., vaccinia virus 7.5K promoter or Moloney murine sarcoma virus long terminal repeat, can be used. Promoters obtained by recombinant DNA or synthetic techniques can also be used to provide for transcription of the inserted sequence. In addition, expression from certain promoters can be elevated in the presence of particular inducers, e.g., zinc and cadmium ions for metallothionein promoters. Non-limiting examples of transcriptional regulatory regions or promoters include for bacteria, the β -gal promoter, the T7 promoter, the TAC promoter, λ left and right promoters, trp and lac promoters, trp-lac fusion promoters, etc.; for yeast, glycolytic enzyme promoters, such as ADH-I and -II promoters, GPK promoter, PGI promoter, TRP promoter, etc.; and for mammalian cells, SV40 early and late promoters, adenovirus major late promoters, among others. The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the promoters of both the *GRA1* and *MAG1* genes of *N. caninum*, which can be used to express any of the coding sequences of the present invention in *Neospora* or other members of the Apicomplexa.

10 [0076] Specific initiation signals are also required for sufficient translation of inserted coding sequences. These signals typically include an ATG initiation codon and adjacent sequences. In cases where the polynucleotide molecule of the present invention including its own initiation codon and adjacent sequences are inserted into the appropriate expression vector, no additional translation control signals may be needed. However, in cases where only a portion of a coding sequence is inserted, exogenous translational control signals, including the ATG initiation codon, may be required. These exogenous translational control signals and initiation codons can be obtained from a variety of sources, both natural and synthetic. Furthermore, the initiation codon must be in phase with the reading frame of the coding regions to ensure in-frame translation of the entire insert.

15 [0077] Expression vectors can also be constructed that will express a fusion protein comprising a protein or polypeptide of the present invention. Such fusion proteins can be used, e.g., to raise antisera against a *Neospora* protein, to study the biochemical properties of the *Neospora* protein, to engineer a *Neospora* protein exhibiting different immunological or functional properties, or to aid in the identification or purification, or to improve the stability, of a recombinantly-expressed *Neospora* protein. Possible fusion protein expression vectors include but are not limited to vectors incorporating sequences that encode β -galactosidase and trpE fusions, maltose-binding protein fusions, glutathione-S-transferase fusions and polyhistidine fusions (carrier regions). Methods are well-known in the art that can be used to construct expression vectors encoding these and other fusion proteins.

20 [0078] The fusion protein can be useful to aid in purification of the expressed protein. In non-limiting embodiments, e.g., a *GRA1*-maltose-binding fusion protein can be purified using amylose resin; a *GRA1*-glutathione-S-transferase fusion protein can be purified using glutathione-agarose beads; and a *GRA1*-polyhistidine fusion protein can be purified using divalent nickel resin. Alternatively, antibodies against a carrier protein or peptide can be used for affinity chromatography purification of the fusion protein. For example, a nucleotide sequence coding for the target epitope of a monoclonal antibody can be engineered into the expression vector in operative association with the regulatory elements and situated so that the expressed epitope is fused to a *Neospora* protein of the present invention. In a non-limiting embodiment, a nucleotide sequence coding for the FLAGTM epitope tag (International Biotechnologies Inc.), which is a hydrophilic marker peptide, can be inserted by standard techniques into the expression vector at a point corresponding, e.g., to the amino or carboxyl terminus of the *GRA1* protein. The expressed *GRA1* protein-FLAGTM epitope fusion product can then be detected and affinity-purified using commercially available anti-FLAGTM antibodies.

25 [0079] The expression vector can also be engineered to contain polylinker sequences that encode specific protease cleavage sites so that the expressed *Neospora* protein can be released from the carrier region or fusion partner by treatment with a specific protease. For example, the fusion protein vector can include a nucleotide sequence encoding a thrombin or factor Xa cleavage site, among others.

30 [0080] A signal sequence upstream from and in reading frame with the *Neospora* coding sequence can be engineered into the expression vector by known methods to direct the trafficking and secretion of the expressed protein. Non-limiting examples of signal sequences include those from α -factor, immunoglobulins, outer membrane proteins, penicillinase, and T-cell receptors, among others.

35 [0081] To aid in the selection of host cells transformed or transfected with a recombinant vector of the present invention, the vector can be engineered to further comprise a coding sequence for a reporter gene product or other selectable marker. Such a coding sequence is preferably in operative association with the regulatory elements, as described above. Reporter genes that are useful in practicing the invention are well-known in the art and include those encoding chloramphenicol acetyltransferase (CAT), green fluorescent protein, firefly luciferase, and human growth

hormone, among others. Nucleotide sequences encoding selectable markers are well-known in the art, and include those that encode gene products conferring resistance to antibiotics or anti-metabolites, or that supply an auxotrophic requirement. Examples of such sequences include those that encode thymidine kinase activity, or resistance to methotrexate, ampicillin, kanamycin, chloramphenicol, zeocin, pyrimethamine, aminoglycosides, or hygromycin, among others.

4.4.2. Transformation Of Host Cells

[0082] The present invention further provides transformed host cells comprising a polynucleotide molecule or recombinant vector of the present invention, and cell lines derived therefrom. Host cells useful in practicing the invention can be eukaryotic or prokaryotic cells. Such transformed host cells include but are not limited to microorganisms, such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA vectors, or yeast transformed with a recombinant vector, or animal cells, such as insect cells infected with a recombinant virus vector, e.g., baculovirus, or mammalian cells infected with a recombinant virus vector, e.g., adenovirus or vaccinia virus, among others. For example, a strain of *E. coli* can be used, such as, e.g., the DH5 α strain available from the ATCC, Rockville, MD, USA (Accession No. 31343), or from Stratagene (La Jolla, CA). Eukaryotic host cells include yeast cells, although mammalian cells, e.g., from a mouse, hamster, cow, monkey, or human cell line, among others, can also be utilized effectively. Examples of eukaryotic host cells that can be used to express a recombinant protein of the invention include Chinese hamster ovary (CHO) cells (e.g., ATCC Accession No. CCL-61), NIH Swiss mouse embryo cells NIH/3T3 (e.g., ATCC Accession No. CRL-1658), and Madin-Darby bovine kidney (MDBK) cells (ATCC Accession No. CCL-22).

[0083] The recombinant vector of the invention is preferably transformed or transfected into one or more host cells of a substantially homogeneous culture of cells. The vector is generally introduced into host cells in accordance with known techniques, such as, e.g., by protoplast transformation, calcium phosphate precipitation, calcium chloride treatment, microinjection, electroporation, transfection by contact with a recombined virus, liposome-mediated transfection, DEAE-dextran transfection, transduction, conjugation, or microprojectile bombardment, among others. Selection of transformants can be conducted by standard procedures, such as by selecting for cells expressing a selectable marker, e.g. antibiotic resistance, associated with the recombinant expression vector.

[0084] Once an expression vector is introduced into the host cell, the integration and maintenance of the polynucleotide molecule of the present invention, either in the host cell genome or episomally, can be confirmed by standard techniques, e.g., by Southern hybridization analysis, restriction enzyme analysis, PCR analysis including reverse transcriptase PCR (rt-PCR), or by immunological assay to detect the expected protein product. Host cells containing and/or expressing a polynucleotide molecule of the present invention can be identified by any of at least four general approaches that are well-known in the art, including: (i) DNA-DNA, DNA-RNA, or RNA-antisense RNA hybridization, (ii) detecting the presence of "marker" gene functions; (iii) assessing the level of transcription as measured by the expression of specific mRNA transcripts in the host cell; or (iv) detecting the presence of mature polypeptide product, e.g., by immunoassay, as known in the art.

4.4.3. Expression And Purification Of Recombinant Polypeptides

[0085] Once a polynucleotide molecule of the present invention has been stably introduced into an appropriate host cell, the transformed host cell is clonally propagated, and the resulting cells are grown under conditions conducive to the maximum production of the encoded polypeptide. Such conditions typically include growing transformed cells to high density. Where the expression vector comprises an inducible promoter, appropriate induction conditions such as, e.g., temperature shift, exhaustion of nutrients, addition of gratuitous inducers (e.g., analogs of carbohydrates, such as isopropyl- β -D-thiogalactopyranoside (IPTG)), accumulation of excess metabolic by-products, or the like, are employed as needed to induce expression.

[0086] Where the polypeptide is retained inside the host cells, the cells are harvested and lysed, and the product is substantially purified or isolated from the lysate under extraction conditions known in the art to minimize protein degradation such as, e.g., at 4°C, or in the presence of protease inhibitors, or both. Where the polypeptide is secreted from the host cells, the exhausted nutrient medium can simply be collected and the polypeptide substantially purified or isolated therefrom.

[0087] The polypeptide can be substantially purified or isolated from cell lysates or culture medium, as necessary, using standard methods, including but not limited to one or more of the following methods: ammonium sulfate precipitation, size fractionation, ion exchange chromatography, HPLC, density centrifugation, and affinity chromatography. If the polypeptide lacks biological activity, it can be detected as based, e.g., on size, or reactivity with a polypeptide-specific antibody, or by the presence of a fusion tag. For use in practicing the present invention, the polypeptide can be in an unpurified state as secreted into the culture fluid or as present in a cell lysate, but is preferably substantially purified or isolated therefrom. As used herein, a polypeptide is "substantially purified" where the polypeptide constitutes

at least about 20 wt% of the protein in a particular preparation. Also as used herein, a polypeptide is "isolated" where the polypeptide constitutes at least about 80 wt% of the protein in a particular preparation.

[0088] Thus, the present invention provides a substantially purified or isolated polypeptide encoded by a polynucleotide of the present invention. In a non-limiting embodiment, the polypeptide is a *N. caninum* protein selected from the group consisting of GRA1, GRA2, SAG1, MIC1 and MAG1 proteins. In a preferred embodiment, the *N. caninum* GRA1 protein has the amino acid sequence of SEQ ID NO:2. In another preferred embodiment, the *N. caninum* GRA2 protein has the amino acid sequence of SEQ ID NO:5. In another preferred embodiment, the *N. caninum* SAG1 protein has the amino acid sequence of SEQ ID NO:7. In another preferred embodiment, the *N. caninum* MIC1 protein has the amino acid sequence of SEQ ID NO:9. In another preferred embodiment, the *N. caninum* MAG1 protein has the amino acid sequence of SEQ ID NO:13.

[0089] The present invention further provides polypeptides that are homologous to any of the aforementioned *N. caninum* proteins, as the term "homologous" is defined above for polypeptides. Polypeptides of the present invention that are homologous to any of the aforementioned GRA1, GRA2, SAG1, MIC1 or MAG1 proteins of *N. caninum* do not include polypeptides having the native amino acid sequence of a *T. gondii* GRA, SAG, MIC or MAG protein, and further have no more than about 90%, and preferably no more than about 80%, amino acid sequence identity to such a *T. gondii* polypeptide, wherein sequence identity is determined by use of the BLASTP algorithm (GenBank, NCBI).

[0090] The present invention further provides polypeptides consisting of a substantial portion of any one of the aforementioned polypeptides of the present invention. As used herein, a "substantial portion" of a polypeptide of the present invention, or "peptide fragment," means a polypeptide consisting of less than the complete amino acid sequence of the corresponding full-length polypeptide, but comprising at least about 10%, and more preferably at least about 20%, of the amino acid sequence thereof, and that is useful in practicing the present invention, as defined above for polypeptides. Particularly preferred are peptide fragments that are immunogenic, i.e., capable of inducing an immune response which results in production of antibodies that react specifically against the corresponding full-length *Neospora* polypeptide.

[0091] The present invention further provides fusion proteins comprising any of the aforementioned polypeptides fused to a carrier or fusion partner as known in the art.

[0092] The present invention further provides a method of preparing any of the aforementioned polypeptides, comprising culturing a host cell transformed with a recombinant expression vector, said recombinant expression vector comprising a polynucleotide molecule comprising a nucleotide sequence encoding the particular polypeptide, which polynucleotide molecule is in operative association with one or more regulatory elements, under conditions conducive to the expression of the polypeptide, and recovering the expressed polypeptide from the cell culture.

4.5. Use Of Polypeptides

[0093] Once a polypeptide of the present invention of sufficient purity has been obtained, it can be characterized by standard methods, including by SDS-PAGE, size exclusion chromatography, amino acid sequence analysis, immunological activity, biological activity, etc. The polypeptide can be further characterized using hydrophilicity analysis (see, e.g., Hopp and Woods, 1981, Proc. Natl. Acad. Sci. USA 78:3824), or analogous software algorithms, to identify hydrophobic and hydrophilic regions. Structural analysis can be carried out to identify regions of the polypeptide that assume specific secondary structures. Biophysical methods such as X-ray crystallography (Engstrom, 1974, Biochem. Exp. Biol. 11: 7-13), computer modeling (Fletterick and Zoller (eds), 1986, in: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), and nuclear magnetic resonance (NMR) can be used to map and study potential sites of interaction between the polypeptide and other putative interacting proteins/receptors/molecules. Information obtained from these studies can be used to design deletion mutants and vaccine compositions, and to design or select therapeutic or pharmacologic compounds that can specifically block the biological function of the polypeptide *in vivo*.

[0094] Polypeptides of the present invention are useful for a variety of purposes, including as components of vaccine compositions to protect mammals against neosporosis; or as diagnostic reagents, e.g., using standard techniques such as ELISA assays, to screen for *Neospora*-specific antibodies in blood or serum samples from animals; or as antigens to raise polyclonal or monoclonal antibodies, as described below, which antibodies are useful as diagnostic reagents, e.g., using standard techniques such as Western blot assays, to screen for *Neospora*-specific proteins in cell, tissue or fluid samples from an animal.

4.6. Analogs And Derivatives Of Polypeptides

[0095] Any polypeptide of the present invention can be modified at the protein level to improve or otherwise alter its biological or immunological characteristics. One or more chemical modifications of the polypeptide can be carried out using known techniques to prepare analogs therefrom, including but not limited to any of the following: substitution of

one or more L-amino acids of the polypeptide with corresponding D-amino acids, amino acid analogs, or amino acid mimics, so as to produce, e.g., carbazates or tertiary centers; or specific chemical modification, such as, e.g., proteolytic cleavage with trypsin, chymotrypsin, papain or V8 protease, or treatment with NaBH₄ or cyanogen bromide, or acetylation, formylation, oxidation or reduction, etc. Alternatively or additionally, polypeptides of the present invention can be modified by genetic recombination techniques.

[0096] A polypeptide of the present invention can be derivatized by conjugation thereto of one or more chemical groups, including but not limited to acetyl groups, sulfur bridging groups, glycosyl groups, lipids, and phosphates, and/or by conjugation to a second polypeptide of the present invention, or to another protein, such as, e.g., serum albumin, keyhole limpet hemocyanin, or commercially activated BSA, or to a polyamino acid (e.g., polylysine), or to a polysaccharide, (e.g., sepharose, agarose, or modified or unmodified celluloses), among others. Such conjugation is preferably by covalent linkage at amino acid side chains and/or at the N-terminus or C-terminus of the polypeptide. Methods for carrying out such conjugation reactions are well-known in the field of protein chemistry.

[0097] Derivatives useful in practicing the claimed invention also include those in which a water-soluble polymer such as, e.g., polyethylene glycol, is conjugated to a polypeptide of the present invention, or to an analog or derivative thereof, thereby providing additional desirable properties while retaining, at least in part, the immunogenicity of the polypeptide. These additional desirable properties include, e.g., increased solubility in aqueous solutions, increased stability in storage, increased resistance to proteolytic degradation, and increased *in vivo* half-life. Water-soluble polymers suitable for conjugation to a polypeptide of the present invention include but are not limited to polyethylene glycol homopolymers, polypropylene glycol homopolymers, copolymers of ethylene glycol with propylene glycol, wherein said homopolymers and copolymers are unsubstituted or substituted at one end with an alkyl group, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides, polyvinyl ethyl ethers, and α,β -poly[2-hydroxyethyl]-DL-aspartamide. Polyethylene glycol is particularly preferred. Methods for making water-soluble polymer conjugates of polypeptides are known in the art and are described in, among other places, U.S. Patent 3,788,948; U.S. Patent 3,960,830; U.S. Patent 4,002,531; U.S. Patent 4,055,635; U.S. Patent 4,179,337; U.S. Patent 4,261,973; U.S. Patent 4,412,989; U.S. Patent 4,414,147; U.S. Patent 4,415,665; U.S. Patent 4,609,546; U.S. Patent 4,732,863; U.S. Patent 4,745,180; European Patent (EP) 152,847; EP 98,110; and Japanese Patent 5,792,435, which patents are incorporated herein by reference.

4.7. Antibodies

[0098] The present invention further provides isolated antibodies directed against a polypeptide of the present invention. In a preferred embodiment, antibodies can be raised against a GRA1, GRA2, SAG1, MIC1 or MAG1 protein from *N. caninum* using known methods. Various host animals selected from pigs, cows, horses, rabbits, goats, sheep, or mice, can be immunized with a partially or substantially purified, or isolated, *N. caninum* protein, or with a homolog, fusion protein, substantial portion, analog or derivative thereof, as these are described above. An adjuvant, such as described below, can be used to enhance antibody production.

[0099] Polyclonal antibodies can be obtained and isolated from the serum of an immunized animal and tested for specificity against the antigen using standard techniques. Alternatively, monoclonal antibodies can be prepared and isolated using any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein (Nature, 1975, 256: 495-497); the human B-cell hybridoma technique (Kosbor *et al.*, 1983, Immunology Today 4:72; Cote *et al.*, 1983, Proc. Natl. Acad. Sci. USA 80: 2026-2030); and the EBV-hybridoma technique (Cole *et al.*, 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Alternatively, techniques described for the production of single chain antibodies (see, e.g., U.S. Patent 4,946,778) can be adapted to produce *N. caninum* antigen-specific single chain antibodies. These publications are incorporated herein by reference.

[0100] Antibody fragments that contain specific binding sites for a polypeptide of the present invention are also encompassed within the present invention, and can be generated by known techniques. Such fragments include but are not limited to F(ab')₂ fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries can be constructed (Huse *et al.*, 1989, Science 246: 1275-1281) to allow rapid identification of Fab fragments having the desired specificity to the *N. caninum* protein.

[0101] Techniques for the production and isolation of monoclonal antibodies and antibody fragments are well-known in the art, and are additionally described, among other places, in Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, and in J. W. Goding, 1986, Monoclonal Antibodies: Principles and Practice, Academic Press, London, which are incorporated herein by reference.

4.8. Targeted Mutation Of *Neospora* Genes

[0102] Based on the disclosure of the polynucleotide molecules of the present invention, genetic constructs can be

prepared for use in disabling or otherwise mutating a *Neospora* *GRA1*, *GRA2*, *SAG1*, *MIC1* or *MAG1* gene (which genes are hereinafter referred to collectively or individually as the "*Neospora* genes" or a "*Neospora* gene," respectively). Each of the *Neospora* genes can be mutated using an appropriately designed genetic construct in combination with genetic techniques now known or to be developed in the future. For example, a *Neospora* gene can be mutated using a genetic construct of the present invention that functions to: (a) delete all or a portion of the coding sequence or regulatory sequence of the *Neospora* gene; or (b) replace all or a portion of the coding sequence or regulatory sequence of the *Neospora* gene with a different nucleotide sequence; or (c) insert into the coding sequence or regulatory sequence of the *Neospora* gene one or more nucleotides, or an oligonucleotide molecule, or polynucleotide molecule, which can comprise a nucleotide sequence from *Neospora* or from a heterologous source; or (d) carry out some combination of (a), (b) and (c).

[0103] *Neospora* cells in which a *Neospora* gene has been mutated are useful in practicing the present invention where mutating the gene reduces the pathogenicity of the *Neospora* cells carrying the mutated gene compared to cells of the same strain of *Neospora* where the gene has not been so mutated, and where such *Neospora* cells carrying the disabled gene can be used in a vaccine composition, particularly in a modified live vaccine, to induce or contribute to the induction of, a protective response in a mammal against neosporosis. In a preferred embodiment, the mutation serves to partially or completely disable the *Neospora* gene, or partially or completely disable the protein encoded by the *Neospora* gene. In this context, a *Neospora* gene or protein is considered to be partially or completely disabled if either no protein product is made (for example, the gene is deleted), or a protein product is made that can no longer carry out its normal biological function or can no longer be transported to its normal cellular location, or a product is made that carries out its normal biological function but at a significantly reduced rate, or if such mutation results in a detectable decrease in the pathogenicity of cells of a pathogenic strain of *Neospora* wherein the gene has been so mutated compared to cells of the same strain but in which the gene has not been so mutated.

[0104] In a non-limiting embodiment, a genetic construct of the present invention is used to mutate a wild-type *Neospora* gene by replacement of the coding sequence of the wild-type gene, or a promoter or other regulatory region thereof, or a portion thereof, with a different nucleotide sequence such as, e.g., a mutated coding sequence or mutated regulatory region, or portion thereof. Mutated *Neospora* gene sequences for use in such a genetic construct can be produced by any of a variety of known methods, including by use of error-prone PCR, or by cassette mutagenesis. For example, oligonucleotide-directed mutagenesis can be employed to alter the coding sequence or promoter sequence of a wild-type *Neospora* gene in a defined way, e.g., to introduce a frame-shift or a termination codon at a specific point within the sequence. Alternatively or additionally, a mutated nucleotide sequence for use in the genetic construct of the present invention can be prepared by insertion into the coding sequence or promoter sequence of one or more nucleotides, oligonucleotide molecules or polynucleotide molecules, or by replacement of a portion of the coding sequence or promoter sequence with one or more different nucleotides, oligonucleotide molecules or polynucleotide molecules. Such oligonucleotide molecules or polynucleotide molecules can be obtained from any naturally occurring source or can be synthetic. The inserted sequence can serve simply to disrupt the reading frame of the *Neospora* gene, or can further encode a heterologous gene product such as a selectable marker.

[0105] Alternatively or additionally, random mutagenesis can be used to produce a mutated *Neospora* gene sequence for use in a genetic construct of the present invention. Random mutagenesis can be carried out by any techniques now known or to be developed in the future such as, e.g., by exposing cells carrying a *Neospora* gene to ultraviolet radiation or x-rays, or to chemical mutagens such as N-methyl-N'-nitrosoguanidine, ethyl methane sulfonate, nitrous acid or nitrogen mustards, and then selecting for cells carrying a mutation in the particular gene. See, e.g., Ausubel, 1989, above, for a review of mutagenesis techniques.

[0106] Mutations to produce modified *Neospora* cells that are useful in practicing the present invention, as defined above, can occur anywhere in the *Neospora* gene, including in the ORF, or in the promoter or other regulatory region, or in any other sequences that naturally comprise the gene or ORF. Such *Neospora* cells include mutants in which a modified form of the protein normally encoded by the *Neospora* gene is produced, or in which no protein normally encoded by the *Neospora* gene is produced, and can be null, conditional or leaky mutants.

[0107] Alternatively, a genetic construct of the present invention can comprise nucleotide sequences that naturally flank the *Neospora* gene or ORF *in situ*, such as those presented in SEQ ID NOS:1, 3, 4, 6, 8, 10, 11 and 12, with only a portion or no nucleotide sequences from the coding region of the gene itself. Such a genetic construct would be useful, e.g., to delete the entire *Neospora* gene or ORF.

[0108] In a preferred embodiment, a genetic construct of the present invention comprises a polynucleotide molecule that can be used to disable a *Neospora* gene, comprising: (a) a polynucleotide molecule having a nucleotide sequence that is otherwise the same as a nucleotide sequence encoding a *GRA1*, *GRA2*, *SAG1*, *MIC1* or *MAG1* protein from *N. caninum*, but which nucleotide sequence further comprises one or more disabling mutations; or (b) a polynucleotide molecule comprising a nucleotide sequence that naturally flanks the ORF of a *Neospora* gene *in situ*. Once transformed into cells of a strain of *Neospora*, the polynucleotide molecule of the genetic construct is specifically targeted to the particular *Neospora* gene by homologous recombination, and thereby either replaces the gene or portion thereof or

inserts into the gene. As a result of this recombination event, the *Neospora* gene otherwise native to that particular strain of *Neospora* is disabled.

[0109] Methods for carrying out homologous gene replacement in parasitic protozoans are known in the art, and are described, among other places, in Cruz and Beverley, 1990, Nature 348:171-173; Cruz *et al.*, 1991, Proc. Natl. Acad. Sci. USA 88:7170-7174; Donald and Roos, 1994, Mol. Biochem. Parasitol. 63:243-253; and Titus *et al.*, 1995, Proc Natl Acad Sci. USA 92:10267-10271, all of which are incorporated herein by reference.

[0110] For targeted gene mutation through homologous recombination, the genetic construct is preferably a plasmid, either circular or linearized, comprising a mutated nucleotide sequence as described above. In a non-limiting embodiment, at least about 200 nucleotides of the mutated sequence are used to specifically direct the genetic construct of the present invention to the particular targeted *Neospora* gene for homologous recombination, although shorter lengths of nucleotides can also be effective. In addition, the plasmid preferably comprises an additional nucleotide sequence encoding a reporter gene product or other selectable marker that is constructed so that it will insert into the *Neospora* genome in operative association with the regulatory element sequences of the native *Neospora* gene to be disrupted. Reporter genes that can be used in practicing the invention are well-known in the art and include those encoding CAT, green fluorescent protein, and β -galactosidase, among others. Nucleotide sequences encoding selectable markers are also well-known in the art, and include those that encode gene products conferring resistance to antibiotics or anti-metabolites, or that supply an auxotrophic requirement. Examples of such sequences include those that encode pyrimethamine resistance, or neomycin phosphotransferase (which confers resistance to aminoglycosides), or hygromycin phosphotransferase (which confers resistance to hygromycin).

[0111] Methods that can be used for creating the genetic constructs of the present invention are well-known in the art, and include *in vitro* recombinant techniques, synthetic techniques, and *in vivo* genetic recombination, as described, among other places, in Maniatis *et al.*, 1989, above; Ausubel *et al.*, 1989, above; Sambrook *et al.*, 1989, above; Innis *et al.*, 1995, above; and Erlich, 1992, above.

[0112] *Neospora* cells can be transformed or transfected with a genetic construct of the present invention in accordance with known techniques, such as, *e.g.*, by electroporation. Selection of transformants can be carried out using standard techniques, such as by selecting for cells expressing a selectable marker associated with the construct. Identification of transformants in which a successful recombination event has occurred and the particular target gene has been disabled can be carried out by genetic analysis, such as by Southern blot analysis, or by Northern analysis to detect a lack of mRNA transcripts encoding the particular protein, or by the appearance of a novel phenotype, such as reduced pathogenicity, or cells lacking the particular protein, as determined, *e.g.*, by immunological analysis, or some combination thereof.

[0113] *Neospora* cells that can be modified according to the present invention are preferably tachyzoites, but can alternatively be bradyzoites or oocysts. Although cells in certain stages of the *Neospora* life cycle are diploid, tachyzoites are haploid. Thus, the use of tachyzoites in the production of modified *Neospora* cells expressing the appropriate mutant phenotype is preferred because tachyzoites require only a single successful recombination event to disrupt the particular *Neospora* gene. Alternatively, in diploid cells of *Neospora*, two alleles must be disrupted for each gene. This can be accomplished by sequentially targeting the first allele and then the second allele with genetic constructs bearing two different selectable markers.

[0114] In a further non-limiting embodiment, the genetic construct of the present invention can additionally comprise a different gene or coding region from *Neospora* or from a different pathogen that infects the animal, which gene or coding region encodes an antigen useful to induce, or contribute to the induction of, a separate and distinct protective immune response in the animal upon vaccination with the modified live *Neospora* cells of the present invention. This additional gene or coding region can be further engineered to contain a signal sequence that leads to secretion of the encoded antigen from the modified live *Neospora* cell, thereby allowing for the antigen to be displayed to the immune system of the vaccinated animal.

[0115] The present invention thus provides modified live *Neospora* cells in which the *GRA1*, *GRA2*, *SAG1*, *MIC1* or *MAG1* gene has been mutated. The present invention further provides modified live *Neospora* cells in which a combination of two or more of the *GRA1*, *GRA2*, *SAG1*, *MIC1*, and *MAG1* genes have been mutated, which cells can be prepared using the general methods presented above. In addition, the present invention provides a method of preparing modified live *Neospora* cells, comprising: (a) transforming cells of *Neospora* with a genetic construct of the invention; (b) selecting transformed cells in which the *GRA1*, *GRA2*, *SAG1*, *MIC1*, or *MAG1* gene has been mutated by the genetic construct; and (c) selecting from among the cells of step (b) those cells that can be used in a vaccine to protect a mammal against neosporosis.

4.9. Culturing *Neospora* Cells

[0116] *Neospora* cells for use in the present invention can be cultured and maintained *in vitro* by infecting any receptive host cell line, preferably a mammalian cell line, with tachyzoites according to known techniques described in

the art. Mammalian cell lines in which tachyzoites of *Neospora* can be cultured include, *e.g.*, human foreskin fibroblasts (Lindsay *et al.*, 1993, Am. J. Vet. Res. 54:103-106), bovine cardiopulmonary aortic endothelial cells (Marsh *et al.*, 1995, above), bovine monocytes (Lindsay and Dubey, 1989, above), and monkey kidney cells, among others. For example, tachyzoites of *N. caninum* can be cultured in monolayers of Hs68 human foreskin fibroblast cells (ATCC Accession No. CRL-1635) (Lindsay *et al.*, 1993, above); and MARC145 monkey kidney cells infected with tachyzoites of *N. caninum* strain NC-1 for use in the present invention are on deposit with the ATCC (Accession No 12231). Bradyzoites can be similarly cultured and manipulated.

[0117] Mammalian cell cultures can be grown, and cell cultures that have been infected with *Neospora* cells can be maintained, in any of several types of culture media described in the art. For example, stationary monolayer cultures of bovine cardiopulmonary aortic endothelial cells infected with tachyzoites of *N. caninum* can be grown in Dulbecco's Minimum Essential Medium (DMEM; Gibco Laboratories, N.Y.), supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) or adult equine serum (ES), 2 mM L-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin (Conrad *et al.*, 1993, above). Monolayers of Hs68 human foreskin fibroblast cells can be maintained in RPMI 1640 containing 2% (v/v) FBS, 1.0 mM sodium pyruvate, 1 x 10⁴ U/ml penicillin, 1 x 10⁴ µg/ml streptomycin, 5 x 10⁻² mM 2-mercaptoethanol and 0.3 mg/ml L-glutamine (maintenance medium). Monolayer cultures of Hs68 human foreskin fibroblast cells infected with *Neospora* can be maintained in identical media, but in which the FBS is increased to 10% (v/v) (growth medium).

[0118] *Neospora*-infected monolayer cultures of mammalian cells are typically maintained under standard tissue culture conditions such as, *e.g.*, at 37°C and 5% CO₂. Tachyzoites are typically passaged to uninfected monolayer cultures when 70-90% of the mammalian cells in the culture have become infected, which can be determined microscopically using standard techniques. Tachyzoites can be collected from the infected mammalian cell cultures by lysing the host cells using any standard technique and collecting the tachyzoites, *e.g.*, by filtration or by centrifugation.

[0119] Modified live *Neospora* cells of the present invention can also be cultured in mammalian cells, as described above.

4.10. Anti-*Neospora* Vaccines

[0120] The present invention further provides a vaccine against neosporosis, comprising an immunologically effective amount of one or more proteins or polypeptides of the present invention, and a veterinarily acceptable carrier. In a preferred embodiment, the vaccine comprises a *N. caninum* protein selected from the group consisting of GRA1, GRA2, SAG1, MIC1 and MAG1.

[0121] The present invention further provides a vaccine against neosporosis, comprising an immunologically effective amount of one or more polynucleotide molecules of the present invention, and a veterinarily acceptable carrier. In a preferred embodiment, the vaccine comprises a polynucleotide molecule having a nucleotide sequence encoding a *N. caninum* protein selected from the group consisting of GRA1, GRA2, SAG1, MIC1, and MAG1.

[0122] The present invention further provides a vaccine against neosporosis, comprising an immunologically effective amount of modified *Neospora* cells of the present invention, and a veterinarily acceptable carrier. In a preferred embodiment, the modified *Neospora* cells for use in the vaccine of the present invention are live cells of *N. caninum* which express a *GRA1*⁺, *GRA2*⁺, *SAG1*⁺, *MIC1*⁺, or *MAG1*⁺ phenotype. Alternatively, the vaccine of the present invention can comprise any of such modified *Neospora* cells of the present invention that have been inactivated. Inactivation of modified *Neospora* cells can be carried out using any techniques known in the art, including by chemical treatment, such as with binary ethylenimine (BEI), or beta-propiolactone, or by freeze-thawing or heat treatment, or by homogenization of cells, or by a combination of these types of techniques. Vaccines prepared from homogenized, modified *Neospora* cells can consist of either the entire unfractionated cell homogenate, or an immunologically effective sub-fraction thereof.

[0123] As used herein, the term "immunologically effective amount" refers to that amount of antigen, *e.g.*, protein, polypeptide, polynucleotide molecule, or modified cells, capable of inducing a protective response against neosporosis when administered to a member of a mammalian species after either a single administration, or after multiple administrations.

[0124] The phrase "capable of inducing a protective response" is used broadly herein to include the induction or enhancement of any immune-based response in the animal in response to vaccination, including either an antibody or cell-mediated immune response, or both, that serves to protect the vaccinated animal against neosporosis. The terms "protective response" and "protect" as used herein refer not only to the absolute prevention of neosporosis or absolute prevention of infection by a neosporosis-causing pathogen, but also to any detectable reduction in the degree or rate of infection by such a pathogen, or any detectable reduction in the severity of the disease or any symptom or condition resulting from infection by the pathogen, including, *e.g.*, any detectable reduction in the rate of formation, or in the absolute number, of lesions formed in one or more tissues, or any detectable reduction in the occurrence of abortion, or the transmission of infection from a pregnant mammal to its fetus or from a mammal parent to its offspring,

in the vaccinated animal as compared to an unvaccinated infected animal of the same species.

[0125] In a further preferred embodiment, the vaccine of the present invention is a combination vaccine for protecting a mammal against neosporosis and, optionally, one or more other diseases or pathological conditions that can afflict the mammal, which combination vaccine comprises an immunologically effective amount of a first component comprising a polypeptide, polynucleotide molecule, or modified *Neospora* cells of the present invention; an immunologically effective amount of a second component that is different from the first component, and that is capable of inducing, or contributing to the induction of, a protective response against a disease or pathological condition that can afflict the mammal; and a veterinarily acceptable carrier.

[0126] The second component of the combination vaccine is selected based on its ability to induce, or contribute to the induction of, a protective response against either neosporosis or another disease or pathological condition that can afflict members of the mammalian species, as known in the art. Any antigenic component now known in the art, or to be determined in the future, to be useful in a vaccine composition in the particular mammalian species can be used as the second component of the combination vaccine. Such antigenic components include but are not limited to those that provide protection against pathogens selected from the group consisting of bovine herpes virus (syn., infectious bovine rhinotracheitis), bovine respiratory syncytial virus, bovine viral diarrhea virus, parainfluenza virus types I, II, or III, *Leptospira* spp., *Campylobacter* spp., *Staphylococcus aureus*, *Streptococcus agalactiae*, *Mycoplasma* spp., *Klebsiella* spp., *Salmonella* spp., rotavirus, coronavirus, rabies, *Pasteurella hemolytica*, *Pasteurella multocida*, *Clostridia* spp., *Tetanus* toxoid, *E. coli*, *Cryptosporidium* spp., *Eimeria* spp., *Trichomonas* spp., and other eukaryotic parasites, among others.

[0127] In a non-limiting embodiment, the combination vaccine of the present invention comprises a combination of two or more components selected from the group consisting of an immunologically effective amount of a protein or polypeptide of the present invention, an immunologically effective amount of a polynucleotide molecule of the present invention, and an immunologically effective amount of modified *Neospora* cells of the present invention. In a preferred embodiment, the combination vaccine of the present invention comprises a combination of two or more components selected from the group consisting of *N. caninum* GRA1, GRA2, SAG1, MIC1, and MAG1 proteins, polynucleotide molecules encoding any of the *N. caninum* GRA1, GRA2, SAG1, MIC1, and MAG1 proteins, and modified live *Neospora* cells exhibiting any of the *GRA1*⁻, *GRA2*⁻, *SAG1*⁻, *MIC1*⁻, and *MAG1*⁻ phenotypes.

[0128] The vaccines of the present invention can further comprise one or more additional immunomodulatory components including, e.g., an adjuvant or cytokine, as described below.

[0129] The present invention further provides a method of preparing a vaccine against neosporosis, comprising combining an immunologically effective amount of a *N. caninum* protein or polypeptide, or polynucleotide molecule, or modified *Neospora* cells of the present invention, with a veterinarily acceptable carrier, in a form suitable for administration to a mammal. In a preferred embodiment, the protein is a *N. caninum* protein selected from the group consisting of GRA1, GRA2, SAG1, MIC1 and MAG1; the polynucleotide molecule preferably comprises a nucleotide sequence encoding a *N. caninum* protein selected from the group consisting of GRA1, GRA2, SAG1, MIC1 and MAG1; and the modified *Neospora* cells preferably are live cells that exhibit a phenotype selected from the group consisting of *GRA1*⁻, *GRA2*⁻, *SAG1*⁻, *MIC1*⁻, and *MAG1*⁻.

[0130] A vaccine comprising modified live *Neospora* cells of the present invention can be prepared using an aliquot of culture fluid containing said *Neospora* cells, either free in the medium or residing in mammalian host cells, or both, and can be administered directly or in concentrated form to the mammal. Alternatively, modified live *Neospora* cells can be combined with a veterinarily acceptable carrier, with or without an immunomodulatory agent, selected from those known in the art and appropriate to the chosen route of administration, preferably where at least some degree of viability of the modified live *Neospora* cells in the vaccine composition is maintained. Modified *Neospora* cells that can be used in the vaccine of the present invention are preferably tachyzoites, but can alternatively be bradyzoites or oocysts, or some combination thereof.

[0131] Vaccine compositions of the present invention can be formulated following accepted convention to include veterinarily acceptable carriers, such as standard buffers, stabilizers, diluents, preservatives, and/or solubilizers, and can also be formulated to facilitate sustained release. Diluents include water, saline, dextrose, ethanol, glycerol, and the like. Additives for isotonicity include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others. Stabilizers include albumin, among others. Suitable other vaccine vehicles and additives, including those that are particularly useful in formulating modified live vaccines, are known or will be apparent to those skilled in the art. See, e.g., Remington's Pharmaceutical Science, 18th ed., 1990, Mack Publishing, which is incorporated herein by reference.

[0132] The vaccine of the present invention can further comprise one or more additional immunomodulatory components such as, e.g., an adjuvant or cytokine, among others. Non-limiting examples of adjuvants that can be used in the vaccine of the present invention include the RIBI adjuvant system (Ribi Inc., Hamilton, MT), alum, mineral gels such as aluminum hydroxide gel, oil-in-water emulsions, water-in-oil emulsions such as, e.g., Freund's complete and incomplete adjuvants, Block co polymer (CytRx, Atlanta GA), QS-21 (Cambridge Biotech Inc., Cambridge MA), SAF-M (Chiron, Emeryville CA), AMPHIGEN® adjuvant, saponin, Quil A or other saponin fraction, monophosphoryl lipid A,

and Avridine lipid-amine adjuvant. Specific non-limiting examples of oil-in-water emulsions useful in the vaccine of the invention include modified SEAM62 and SEAM 1/2 formulations. Modified SEAM62 is an oil-in-water emulsion containing 5% (v/v) squalene (Sigma), 1% (v/v) SPAN® 85 detergent (ICI Surfactants), 0.7% (v/v) TWEEN® 80 detergent (ICI Surfactants), 2.5% (v/v) ethanol, 200 µg/ml Quil A, 100 µg/ml cholesterol, and 0.5% (v/v) lecithin. Modified SEAM 1/2 is an oil-in-water emulsion comprising 5% (v/v) squalene, 1% (v/v) SPAN® 85 detergent, 0.7% (v/v) Tween 80 detergent, 2.5% (v/v) ethanol, 100 µg/ml Quil A, and 50 µg/ml cholesterol. Other immunomodulatory agents that can be included in the vaccine include, *e.g.*, one or more interleukins, interferons, or other known cytokines. Where the vaccine comprises modified live *Neospora* cells, the adjuvant is preferably selected based on the ability of the resulting vaccine formulation to maintain at least some degree of viability of the modified live *Neospora* cells.

[0133] Where the vaccine composition comprises modified live *Neospora* cells, the vaccine can be stored cold or frozen. Where the vaccine composition instead comprises a protein, polypeptide, polynucleotide molecule, or inactivated modified *Neospora* cells of the present invention, the vaccine may be stored frozen, or in lyophilized form to be rehydrated prior to administration using an appropriate diluent.

[0134] The vaccine of the present invention can optionally be formulated for sustained release of the antigen. Examples of such sustained release formulations include antigen in combination with composites of biocompatible polymers, such as, *e.g.*, poly(lactic acid), poly(lactic-co-glycolic acid), methylcellulose, hyaluronic acid, collagen and the like. The structure, selection and use of degradable polymers in drug delivery vehicles have been reviewed in several publications, including A. Domb *et al.*, 1992, *Polymers for Advanced Technologies* 3: 279-292, which is incorporated herein by reference. Additional guidance in selecting and using polymers in pharmaceutical formulations can be found in the text by M. Chasin and R. Langer (eds), 1990, "Biodegradable Polymers as Drug Delivery Systems" in: Drugs and the Pharmaceutical Sciences, Vol. 45, M. Dekker, NY, which is also incorporated herein by reference. Alternatively, or additionally, the antigen can be microencapsulated to improve administration and efficacy. Methods for microencapsulating antigens are well-known in the art, and include techniques described, *e.g.*, in U.S. Patent 3,137,631; U.S. Patent 3,959,457; U.S. Patent 4,205,060; U.S. Patent 4,606,940; U.S. Patent 4,744,933; U.S. Patent 5,132,117; and International Patent Publication WO 95/28227, all of which are incorporated herein by reference.

[0135] Liposomes can also be used to provide for the sustained release of antigen. Details concerning how to make and use liposomal formulations can be found in, among other places, U.S. Patent 4,016,100; U.S. Patent 4,452,747; U.S. Patent 4,921,706; U.S. Patent 4,927,637; U.S. Patent 4,944,948; U.S. Patent 5,008,050; and U.S. Patent 5,009,956, all of which are incorporated herein by reference.

[0136] The present invention further provides a method of vaccinating a mammal against neosporosis, comprising administering to the mammal an immunologically effective amount of a vaccine of the present invention. The vaccine is preferably administered parenterally, *e.g.*, either by subcutaneous or intramuscular injection. However, the vaccine can alternatively be administered by intraperitoneal or intravenous injection, or by other routes, including, *e.g.*, orally, intranasally, rectally, vaginally, intra-ocularly, or by a combination of routes, and also by delayed release devices as known in the art. The skilled artisan will be able to determine the most optimal route of vaccine administration, and will also recognize acceptable formulations for the vaccine composition according to the chosen route of administration.

[0137] An effective dosage can be determined by conventional means, starting with a low dose of antigen, and then increasing the dosage while monitoring the effects. Numerous factors may be taken into consideration when determining an optimal dose per animal. Primary among these is the species, size, age and general condition of the animal, the presence of other drugs in the animal, the virulence of a particular species or strain of *Neospora* against which the animal is being vaccinated, and the like. The actual dosage is preferably chosen after consideration of the results from other animal studies.

[0138] The dose amount of a *Neospora* protein or polypeptide of the present invention in a vaccine of the present invention preferably ranges from about 10 µg to about 10 mg, more preferably from about 50 µg to about 1 mg, and most preferably from about 100 µg to about 0.5 mg. The dose amount of a *Neospora* polynucleotide molecule of the present invention in a vaccine of the present invention preferably ranges from about 50 µg to about 1 mg. The dose amount of modified *Neospora* cells of the present invention in a vaccine of the present invention preferably ranges from about 1×10^3 to about 1×10^8 cells/ml, and more preferably from about 1×10^5 to about 1×10^7 cells/ml. A suitable dosage size ranges from about 0.5 ml to about 10 ml, and more preferably from about 1 ml to about 5 ml. The dose amounts of these antigens are also applicable to combination vaccines of the present invention. Where the second component of the combination vaccine is an antigen other than a *Neospora* protein, polypeptide, polynucleotide or modified cell of the present invention, the dose amount of the second component for use in the combination vaccine can be determined from prior vaccine applications of that second component, as known in the art.

[0139] The vaccine of the present invention is useful to protect mammals against neosporosis. As used herein, the term "mammal" refers to any mammalian species that can be protected against neosporosis using the vaccine of the invention, including dogs, cows, goats, sheep and horses, among others. The vaccine of the invention can be administered at any time during the life of a particular animal depending upon several factors including, *e.g.*, the timing of an outbreak of neosporosis among other animals, *etc.* The vaccine can be administered to animals of weaning age or

younger, or to more mature animals, e.g., as a pre-breeding vaccine to protect against *Neospora*-related congenital disease or abortion. Effective protection may require only a primary vaccination, or one or more booster vaccinations may also be needed. One method of detecting whether adequate immune protection has been achieved is to determine seroconversion and antibody titer in the animal after vaccination. The timing of vaccination and the number of boosters, if any, will preferably be determined by a veterinarian based on analysis of all relevant factors, some of which are described above.

[0140] The present invention further provides a kit for vaccinating a mammal against neosporosis, comprising a container having an immunologically effective amount of a polypeptide, polynucleotide molecule, or modified *Neospora* cells of the present invention, or a combination thereof. The kit can optionally comprise a second container having a veterinarily acceptable carrier or diluent. In a preferred embodiment, the polypeptide is selected from the group consisting of GRA1, GRA2, SAG1, MIC1 and MAG1 proteins of *N. caninum*; the polynucleotide molecule preferably has a nucleotide sequence that encodes a *N. caninum* protein selected from the group consisting of GRA1, GRA2, SAG1, MIC1, and MAG1; and the modified *Neospora* cells preferably are live cells that express a GRA1⁺, GRA2⁺, SAG1⁺, MIC1⁺ or MAG1⁺ phenotype.

[0141] The following example is illustrative only, and is not intended to limit the scope of the present invention.

5. EXAMPLE: ISOLATION OF *N. CANINUM* cDNA AND GENE SEQUENCES

5.1. Identification of λ Clones Containing GRA1, GRA2, SAG1 and MIC1 cDNAs

[0142] A cDNA library of *N. caninum* tachyzoites was obtained from Dr. T. Baszler, Washington State University, Pullman, WA. Briefly, this library was constructed using RNA purified from *N. caninum* NC-1 tachyzoites. cDNAs were cloned in bacteriophage λ ZAPEXpress (Stratagene, La Jolla, CA) following addition of *Eco*RI and *Xho*I linkers to the cDNA ends. The library was estimated to contain ~99% recombinants based on the formation of white plaques when aliquots of the library were mixed with *E. coli* XL-1 Blue MRA(P2) (Stratagene) and plated on NZY agar plates containing IPTG.

[0143] The recombinant insert DNA sequences of individual putative λ ZAPEXpress clones identified as described above were subjected to PCR analyses essentially as described by Krishnan *et al.*, 1991, Nucl Acids. Res. 19: 6177-6182; and Krishnan *et al.*, 1993, Meth. Enzym. 218:258-279, which publications are incorporated herein by reference. Thus, plugs of agar containing well separated bacteriophage λ plaques were recovered using a sterile Pasteur pipette and immersed in 100 μ l of sterile water for at least 1 hr. About 10 μ l of the diffused bacteriophage λ particles was used to perform PCR in a total volume of 100 μ l containing: (1) 100 ng each of λ DASH-T3 and λ DASH-T7 oligonucleotide primers specific to the λ bacteriophage vectors, i.e., λ ZAPEXpress, with specificity to the sequences adjacent to the cloning sites (i.e., *Eco*RI and *Xho*I), and oriented in a 5' to 3' direction towards the insert DNA sequences; (2) 200 μ M dNTPs; (3) PCR buffer (Life Technologies, Inc., Gaithersburg, MD); and (4) ~1 unit of Taq DNA polymerase buffer (Life Technologies, Inc.). The sequence of λ DASH-T3 is 5'-AATTAACCCTCACTAAAGGG (SEQ ID NO:14). The sequence of λ DASH-T7 is 5'-GTAATACGACTCACTATAGGGC (SEQ ID NO:15). Thermal cycling conditions were as follows: 94°C, 5 min, 1 cycle; 94°C, 1 min, 55°C, 1 min, 72°C, 1 min, 30 cycles; 72°C, 7 min, 1 cycle. An aliquot of the reaction mixture (typically 10 μ l) was examined by standard agarose gel electrophoresis, ethidium bromide staining and visualization under UV illumination. The PCR mixtures were purified by ion exchange column chromatography using a PCR purification system (Qiagen), and sequenced directly using the λ DASH-T3 and λ DASH-T7 primers employing fluorescent labeling and the Sanger dideoxy chain termination DNA sequencing technology. Sequences were analyzed for homology to other known sequences by comparison to DNA sequence databases at the National Center for Biotechnology Information, Bethesda, Maryland, 20894, USA. Four sequences, with homology to *T. gondii* GRA1, GRA2, SAG1 and MIC1 genes, respectively, were identified.

5.2. Identification of Complete ORFs for *N. caninum* GRA1, GRA2, SAG1 and MIC1 cDNAs

[0144] The above-described bacteriophage λ ZAPEXpress particles identified as containing *N. caninum* sequences having homology to *T. gondii* GRA1, GRA2, SAG1, and MIC1 genes, respectively, were subjected to an *in vivo* excision protocol following manufacturer's instructions (Stratagene) to recover the insert sequences in plasmid pBluescript. Briefly, the phage particles were allowed to infect *E. coli* XL-1 Blue MRF' co-infected with ExAssist helper phage (Stratagene). Following this treatment, the supernatant was collected and used to mix with *E. coli* XL0LR cells (Stratagene). Aliquots of the cell suspension were then plated on media containing kanamycin (~50 μ g/ml), and kanamycin-resistant colonies were examined for plasmid profile. Plasmid DNA was purified and the recombinant portion sequenced using the Sanger dideoxy chain termination DNA sequencing technology. DNA sequences obtained were analyzed by DNASTAR (DNASTAR, Inc., Madison, WI) to identify ORFs and other features. The sequences were also analyzed using BLAST algorithms (National Center for Biotechnology Information) for homology comparison to DNA sequences in the

public databases.

[0145] The recombinant plasmid clone identified as containing the complete *N. caninum* GRA1 ORF was designated as pRC77 (ATCC 209685). The total length of the cDNA insert sequence in pRC77 is 1,265 bp, with the GRA1 ORF extending from nts 205-777 (SEQ ID NO:1). The deduced amino acid sequence of the *N. caninum* GRA1 protein is presented as SEQ ID NO:2. The nucleotide sequence of the *N. caninum* GRA1 ORF has ~55% similarity to the nucleotide sequence of the *T. gondii* GRA1 ORF. The deduced amino acid sequence of the *N. caninum* GRA1 protein has ~51% similarity to the deduced amino acid sequence of the *T. gondii* GRA1 protein.

[0146] The recombinant plasmid clone identified as containing the complete *N. caninum* GRA2 ORF was designated as pRC5 (ATCC 209686). The total length of the cDNA insert sequence in pRC5 is 1,031 bp, with the GRA2 ORF extending from nts 25-660 (SEQ ID NO:4). The deduced amino acid sequence of the *N. caninum* GRA2 protein is presented as SEQ ID NO: 5. The nucleotide sequence of the *N. caninum* GRA2 ORF has ~37% similarity to the nucleotide sequence of the *T. gondii* GRA2 ORF. The deduced amino acid sequence of the *N. caninum* GRA2 protein has ~26% similarity to the deduced amino acid sequence of the *T. gondii* GRA2 protein.

[0147] The recombinant plasmid clone identified as containing the complete *N. caninum* SAG1 ORF was designated as pRC102 (ATCC 209687). The total length of the cDNA insert sequence in pRC102 is 1,263 bp, with the SAG1 ORF extending from nts 130-1,089 (SEQ ID NO:6). The deduced amino acid sequence of the *N. caninum* SAG1 protein is presented as SEQ ID NO:7. The nucleotide sequence of the *N. caninum* SAG1 ORF has ~58% similarity to the nucleotide sequence of the *T. gondii* SAG1 ORF. The deduced amino acid sequence of the *N. caninum* SAG1 protein has ~49% similarity to the deduced amino acid sequence of the *T. gondii* SAG1 protein.

[0148] The recombinant plasmid clone identified as containing the complete *N. caninum* MIC1 ORF was designated as pRC340 (ATCC 209688). The total length of the cDNA insert sequence in pRC340 is 2,069 bp, with the MIC1 ORF extending from nts 138-1,520 (SEQ ID NO:8). The deduced amino acid sequence of the *N. caninum* MIC1 protein is presented as SEQ ID NO:9. The nucleotide sequence of the *N. caninum* MIC1 ORF has ~58% similarity to the nucleotide sequence of the *T. gondii* MIC1 ORF. The deduced amino acid sequence of the *N. caninum* MIC1 protein has ~47% similarity to the deduced amino acid sequence of the *T. gondii* MIC1 protein.

5.3. Identification Of The GRA1 Gene Sequence

[0149] A genomic DNA library of *N. caninum* strain NC-1 was constructed in bacteriophage λ -II vector (Stratagene) according to conventional techniques. cDNA sequences derived from pRC77 (ATCC 209685) were PCR amplified as follows, and the resulting PCR amplified DNA fragment was used as a probe to screen the *N. caninum* strain NC-1 genomic DNA library. Primers bd219 and bd220 specific to *N. caninum* GRA1 cDNA were used to amplify a 563 bp fragment corresponding to the ORF of *N. caninum* GRA1 cDNA (pRC77). bd219 is 5'-GCCGCGACTTCTTTTCTCT (SEQ ID NO:16) and bd220 is 5'-CTCGATCGCCTCCTTTACTG (SEQ ID NO:17). The 563 bp fragment was purified by electrophoresis using SeaPlaque low melting agarose (LMA) (FMC Bioproducts). The band was excised from the gel and subsequently used in random prime labeling reactions to generate a probe in preparation for screening a *Neospora* genomic library.

[0150] 2.5×10^5 pfu from a *N. caninum* genomic library (λ DASH Stratagene #845201) were plaque-lifted onto Hybond N⁺ nylon membrane (Amersham). Duplicate filters were screened using the 563 bp GRA1 cDNA fragment as a probe. Nine duplicate pfus were scored positive and subsequently cored in 1 ml SM buffer. Four of these clones (# 5-8) were carried forward to secondary screening. On secondary screening, 500-1000 pfu per clone were plaque-lifted onto duplicate filters. All four Gra1 clones were positive on secondary screening and were isolated as individual plaques.

[0151] A λ clone designated as Gra1#8 was identified by this procedure, and was used as a template for PCR amplification using primers bd256 and bd254. Primer bd256 is 5'-TGCTAGTACTGGCGAGTGAA (SEQ ID NO:18). Primer bd254 is 5'-CAGGTTTGCCACACATTTT (SEQ ID NO:19). The PCR fragment obtained was subcloned into pGEM-T EASY vector (Promega, Madison, WI). The cloned fragment was sequenced employing fluorescent labelling and Sanger dideoxy chain termination sequencing technology. Sequence analysis revealed that the cloned fragment contained the GRA1 gene. The GRA1 gene sequence (SEQ ID NO:3) contains an ORF from nt 605 to nt 855 and from nt 983 to nt 1304, which shares complete identity to the GRA1 cDNA sequence (SEQ ID NO:1) of pRC77 (ATCC 209685) from nt 205 to nt 777. However, the GRA1 gene sequence (SEQ ID NO:3) differs from the cDNA sequence (SEQ ID NO:1) at a single nucleotide position in the 3' untranslated region at nt 1728 of the GRA1 gene where a thymine resides, instead of a guanine at nt 1201 of pRC77. This difference may be due to a RFLP or a sequencing error in pRC77 because this nucleotide discrepancy was confirmed in 2 separate subclones from the GRA1#8 λ genomic clone. The GRA1 gene sequence (SEQ ID NO:3) further comprises an intron extending from nt 856 to nt 982. Furthermore, three promoter motifs have been identified within 150 bp 5' of the mRNA start site that are similar to those found in *T. gondii* GRA genes (Mercier *et al.*, 1996, Mol. Microbiol. 21:421428).

5.4. Identification Of The SAG1 Gene Sequence

[0152] Oligonucleotide primers specific to the SAG1 gene were synthesized based on the SAG1 ORF of the DNA sequence obtained from pRC102. The first primer, designated as NCSAG1 5', was 5'-ATGTTTCCTCCTCGGGCAGTG (SEQ ID NO:20); and the second primer, designated as NCSAG1 3', was 5'-TCACGCGACGCCAGCCGCTATCG (SEQ ID NO:21). It was later determined that primer NCSAG1 5', as presented above, was inadvertently designed to include an additional three nucleotides (CCT), and the presence of these three additional nucleotides was thus taken into account when determining the actual SAG1 gene sequence.

[0153] PCR was performed using primers NCSAG1 5' (SEQ ID NO:20) and NCSAG1 3' (SEQ ID NO: 21) on *N. caninum* strain NC-1 genomic DNA as template. An ~1 kb amplified fragment was obtained, which was cloned in plasmid pCR2.1 and in pBlunt (Invitrogen, Carlsbad, CA) according to manufacturer's recommendations. Recombinant plasmids identified to contain the genomic SAG1 PCR fragment were sequenced employing fluorescent labeling and Sanger dideoxy chain termination sequencing technology using standard 'universal', 'reverse' and the following oligonucleotides: NCSAG1200: 5'-GCCCTGACAATTGACCGCC (SEQ ID NO 22); NCSAG1500: 5'-CCCACAACATC-CAAGTCGTTC (SEQ ID NO:23); NCSAG1660 5'-GTTTTGCACCATCCTTAGTG (SEQ ID NO:24); and NCSAG1320: 5'-GAGAGTTT GCTTTGCACCG (SEQ ID NO:25). The DNA sequences obtained were assembled using the DNASTar software package, and were found to be identical to the sequence of the SAG1 ORF deduced from pRC102. Thus, the genomic sequence of the SAG1 gene is identical to that obtained from cDNA sequencing.

5.5. Identification Of The MIC1 Gene Sequence

[0154] A ~2.2 kb DNA fragment was PCR amplified from *N. caninum* genomic DNA using oligonucleotides specific for the 5' and 3' ends of the MIC1 cDNA fragment (see sequence of pRC340). Thermal cycling conditions were as follows: 94°C, 1 min, 1 cycle; 94°C, 45 sec, 54°C, 45 sec, 72°C, 2 min, 29 cycles; 72°C, 5 min, 1 cycle. This ~2.2 kb fragment was cloned into pCR2.1 and into pZEROBLUNT (Invitrogen, Carlsbad, CA). Recombinant plasmids were identified by standard restriction analysis, and representative clones were sequenced using fluorescent labelling and Sanger dideoxy chain termination technology. Locations of exons and introns were identified by comparison to the MIC1 cDNA sequence from pRC340.

[0155] The total length of the MIC1 gene region is 2278 bp (SEQ ID NO:10), comprising an ORF from nt 1 to nt 73, nt 345 to nt 811, nt 1187 to nt 1265, and nt 1515 to nt 2278, with three intervening introns.

5.6. Identification Of The MAG1 Gene Sequence

[0156] BspDI, EcoRI and HindIII Vectorette libraries (Genosys) were prepared according to manufacturer's protocols using genomic clone Gra1#8 as template DNA. Using the antisense primer bd234 specific for 5' GRA1 cDNA, and Vectorette primer II (ER-70), a ~2 kb fragment was amplified from the HindIII Vectorette library using KlenTaq (AB Peptide Inc.) and PFU (Stratagene) polymerases. Primer bd234 is 5'-CCAGCCGAGTTCGTGTTTCA (SEQ ID NO: 26), and primer ER-70 is CAACGTGGATCCGATTCAAGCTTC (SEQ ID NO:27). The product was run on a 1% LMA gel, excised, and used directly in a cloning reaction with pGEM-T EASY vector. Transformation into *E. coli* DH5 α produced several white colonies. NotI restriction analysis of DNA from twenty different white clones indicated that 18 of 20 clones contained the appropriate sized insert. Subclone 2 was selected to be grown as stock and this plasmid was renamed bd245. The PCR product from the Vectorette 2 kb Gra1 promoter fragment was sequenced from both ends using nested primer bd218 and the Vectorette sequencing primer. The sequence of primer bd218 is 5'-AAAGCTCTTCGGCAGTTCAA (SEQ ID NO:28). The complete sequence of plasmid bd245 was generated by standard primer walking using Sanger fluorescent dideoxy chain termination sequencing technology.

[0157] Primer bd252 was used in combination with a variant of primer T7, and Gra1#8 DNA as template, in a PCR to map one end of clone Gra1#8. Primer bd252 is 5'-CCGCGCTACCACTTTCCA (SEQ ID NO:29). The T7 primer variant is 5'-GTAATACGACTCACTATA (SEQ ID NO:30). A ~2.5 kb fragment was amplified using primer bd252 and the T7 variant, which product was subcloned into pGEM-T EASY vector, and this plasmid was named bd282. Primer walking, using fluorescent labeling and Sanger dideoxy chain termination sequencing technology, was employed to complete the entire sequence of plasmid bd282.

[0158] Sequences from plasmids bd245 and bd282 were used to generate the contiguous sequence shown in SEQ ID NO:11, encoding the MAG1 gene which was identified using WU-BLAST2 (Washington University BLAST version 2). Results indicate that this sequence has homology to the *T. gondii* MAG1 gene (Accession No. U09029). Putative exon/intron boundaries were identified by intron splice site consensus sequences and alignment with the *T. gondii* MAG1 sequence, which suggested an mRNA transcript from nt 704 to nt 820 (exon 1), from nt 1301 to nt 1399 (exon 2), from nt 1510 to nt 1808 (exon 3), and from nt 1921 to nt 3297 (exon 4), with intervening introns. Based on these putative exon/intron boundaries, a proposed cDNA sequence is presented as SEQ ID NO:12, and an amino acid

sequence deduced therefrom is provided as SEQ ID NO:13. Comparison of exon and intron boundaries between *T. gondii* and *N. caninum* indicate that exons 1-3 and introns 1-2 of the *MAG1* gene are relatively positionally conserved between the two organisms. Intron 3 and exon 4 splice sites are unique to *N. caninum* *MAG1*. SEQ ID NO:11 also comprises a portion of the *GRA1* gene sequence of *GRA1*, from nt 1 to nt 126, and the complete intervening putative

[0159] DNA from lambda Gra1#8 clone was digested with NotI to release insert DNA, which was subsequently extracted with phenol/chloroform, precipitated and resuspended in water. DNA from this preparation was ligated to purified NotI digested BS KS+ vector DNA (Stratagene), and thereafter transformed into *E. coli* DH5 α cells. Clones were screened by PCR using primers specific for *GRA1* and *MAG1* genes, and further verified by NotI restriction digestion for the presence of the ~16 kb lambda Gra1#8 NotI insert. The primers used for PCR were *GRA1* primers 219 (SEQ ID NO:16) and 220 (SEQ ID NO: 17), and *MAG1* primers 261 and 270. Primer 261 is 5'-CCGCAACGTGCTGTTCCTA (SEQ ID NO:31); and primer 270 is 5'-CATCAGAGAACTGGAGT (SEQ ID NO:32). A positive plasmid clone containing the BS KS+ vector ligated to the NotI insert from lambda Gra1#8 was identified and named bd304 (ATCC 203413).

5.7. Identification Of The *MAG1* And *GRA1* Promoters of *Neospora*

5.7.1. Background On *T. gondii* *GRA1* Promoter Elements

[0160] Functional mutational analysis of the *T. gondii* *GRA1* promoter and sequence comparison to another well-defined *T. gondii* promoter (*SAG1*) identified a heptanucleotide motif (TGAGACG) which confers basal *GRA1* promoter activity in an orientation-independent manner (Mercier *et al.*, 1996, Mol. Micro. 21:421-428). Two additional heptanucleotide motifs in the *GRA1* promoter confer additional transcriptional activity. The *T. gondii* *GRA1* promoter is contained within the upstream, proximal region from -129 to -47 relative to the *GRA1* transcription start site. Significant promoter elements in this *T. gondii* *GRA1* region include 1 CAAT box, 1 heptanucleotide motif in direct orientation and 2 heptanucleotide motifs in an inverse orientation. Three additional heptanucleotide motifs were identified upstream (-349 to -204) of the *T. gondii* *GRA1* promoter but do not confer significant increase to the -129 to -47 promoter element.

5.7.2. *Neospora* *MAG1-GRA1* Promoter Elements

[0161] Genomic sequence analysis of the complete *MAG1-GRA1* region of *N. caninum* strain NC-1 indicates that the two genes are arranged in a head to head configuration. There is a 577 bp region between the putative translational start sites for the *MAG1* and *GRA1* genes (SEQ ID NO:11, from nt 127 to nt 703) that contains the putative *MAG1/GRA1* bi-directional promoter. Sequence analysis of this 577 bp region identifies three inverted heptanucleotide motifs (CGTCTCA or CGTCTCT) as described for the *T. gondii* *GRA1* promoter (Mercier *et al.*, 1996, above). Two CAAT boxes flank these heptanucleotide motifs one CAAT box is oriented toward the *GRA1* gene and the second CAAT box is oriented toward the *MAG1* gene. The Table below lists the promoter elements found in the *N. caninum* *MAG1/GRA1* bidirectional promoter region.

TABLE

promoter element	position to putative transcriptional start site defined by pRC77 ^a
CAAT box	-133 to -130
CAAT box (reverse)*	-49 to -52
CGTCTCA**	-125 to -119
CGTCTCA**	-106 to -100
CGTCTCT**	-70 to -64

^aNucleotide positions are in reference to the putative transcription start site defined by the 5' end of the *GRA1* cDNA (pRC77).

*This CAAT box is read from the complement strand and is oriented toward the *MAG1* gene (65kDa).

** Inverted heptanucleotide promoter motifs, as defined by Mercier *et al.* 1996. above.

5.7.3. Construction Of *Neospora* *GRA1* Promoter Construct

[0162] The functionality of the 577 bp putative *MAG1/GRA1* bidirectional promoter containing the two heptanucleotide motifs and two CAAT boxes was tested by engineering a plasmid containing the *LacZ* reporter gene downstream of this defined sequence and then transfecting this plasmid into NC-1 tachyzoites. A Bluescript plasmid, designated as GLS, containing the *T. gondii* *GRA1* promoter driving *LacZ* expression and containing a *T. gondii* *SAG1* 3' end, was

provided by Dr. David Sibley, Washington University School of Medicine, St. Louis, MO., USA. HindIII/NsiI digestion of plasmid GLS removed the *T. gondii* *GRA1* promoter fragment, and subsequent LMA purification was performed to generate a promoter-less *LacZ* reporter vector. Primers HindIII-bd256 (5'-GGCCAAGCTTGCTAGTACTGGCGA; SEQ ID NO:33) and bd260-NsiI (5'-ATCCAATGCATCTTGCTGAATGCCTTAAAG; SEQ ID NO:34) were used in an amplification reaction with lambda clone gra1#8 as template, and PFU and KlenTaq polymerases, to generate an ~600bp promoter fragment containing the 5' untranslated region from the *Neospora GRA1* gene. This fragment was digested with HindIII/NsiI, purified on LMA, and subsequently used in a ligation reaction with the above described promoter-less *LacZ* reporter vector to generate plasmid clone bd266. A PCR reaction with primers HindIII-bd256 and bd260-NsiI was performed with plasmid clone bd266 to verify insertion of the *N. caninum GRA1* promoter.

[0163] *N. caninum* NC-1 tachyzoites (1×10^7) were transfected by electroporation with 5 µg or 50 µg of uncut plasmid bd266 or plasmid GLS at 1.4V, 10 µF, in cytomix buffer as described by Howe *et al.*, 1997, METHODS: A COMPANION TO METHODS IN ENZYMOLOGY 13:1-11. Electroporated NC-1 cells were allowed to infect MARC-145 monkey kidney cells in a T25 flask (80% confluency) for 3 days before harvesting for a β-galactosidase assay. Cells were harvested by removing 3 ml of media and using the remaining 1 ml of media to scrape cells from flask. Harvested cells were transferred to a microcentrifuge and spun. Supernatant was discarded, and the pelleted cells were resuspended in 100 µl of lysis buffer (Howe *et al.*, 1997, above). Tubes were stored at -20°C until the β-galactosidase assay was performed.

[0164] To conduct the β-galactosidase assay, tubes were thawed, mixed, incubated at 50°C for 1 hr, and then spun in a microcentrifuge. Fifty µl of supernatant was used per sample. The β-galactosidase assay was performed as described by Howe *et al.*, 1997, above. A standard curve was prepared using a strain of *N. caninum* that had been stably transfected with the plasmid GLS, as provided by Dr. David Sibley. Tachyzoites were harvested, counted, resuspended in lysis buffer at 10^4 parasites/ml, and subsequently processed as above (*i.e.*, incubated at 50°C for 1 hr.). Twelve serial dilutions from this preparation were made in a range of from about 20,000 to about 10 parasites per well, and were used to create a standard curve in the β-galactosidase assay.

5.7.4. Results

[0165] Samples containing cell lysate from *N. caninum* strain NC-1 transfected with plasmid bd266 gave the highest β-galactosidase readings compared to samples containing cell lysate from *N. caninum* strain NC-1 transfected with plasmid GLS. Using the extracted value from the standard curve for bd266 (50 µg plasmid), the β-galactosidase reading was equivalent to 7013 parasites from the *N. caninum* cell line stably transformed with plasmid GLS described above. These experiments provide the first evidence that the *N. caninum GRA1* promoter is functional, and that the promoter elements lie within the ~600bp genomic fragment defined by primers HindIII-bd256 and bd260-NsiI.

6. EXAMPLE: EXPRESSION AND IMMUNOREACTIVITY OF A RECOMBINANT *N. CANINUM* MIC1 PROTEIN

[0166] DNA sequences representing the *MIC1* ORF were PCR-amplified and cloned into pQE50 (Qiagen), which is a recombinant system that facilitates inducible high level expression of the cloned sequence. The recombinant plasmid was designated as pQE_{MIC1}. Whole cell lysates from uninduced and induced *E. coli* cells containing pQE_{MIC1} were examined by SDS-PAGE and Coomassie blue protein staining. A polypeptide with a molecular weight of ~57 kDa was identified in induced, but not in uninduced, *E. coli* cells carrying pQE_{MIC1}. The molecular weight of the *MIC1* polypeptide as estimated from the deduced amino acid sequence of *MIC1* (SEQ ID NO:9) is ~49 kDa.

[0167] Whole cell lysates of induced and uninduced *E. coli* carrying pQE_{MIC1} were run on SDS-PAGE, and the proteins were transferred to PVF membranes (Novex) by standard procedures. The membranes were then blocked using 1% polyvinyl alcohol (PVA) in phosphate buffered saline (PBS). Following this, the membranes were rinsed three times in PBS containing 0.05% Tween-20 (PBST). The membranes were then incubated for about 1 hr either in a solution containing pooled polyclonal antisera from a naturally *N. caninum*-infected cattle herd (a gift from Dr. John Ellis, University of Technology, Sydney, Australia), or in a solution containing polyclonal antisera from rabbits experimentally infected with *T. gondii* (a gift from Dr. R. A. Cole, National Wildlife Health Center, Madison, WI). The membranes were then washed 3x with PBST, and reacted with goat anti-bovine or anti-rabbit IgG alkaline phosphate conjugate (Kirkegaard and Perry Labs, Gaithersburg, MD), as appropriate, diluted 1:500 according to manufacturer's recommendations. The membranes were washed in PBST again and bands were detected by incubating the membranes briefly in BCIP/NBT reagent ((Kirkegaard and Perry Labs), followed by rinsing in dH₂O. The recombinantly-expressed *MIC1* protein was found to have specific reactivity to both *N. caninum* and *T. gondii* polyclonal antisera.

7. EXAMPLE: VACCINE FORMULATIONS

[0168] A vaccine against neosporosis is formulated by combining a *N. caninum* protein of the present invention, such

as, e.g., SAG1, at 100 µg/ml with an equal volume of modified SEAM62 adjuvant, followed by gentle mixing, and storage at 4°C, for primary and boost immunizations. A primary dose of about 2 ml (total 100 µg) is administered subcutaneously to cattle, followed by a booster vaccination three weeks later. After two weeks following boost vaccination, cattle can be bred. Vaccines comprising a GRA1, GRA2, MIC1 or MAG1 protein of the present invention can also be formulated and administered in this manner.

Deposit Of Biological Materials

[0169] The following biological materials were deposited with the American Type Culture Collection (ATCC) at 12301 Parklawn Drive, Rockville, MD, 20852, USA, on March 19, 1998, and were assigned the following accession numbers:

Plasmid	ATCC Accession No.
pRC77	209685
pRC5	209686
pRC102	209687
pRC340	209688

[0170] The following additional biological material was deposited with the ATCC, at 10801 University Blvd, Manassas, VA, 20110, USA, on November 9, 1998, and was assigned the following accession number:

Plasmid	ATCC Accession No.
bd304	203413

[0171] All patents, patent applications, and publications cited above are incorporated herein by reference in their entirety.

[0172] The present invention is not limited in scope by the specific embodiments described, which are intended as single illustrations of individual aspects of the invention. Functionally equivalent compositions and methods are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Annex to the description

[0173]

5

SEQUENCE LISTING

<110> Pfizer Products Inc. (All Non-U.S. Applications)

10

<120> POLYNUCLEOTIDE MOLECULES ENCODING NEOSPORA PROTEINS

<130> PC9943

15

<140> To Be Assigned

<141> 1998-12-15

<150> 60/079,389

<151> 1998-03-26

20

<160> 34

<170> PatentIn Ver. 2.0 - beta

25

<210> 1

<211> 1265

<212> DNA

<213> Neospora caninum

30

<220>

<221> CDS

<222> (205)..(777)

<400> 1

35

gtttcatcgt tgaactgccg aagagcttta tgtttttgcc gcgacttctt tttctctccc 60

ctgaataaat tgtaccgtgg gtggcgtaca cgtctgaaca cgaactcggc tgggtttgct 120

tttgtggacg tgtttttccg gctcaaataa tttcattttc attgttcata cgtgtttgtg 180

40

atctctttta aggcattcag caag atg gtg cgt gtg agc gct att gtt ggg 231

Met Val Arg Val Ser Ala Ile Val Gly

1

5

45

gtt gca gcc tcg gtg gtt ctc tcc ctt tct tcc ggc gtg tac gcg gcc 279

Val Ala Ala Ser Val Val Leu Ser Leu Ser Ser Gly Val Tyr Ala Ala

10

15

20

25

50

gag gga gcg gaa aaa ccc ttg gga ggc gaa ggt caa gcg cct acc ttg 327

Glu Gly Ala Glu Lys Pro Leu Gly Gly Glu Gly Gln Ala Pro Thr Leu

30

35

40

55

ttg tca atg cta ggt ggc ggg cgc gcg gga agg ggg ttg tca gtc gga 375

Leu Ser Met Leu Gly Gly Gly Arg Ala Gly Arg Gly Leu Ser Val Gly

45

50

55

EP 0 953 641 A2

5
 caa tca gta gac ctt gac ctg atg ggc aga cgc tac cga gtg acc aga 423
 Gln Ser Val Asp Leu Asp Leu Met Gly Arg Arg Tyr Arg Val Thr Arg
 60 65 70

10
 tcc gag ggt gcg cca gat gtg ctc gag atc tcc gtt ctg gac gcg gat 471
 Ser Glu Gly Ala Pro Asp Val Leu Glu Ile Ser Val Leu Asp Ala Asp
 75 80 85

15
 ggg aag gct tct cac atc ggc ttt gta agc att ccg gaa gtg atg gac 519
 Gly Lys Ala Ser His Ile Gly Phe Val Ser Ile Pro Glu Val Met Asp
 90 95 100 105

20
 acc gtg gcg cgc atg cag aag gac gag gga att ttc ctt gat gcg tta 567
 Thr Val Ala Arg Met Gln Lys Asp Glu Gly Ile Phe Leu Asp Ala Leu
 110 115 120

25
 agt aaa gga gaa aca gta aag gag gcg atc gag gat gtt gct gca gcg 615
 Ser Lys Gly Glu Thr Val Lys Glu Ala Ile Glu Asp Val Ala Ala Ala
 125 130 135

30
 gaa ggt ctt tct ccc gag cag act gaa aac ctg gag gaa acg gtg gcc 663
 Glu Gly Leu Ser Pro Glu Gln Thr Glu Asn Leu Glu Glu Thr Val Ala
 140 145 150

35
 gct gta gcg act ctt gtt cgt gac gag atg gaa gtt ctt aaa gat cag 711
 Ala Val Ala Thr Leu Val Arg Asp Glu Met Glu Val Leu Lys Asp Gln
 155 160 165

40
 gag aag cta gaa gag gat gca gaa aag ctt gcg gga gat tta gaa gct 759
 Glu Lys Leu Glu Glu Asp Ala Glu Lys Leu Ala Gly Asp Leu Glu Ala
 170 175 180 185

45
 ctt caa ggg caa cat taa tttgcaaagg gattgtcatg tagccatatg 807
 Leu Gln Gly Gln His
 190

50
 ttcaatcgcc ctcaaaagtc gactgggggtg ttttggcaca tgtctgcagt tggtttggat 867
 cgacggcatg ggtagcgtat ggagaaaacg gatcgatggt tgacagttgc cgaaggaaat 927
 cggttgctgc gtgtaaggaa agtgtcacgg gggcattgag atttgaggagg gctcttgaag 987
 ccttcctcgg tggcaccaga ggggcagagc tcaacgcaag cgtggtatat ggagctggag 1047
 cagtggccgc aacgcagcag ggcggcgtga attacgttgc gttagtgtgc gcgtgaaacg 1107
 tcgtgttctc aaccgagta caatgtagtt tcagggtggtc gttgctcgaa tccgtgtgtc 1167
 gcgcctgtgt tgtatagtgt ttcgcattat gtggagacgg ggacgttttt aaaaaatcaa 1227

55

aaatgtgtgg caaacctgaa aaaaaaaaaa aaaaaaaaaa

1265

5 <210> 2
 <211> 190
 <212> PRT
 <213> Neospora caninum

10 <400> 2
 Met Val Arg Val Ser Ala Ile Val Gly Val Ala Ala Ser Val Val Leu
 1 5 10 15

15 Ser Leu Ser Ser Gly Val Tyr Ala Ala Glu Gly Ala Glu Lys Pro Leu
 20 25 30

Gly Gly Glu Gly Gln Ala Pro Thr Leu Leu Ser Met Leu Gly Gly Gly
 35 40 45

20 Arg Ala Gly Arg Gly Leu Ser Val Gly Gln Ser Val Asp Leu Asp Leu
 50 55 60

25 Met Gly Arg Arg Tyr Arg Val Thr Arg Ser Glu Gly Ala Pro Asp Val
 65 70 75 80

Leu Glu Ile Ser Val Leu Asp Ala Asp Gly Lys Ala Ser His Ile Gly
 85 90 95

30 Phe Val Ser Ile Pro Glu Val Met Asp Thr Val Ala Arg Met Gln Lys
 100 105 110

35 Asp Glu Gly Ile Phe Leu Asp Ala Leu Ser Lys Gly Glu Thr Val Lys
 115 120 125

Glu Ala Ile Glu Asp Val Ala Ala Ala Glu Gly Leu Ser Pro Glu Gln
 130 135 140

40 Thr Glu Asn Leu Glu Glu Thr Val Ala Ala Val Ala Thr Leu Val Arg
 145 150 155 160

45 Asp Glu Met Glu Val Leu Lys Asp Gln Glu Lys Leu Glu Glu Asp Ala
 165 170 175

Glu Lys Leu Ala Gly Asp Leu Glu Ala Leu Gln Gly Gln His
 180 185 190

50 <210> 3
 <211> 1774
 <212> DNA
 <213> Neospora caninum

55

<400> 3

5 tgctagtact ggcgagtgaa atgcgacgct cactgtagcc tccagataca cgacctgttg 60
 cggagctgac gctctcccca ctagagttca tgagcgatgg ggcgatggta gaccaacggt 120
 ccctagcgct tcggctgttg cgcggcggtt ctttaagagcg ggacgaccgc ctttcagggtg 180
 10 aaccgcctag tatcccaagc acacgaacat cccactcatg ggctggcgga actgctcgca 240
 gcggttacgc aaacacagtt gcgacgcaat gagccgtctc aagttgctgt cctcgtctca 300
 15 ttccggatcg gttcccaggt cctccggtgc gtctctgtcg gaaggttatt gcaactccgt 360
 tctgcgctgg gattagttta aatcatttca ttaatttgca gtttcacgtg tgaactgccg 420
 aagagcttta tgtttttgcc gcgacttctt tttctctccc ctgaataaat tgtaccgtgg 480
 20 gtggcgtaga cgtctgaaca cgaactcggc tgggtttgct tttgtggacg tgtttttccg 540
 gctcaaataa tttcattttc attgttcata cgtgtttgtg atctctttta aggcatcag 600
 25 caagatgggtg cgtgtgagcg ctattgttgg gggtgcagcc tcggtgggtc tctccctttc 660
 ttccggcggtg tacgcggccg agggagcgga aaaacccttg ggaggcgaag gtcaagcgcc 720
 30 taccttggtg tcaatgctag gtggcgggcg cgcgggaagg gggttgctcag tcggacaatc 780
 agtagacctt gacctgatgg gcagacgcta ccgagtgacc agatccgagg gtgcgccaga 840
 35 tgtgctcgag atctcgtaag tagactactg gtgttcaacg aaaaaaaagt acttgcgctg 900
 tggaatgtcg tctgtgtgtt agctgcatca tgtgataagc aaacatttgt tttcgagcgt 960
 gtgttgcttc gcgtgctttc agcgttctgg acgcggatgg gaaggcttct cacatcggct 1020
 40 ttgtaagcat tccggaagtg atggacaccg tggcgcgcat gcagaaggac gaggggaattt 1080
 tccttgatgc gttaagtaaa ggagaaacag taaaggaggc gatcgaggat gttgctgcag 1140
 45 cggaagggtct ttctcccagag cagactgaaa acctggagga aacggtggcc gctgtagcga 1200
 ctcttggtcg tgacgagatg gaagttctta aagatcagga gaagctagaa gaggatgcag 1260
 50 aaaagcttgc gggagattta gaagctcttc aagggaaca ttaatttgca aagggattgt 1320
 catgtagcca tatgttcaat cgcctcaaaa agtcgactgg ggtgttttgg cacatgtctg 1380
 cagttgggtt ggatcgacgg catgggttag cgatggagaa aacggatcga tggttgacag 1440
 55

ttgccgaagg aaatcggttg cgtcgtgtaa ggaaagtgtc acgggggcat tgagatttgg 1500
 5 aggggctctt gaagccttcc tcggtggcac cagaggggca gagctcaacg caagcgtggg 1560
 atatggagct ggagcagtgg ccgcaacgca gcagggcggc gtgaattacg ttgcgttagt 1620
 gctggcgtga aacgtcgtgt tctcaacccg agtacaatgt agtttcaggt ggtcgttgc 1680
 10 cgaatccgtg tgtcgcgcct gtgttgata gtgtttcgca ttatcgttag acgggggacgt 1740
 ttttaaaaaa tcaaaaatgt gtggcaaacc tgaa 1774

<210> 4
 <211> 1031
 <212> DNA
 <213> Neospora caninum

<220>
 <221> CDS
 <222> (25) .. (660)

<400> 4

aaataggggt ttcagcacca cacg atg ttc acg ggg aaa cgt tgg ata ctt 51
 Met Phe Thr Gly Lys Arg Trp Ile Leu
 1 5

30 gtt gtt gcc gtt ggc gcc ctg gtc ggc gcc tcg gta aag gca gcc gat 99
 Val Val Ala Val Gly Ala Leu Val Gly Ala Ser Val Lys Ala Ala Asp
 10 15 20 25

35 ttt tct ggc agg gga acc gtc aat gga cag ccg gtt ggc agc ggt tat 147
 Phe Ser Gly Arg Gly Thr Val Asn Gly Gln Pro Val Gly Ser Gly Tyr
 30 35 40

40 tcc gga tat ccc cgt ggc gat gat gtt aga gaa tca atg gct gca ccc 195
 Ser Gly Tyr Pro Arg Gly Asp Asp Val Arg Glu Ser Met Ala Ala Pro
 45 50 55

45 gaa gat ctg cca ggc gag agg caa ccg gag aca ccc acg gcg gaa gct 243
 Glu Asp Leu Pro Gly Glu Arg Gln Pro Glu Thr Pro Thr Ala Glu Ala
 60 65 70

50 gta aaa cag gca gcg gca aaa gct tat cga tta ctc aag cag ttt act 291
 Val Lys Gln Ala Ala Ala Lys Ala Tyr Arg Leu Leu Lys Gln Phe Thr
 75 80 85

55 gcg aag gtc gga cag gaa act gag aac gcc tac tac cac gtg aag aaa 339
 Ala Lys Val Gly Gln Glu Thr Glu Asn Ala Tyr Tyr His Val Lys Lys
 90 95 100 105

EP 0 953 641 A2

5 gcg aca atg aaa ggc ttt gac gtt gca aaa gac cag tcg tat aag ggc 387
 Ala Thr Met Lys Gly Phe Asp Val Ala Lys Asp Gln Ser Tyr Lys Gly
 110 115 120

10 tac ttg gcc gtc agg aaa gcc aca gct aag ggc ctg cag agc gct ggc 435
 Tyr Leu Ala Val Arg Lys Ala Thr Ala Lys Gly Leu Gln Ser Ala Gly
 125 130 135

15 aag agc ctt gag ctt aaa gag tcg gca ccg aca ggc act acg act gcg 483
 Lys Ser Leu Glu Leu Lys Glu Ser Ala Pro Thr Gly Thr Thr Thr Ala
 140 145 150

20 gcg ccg act gaa aaa gtg ccc ccc agt ggc ccg cga tca ggt gaa gtt 531
 Ala Pro Thr Glu Lys Val Pro Pro Ser Gly Pro Arg Ser Gly Glu Val
 155 160 165

25 cag cgt act cgt aaa gag caa aat gac gtg cag caa acc gca gag atg 579
 Gln Arg Thr Arg Lys Glu Gln Asn Asp Val Gln Gln Thr Ala Glu Met
 170 175 180 185

30 ttg gct gag gaa att ctt gag gct ggg ctt aag aag gac gat gga gaa 627
 Leu Ala Glu Glu Ile Leu Glu Ala Gly Leu Lys Lys Asp Asp Gly Glu
 190 195 200

35 gga cgg gga acg cca gaa gct gaa gtc aat taa gaaaatcact aaacgtcaag 680
 Gly Arg Gly Thr Pro Glu Ala Glu Val Asn
 205 210

40 ttcttttatga ctgctgtaca ccaccacccc cctggactgc ttaagacagc taacaagcgt 740
 tggatttcaa tatectactt aaggtatgtg gggcggatgc cgtgtcacgg tgtgtatggc 800
 gttaaaaaaac ggcacacggc attaaatgca gtgcaagtat gaattgtgcg caggttgtgt 860
 gtgacattttt tcggatgtcc tgggctttgt gtgcgtgcgt gggctgcgaa gagattagat 920
 ttattttcttg cgattgcgat gcgtagtttg ttgcatcgtt atggtcatga aaaaagtcta 980
 acgacacaca taaacgatgg agcaaattaa aaaaaaaaaa aaaaaaaaaa a 1031

45 <210> 5
 <211> 211
 <212> PRT
 <213> Neospora caninum

50 <400> 5
 Met Phe Thr Gly Lys Arg Trp Ile Leu Val Val Ala Val Gly Ala Leu
 1 5 10 15

55

Val Gly Ala Ser Val Lys Ala Ala Asp Phe Ser Gly Arg Gly Thr Val
 20 25 30

5 Asn Gly Gln Pro Val Gly Ser Gly Tyr Ser Gly Tyr Pro Arg Gly Asp
 35 40 45

10 Asp Val Arg Glu Ser Met Ala Ala Pro Glu Asp Leu Pro Gly Glu Arg
 50 55 60

Gln Pro Glu Thr Pro Thr Ala Glu Ala Val Lys Gln Ala Ala Ala Lys
 65 70 75 80

15 Ala Tyr Arg Leu Leu Lys Gln Phe Thr Ala Lys Val Gly Gln Glu Thr
 85 90 95

20 Glu Asn Ala Tyr Tyr His Val Lys Lys Ala Thr Met Lys Gly Phe Asp
 100 105 110

Val Ala Lys Asp Gln Ser Tyr Lys Gly Tyr Leu Ala Val Arg Lys Ala
 115 120 125

25 Thr Ala Lys Gly Leu Gln Ser Ala Gly Lys Ser Leu Glu Leu Lys Glu
 130 135 140

30 Ser Ala Pro Thr Gly Thr Thr Thr Ala Ala Pro Thr Glu Lys Val Pro
 145 150 155 160

Pro Ser Gly Pro Arg Ser Gly Glu Val Gln Arg Thr Arg Lys Glu Gln
 165 170 175

35 Asn Asp Val Gln Gln Thr Ala Glu Met Leu Ala Glu Glu Ile Leu Glu
 180 185 190

40 Ala Gly Leu Lys Lys Asp Asp Gly Glu Gly Arg Gly Thr Pro Glu Ala
 195 200 205

Glu Val Asn
 210

45

<210> 6
 <211> 1263
 <212> DNA

50 <213> Neospora caninum

<220>
 <221> CDS
 <222> (130)..(1089)

55

<400> 6

tctgcgtgca gccttccggt gttctcgctt gtatcacagg tgcctttgtc gtacataaac 60

5

attgtttcga ttgtagtcta gtcacaccgc actcgtttca tcaactggcgc ttttgtttat 120

tcatcgaat atg ttt cct cgg gca gtg aga cgc gcc gtc tcg gtg ggt gtg 171

Met Phe Pro Arg Ala Val Arg Arg Ala Val Ser Val Gly Val

10

1

5

10

ttc gcc gcg ccc gca ctg gtg gcg ttc ttt gac tgt gga act atg gca 219

Phe Ala Ala Pro Ala Leu Val Ala Phe Phe Asp Cys Gly Thr Met Ala

15

20

25

30

15

tca gaa aaa tca cct cta ctt gtc aat caa gtt gtc acc tgt gac aac 267

Ser Glu Lys Ser Pro Leu Leu Val Asn Gln Val Val Thr Cys Asp Asn

35

40

45

20

gaa gag aaa tca tca gtt gcc gtc cta cta tca ccg aag ctg aac cac 315

Glu Glu Lys Ser Ser Val Ala Val Leu Leu Ser Pro Lys Leu Asn His

50

55

60

25

atc acg ctc aag tgc cct gac aat tcg acc gcc gtg ccc gct gct ctt 363

Ile Thr Leu Lys Cys Pro Asp Asn Ser Thr Ala Val Pro Ala Ala Leu

65

70

75

30

ggc tat cca aca aac agg acc gtc tgc ccg gcg gag tcc gga ggt caa 411

Gly Tyr Pro Thr Asn Arg Thr Val Cys Pro Ala Glu Ser Gly Gly Gln

80

85

90

35

act tgt aca ggc aag gag ata ccg ttg gaa agc ctg ctt ccc ggg gca 459

Thr Cys Thr Gly Lys Glu Ile Pro Leu Glu Ser Leu Leu Pro Gly Ala

95

100

105

110

40

aac gat agc tgg tgg tca ggt gtt gat atc aag act ggc gtt aag ctc 507

Asn Asp Ser Trp Trp Ser Gly Val Asp Ile Lys Thr Gly Val Lys Leu

115

120

125

45

aca att cct gaa gcg agc ttc ccc aca aca tcc aag tcg ttc gac gtc 555

Thr Ile Pro Glu Ala Ser Phe Pro Thr Thr Ser Lys Ser Phe Asp Val

130

135

140

50

ggc tgc gtc agc agt gat gcc agc aag agt tgt atg gtc aca gtc aca 603

Gly Cys Val Ser Ser Asp Ala Ser Lys Ser Cys Met Val Thr Val Thr

145

150

155

gtg cca ccc aga gcc tca tcg ctt gtc aac ggt gtc gca atg tgc tct 651

Val Pro Pro Arg Ala Ser Ser Leu Val Asn Gly Val Ala Met Cys Ser

160

165

170

55

tac ggt gca aac gaa act ctc ggc cct atc aca ttg tcc gag ggc gga 699

	Tyr	Gly	Ala	Asn	Glu	Thr	Leu	Gly	Pro	Ile	Thr	Leu	Ser	Glu	Gly	Gly	
	175					180					185					190	
5	tct	tct	acg	atg	acc	ctc	gtt	tgc	ggc	acg	gat	ggg	aag	cca	gtt	cct	747
	Ser	Ser	Thr	Met	Thr	Leu	Val	Cys	Gly	Thr	Asp	Gly	Lys	Pro	Val	Pro	
					195					200					205		
10	cct	gat	cct	aag	cag	gtt	tgt	tct	ggg	acg	acc	gtc	aag	gat	tgt	aaa	795
	Pro	Asp	Pro	Lys	Gln	Val	Cys	Ser	Gly	Thr	Thr	Val	Lys	Asp	Cys	Lys	
				210					215					220			
15	gca	aaa	ccg	ttc	act	gat	gtt	ttc	cca	aaa	ttc	agt	gct	gat	tgg	tgg	843
	Ala	Lys	Pro	Phe	Thr	Asp	Val	Phe	Pro	Lys	Phe	Ser	Ala	Asp	Trp	Trp	
			225					230					235				
20	cag	gga	aaa	ccc	gac	act	aag	gat	ggg	gca	aaa	cta	acg	atc	aag	aaa	891
	Gln	Gly	Lys	Pro	Asp	Thr	Lys	Asp	Gly	Ala	Lys	Leu	Thr	Ile	Lys	Lys	
		240					245					250					
25	ggg	gca	ttt	cct	cca	aag	gag	gaa	aag	ttt	act	ctt	ggg	tgc	aag	agc	939
	Gly	Ala	Phe	Pro	Pro	Lys	Glu	Glu	Lys	Phe	Thr	Leu	Gly	Cys	Lys	Ser	
	255					260					265					270	
30	gta	tcg	agt	ccg	gag	gtt	tac	tgt	act	gtg	cag	gtg	gag	gca	gag	cgc	987
	Val	Ser	Ser	Pro	Glu	Val	Tyr	Cys	Thr	Val	Gln	Val	Glu	Ala	Glu	Arg	
					275					280					285		
35	gcg	agt	gca	ggg	atc	aag	tcg	tcg	gct	gaa	aat	gtt	ggg	cgc	gtt	tcc	1035
	Ala	Ser	Ala	Gly	Ile	Lys	Ser	Ser	Ala	Glu	Asn	Val	Gly	Arg	Val	Ser	
				290					295					300			
40	ctt	ttc	gct	gta	aca	att	gga	ctc	gta	ggc	tcg	ata	gcg	gct	ggc	gtc	1083
	Leu	Phe	Ala	Val	Thr	Ile	Gly	Leu	Val	Gly	Ser	Ile	Ala	Ala	Gly	Val	
			305				310						315				
45	gcg	tga	gtg	aca	atc	gga	ctc	gta	ggc	tcg	ata	gcg	gct	ggc	gtc		1139
	Ala																
50	cggtc	gtcat	gtgtgt	cttt	atcata	aaac	aacatt	tact	gattact	tgt	ggtg	gttt	gc				1199
	atat	gtacaa	tccca	aaaaac	tgctct	tactg	taaag	acg	tt	tagag	taaaa	aaaaaaaa					1259
	aaaa																1263
55	<210>	7															
	<211>	319															
	<212>	PRT															
	<213>	Neospora	caninum														

EP 0 953 641 A2

<400> 7

5	Met	Phe	Pro	Arg	Ala	Val	Arg	Arg	Ala	Val	Ser	Val	Gly	Val	Phe	Ala	1	5	10	15
	Ala	Pro	Ala	Leu	Val	Ala	Phe	Phe	Asp	Cys	Gly	Thr	Met	Ala	Ser	Glu	20	25	30	
10	Lys	Ser	Pro	Leu	Leu	Val	Asn	Gln	Val	Val	Thr	Cys	Asp	Asn	Glu	Glu	35	40	45	
	Lys	Ser	Ser	Val	Ala	Val	Leu	Leu	Ser	Pro	Lys	Leu	Asn	His	Ile	Thr	50	55	60	
15	Leu	Lys	Cys	Pro	Asp	Asn	Ser	Thr	Ala	Val	Pro	Ala	Ala	Leu	Gly	Tyr	65	70	75	80
20	Pro	Thr	Asn	Arg	Thr	Val	Cys	Pro	Ala	Glu	Ser	Gly	Gly	Gln	Thr	Cys	85	90	95	
	Thr	Gly	Lys	Glu	Ile	Pro	Leu	Glu	Ser	Leu	Leu	Pro	Gly	Ala	Asn	Asp	100	105	110	
25	Ser	Trp	Trp	Ser	Gly	Val	Asp	Ile	Lys	Thr	Gly	Val	Lys	Leu	Thr	Ile	115	120	125	
30	Pro	Glu	Ala	Ser	Phe	Pro	Thr	Thr	Ser	Lys	Ser	Phe	Asp	Val	Gly	Cys	130	135	140	
	Val	Ser	Ser	Asp	Ala	Ser	Lys	Ser	Cys	Met	Val	Thr	Val	Thr	Val	Pro	145	150	155	160
35	Pro	Arg	Ala	Ser	Ser	Leu	Val	Asn	Gly	Val	Ala	Met	Cys	Ser	Tyr	Gly	165	170	175	
40	Ala	Asn	Glu	Thr	Leu	Gly	Pro	Ile	Thr	Leu	Ser	Glu	Gly	Gly	Ser	Ser	180	185	190	
	Thr	Met	Thr	Leu	Val	Cys	Gly	Thr	Asp	Gly	Lys	Pro	Val	Pro	Pro	Asp	195	200	205	
45	Pro	Lys	Gln	Val	Cys	Ser	Gly	Thr	Thr	Val	Lys	Asp	Cys	Lys	Ala	Lys	210	215	220	
50	Pro	Phe	Thr	Asp	Val	Phe	Pro	Lys	Phe	Ser	Ala	Asp	Trp	Trp	Gln	Gly	225	230	235	240
	Lys	Pro	Asp	Thr	Lys	Asp	Gly	Ala	Lys	Leu	Thr	Ile	Lys	Lys	Gly	Ala	245	250	255	

55

Phe Pro Pro Lys Glu Glu Lys Phe Thr Leu Gly Cys Lys Ser Val Ser
 260 265 270

Ser Pro Glu Val Tyr Cys Thr Val Gln Val Glu Ala Glu Arg Ala Ser
 275 280 285

Ala Gly Ile Lys Ser Ser Ala Glu Asn Val Gly Arg Val Ser Leu Phe
 290 295 300

Ala Val Thr Ile Gly Leu Val Gly Ser Ile Ala Ala Gly Val Ala
 305 310 315

<210> 8

<211> 2069

<212> DNA

<213> Neospora caninum

<220>

<221> CDS

<222> (138)..(1520)

<400> 8

tcaatccttt cccgtgctaa cttgtaaaat cgctgctttc gttgggttggt tttgtttcac 60

gtggctgtta agaggtcgac gcagctgttt aaccctgccc cctgggttctc caggtgatct 120

gcacgcgatt tgcaaag atg ggc cag tcg gtg gtt ttc gtc atg ctt ttg 170
 Met Gly Gln Ser Val Val Phe Val Met Leu Leu
 1 5 10

tcg gta ata ttt acc gct ggg gca aaa aca tac gga gaa gcg tcg caa 218
 Ser Val Ile Phe Thr Ala Gly Ala Lys Thr Tyr Gly Glu Ala Ser Gln
 15 20 25

cca tcg gcc tca gca cgt tcg tta cag ggg gcc ctc gat aca tgg tgc 266
 Pro Ser Ala Ser Ala Arg Ser Leu Gln Gly Ala Leu Asp Thr Trp Cys
 30 35 40

cag gag gtt ttt aaa aaa ctg tgc gat gac gga tat tca aaa atg tgt 314
 Gln Glu Val Phe Lys Lys Leu Cys Asp Asp Gly Tyr Ser Lys Met Cys
 45 50 55

att cca gcc aac cag gta gtt gca cga caa ggc ctg ggt aga aaa gac 362
 Ile Pro Ala Asn Gln Val Val Ala Arg Gln Gly Leu Gly Arg Lys Asp
 60 65 70 75

caa caa aag ctc gta tgg cgg tgc tac gat tca gcg gcg ttt ctg gcc 410
 Gln Gln Lys Leu Val Trp Arg Cys Tyr Asp Ser Ala Ala Phe Leu Ala
 80 85 90

EP 0 953 641 A2

	gaa ggc gac gaa aac aat gtc ctc agc tgc gtg gac gac tgt ggc gtt	458
	Glu Gly Asp Glu Asn Asn Val Leu Ser Cys Val Asp Asp Cys Gly Val	
5	95 100 105	
	tcg ata ccg tgt cct ggc gga gtt gat agg gat aat agt acc cac gct	506
	Ser Ile Pro Cys Pro Gly Gly Val Asp Arg Asp Asn Ser Thr His Ala	
	110 115 120	
10	acg cga cat gat gag ctt tcc caa tta atc aag gaa gga gta gtg cgc	554
	Thr Arg His Asp Glu Leu Ser Gln Leu Ile Lys Glu Gly Val Val Arg	
	125 130 135	
15	tat tgc agt ggt ttc caa gcg gct gcc aac agc tac tgc aac aaa cga	602
	Tyr Cys Ser Gly Phe Gln Ala Ala Ala Asn Ser Tyr Cys Asn Lys Arg	
	140 145 150 155	
20	tat cct ggg act gtt gcg agg aag tcg aag ggc ttc gga cac aag gaa	650
	Tyr Pro Gly Thr Val Ala Arg Lys Ser Lys Gly Phe Gly His Lys Glu	
	160 165 170	
25	cca gtt aaa tgg aga tgt tac aag cca gag agc tta tta ttt tcg gtt	698
	Pro Val Lys Trp Arg Cys Tyr Lys Pro Glu Ser Leu Leu Phe Ser Val	
	175 180 185	
30	ttt tct gag tgc gtg agt aac tgc gga aca acc tgg tcc tgc cct gga	746
	Phe Ser Glu Cys Val Ser Asn Cys Gly Thr Thr Trp Ser Cys Pro Gly	
	190 195 200	
35	gga cga tta ggg aca gcg aca aat cta gac aaa aag cat ttc aca gat	794
	Gly Arg Leu Gly Thr Ala Thr Asn Leu Asp Lys Lys His Phe Thr Asp	
	205 210 215	
40	gag tcc ggg att ctc cag gca ctc acc tct gtg ccg aaa gca tgt cca	842
	Glu Ser Gly Ile Leu Gln Ala Leu Thr Ser Val Pro Lys Ala Cys Pro	
	220 225 230 235	
45	gta ggc ctt gtt tgc ctc ccg agg gat cag aat ccc ccg gcg tgt tta	890
	Val Gly Leu Val Cys Leu Pro Arg Asp Gln Asn Pro Pro Ala Cys Leu	
	240 245 250	
50	gat gat aac ggc aac gtc cca gaa gag gag gga ggg cag ccc gta caa	938
	Asp Asp Asn Gly Asn Val Pro Glu Glu Glu Gly Gly Gln Pro Val Gln	
	255 260 265	
55	ccg cgt gac acg aag ttg ccc gtt gat gat tcg gaa ccg acc gat gaa	986
	Pro Arg Asp Thr Lys Leu Pro Val Asp Asp Ser Glu Pro Thr Asp Glu	
	270 275 280	
	agt gaa act aca cct ggt gga ggt gat gat cag ccg agc cca aaa gag	1034

	Ser	Glu	Thr	Thr	Pro	Gly	Gly	Gly	Asp	Asp	Gln	Pro	Ser	Pro	Lys	Glu	
	285						290					295					
5	gac	ggg	gac	aca	gac	tca	cct	gat	gaa	ggt	gac	cag	tcc	ggg	ggt	tca	1082
	Asp	Gly	Asp	Thr	Asp	Ser	Pro	Asp	Glu	Gly	Asp	Gln	Ser	Gly	Gly	Ser	
	300					305					310					315	
10	gag	tgg	tac	aaa	cag	att	ccg	gaa	atc	cgt	gtc	atc	ggt	gac	agc	ctg	1130
	Glu	Trp	Tyr	Lys	Gln	Ile	Pro	Glu	Ile	Arg	Val	Ile	Gly	Asp	Ser	Leu	
					320					325					330		
15	caa	gca	atg	ctc	cac	gct	ggg	cag	cag	ctg	atg	gtc	acc	tat	agc	tct	1178
	Gln	Ala	Met	Leu	His	Ala	Gly	Gln	Gln	Leu	Met	Val	Thr	Tyr	Ser	Ser	
				335					340					345			
20	ccc	caa	ctc	cat	gtt	agt	gtg	gga	tca	tgt	cac	aaa	ctc	acg	gtg	aat	1226
	Pro	Gln	Leu	His	Val	Ser	Val	Gly	Ser	Cys	His	Lys	Leu	Thr	Val	Asn	
			350					355					360				
25	ttc	tcc	gat	tat	tat	ttg	tct	ttt	gac	acc	acc	tca	aag	tcg	ggg	tcc	1274
	Phe	Ser	Asp	Tyr	Tyr	Leu	Ser	Phe	Asp	Thr	Thr	Ser	Lys	Ser	Gly	Ser	
		365					370					375					
30	gac	gaa	gtg	gaa	ctg	gac	gat	gca	gcg	gga	agc	gga	gag	ctc	acg	ata	1322
	Asp	Glu	Val	Glu	Leu	Asp	Asp	Ala	Ala	Gly	Ser	Gly	Glu	Leu	Thr	Ile	
	380					385					390					395	
35	gga	ctg	gga	agc	agc	ggc	cgt	gtg	act	gtt	gtc	ttc	cag	tat	gcc	aca	1370
	Gly	Leu	Gly	Ser	Ser	Gly	Arg	Val	Thr	Val	Val	Phe	Gln	Tyr	Ala	Thr	
					400					405					410		
40	aac	ggt	ggg	gga	aac	aga	tat	gtt	gct	tac	acc	gtc	gga	gat	tct	gga	1418
	Asn	Gly	Gly	Gly	Asn	Arg	Tyr	Val	Ala	Tyr	Thr	Val	Gly	Asp	Ser	Gly	
				415					420					425			
45	tgc	aaa	aca	att	gaa	gct	gtt	ctc	ctt	cac	ggc	ctg	aat	cct	gga	gcg	1466
	Cys	Lys	Thr	Ile	Glu	Ala	Val	Leu	Leu	His	Gly	Leu	Asn	Pro	Gly	Ala	
			430					435					440				
50	aag	ctc	gtt	agg	aat	acg	ata	ggc	gat	aat	tct	ccg	ggt	gaa	tct	gaa	1514
	Lys	Leu	Val	Arg	Asn	Thr	Ile	Gly	Asp	Asn	Ser	Pro	Gly	Glu	Ser	Glu	
		445					450				455						
55	ttg	taa	cgactctttg	tgtagtagt	agccctccct	atacagaatg	ggagtgtatt										1570
	Leu																
	460																
	acattttgtg	atcaagggaa	gaggagcgat	cactacactt	gatcacgcgt	cgaggtcatt											1630
	cgtgcggggc	tgacagcttta	tggtttgatc	acgcaagaaa	agaagcgcaa	cacctgcaag											1690

tcgggcatgc gcgagggtcc catccttagt tttttttagt ttttttttg ccttcccgtc 1750
 5 cgtccatatt tctcgggtct gtattttcta gcctgagatt ctagcctaga tccaatgcag 1810
 tatgtcgcct gaagtcattg taagtgggtca gatgtttctg tctcagtgaa gaaaactgtg 1870
 10 ttatgggtgca ttctgtccga ttttatacgt aattcgtcgt acgttccatt gagttacgtg 1930
 aggatgagaa cgcagcaagt gatgtacgac aagttcgtag catgggtgaca ctgtagaata 1990
 caagtgtatt ttacagtcag gcggccggct actacacatt caagctgagt gacgtcgctt 2050
 15 caaaaaaaaa aaaaaaaaaa 2069

<210> 9
 20 <211> 460
 <212> PRT
 <213> Neospora caninum

<400> 9
 25 Met Gly Gln Ser Val Val Phe Val Met Leu Leu Ser Val Ile Phe Thr
 1 5 10 15
 Ala Gly Ala Lys Thr Tyr Gly Glu Ala Ser Gln Pro Ser Ala Ser Ala
 30 20 25 30
 Arg Ser Leu Gln Gly Ala Leu Asp Thr Trp Cys Gln Glu Val Phe Lys
 35 35 40 45
 Lys Leu Cys Asp Asp Gly Tyr Ser Lys Met Cys Ile Pro Ala Asn Gln
 50 55 60
 Val Val Ala Arg Gln Gly Leu Gly Arg Lys Asp Gln Gln Lys Leu Val
 40 65 70 75 80
 Trp Arg Cys Tyr Asp Ser Ala Ala Phe Leu Ala Glu Gly Asp Glu Asn
 85 90 95
 45 Asn Val Leu Ser Cys Val Asp Asp Cys Gly Val Ser Ile Pro Cys Pro
 100 105 110
 Gly Gly Val Asp Arg Asp Asn Ser Thr His Ala Thr Arg His Asp Glu
 50 115 120 125
 Leu Ser Gln Leu Ile Lys Glu Gly Val Val Arg Tyr Cys Ser Gly Phe
 130 135 140
 55 Gln Ala Ala Ala Asn Ser Tyr Cys Asn Lys Arg Tyr Pro Gly Thr Val

	145		150		155		160
5	Ala Arg Lys Ser Lys Gly Phe Gly His Lys Glu Pro Val Lys Trp Arg	165		170		175	
	Cys Tyr Lys Pro Glu Ser Leu Leu Phe Ser Val Phe Ser Glu Cys Val	180		185		190	
10	Ser Asn Cys Gly Thr Thr Trp Ser Cys Pro Gly Gly Arg Leu Gly Thr	195		200		205	
15	Ala Thr Asn Leu Asp Lys Lys His Phe Thr Asp Glu Ser Gly Ile Leu	210		215		220	
	Gln Ala Leu Thr Ser Val Pro Lys Ala Cys Pro Val Gly Leu Val Cys	225		230		235	240
20	Leu Pro Arg Asp Gln Asn Pro Pro Ala Cys Leu Asp Asp Asn Gly Asn	245		250		255	
25	Val Pro Glu Glu Glu Gly Gly Gln Pro Val Gln Pro Arg Asp Thr Lys	260		265		270	
	Leu Pro Val Asp Asp Ser Glu Pro Thr Asp Glu Ser Glu Thr Thr Pro	275		280		285	
30	Gly Gly Gly Asp Asp Gln Pro Ser Pro Lys Glu Asp Gly Asp Thr Asp	290		295		300	
35	Ser Pro Asp Glu Gly Asp Gln Ser Gly Gly Ser Glu Trp Tyr Lys Gln	305		310		315	320
	Ile Pro Glu Ile Arg Val Ile Gly Asp Ser Leu Gln Ala Met Leu His	325		330		335	
40	Ala Gly Gln Gln Leu Met Val Thr Tyr Ser Ser Pro Gln Leu His Val	340		345		350	
45	Ser Val Gly Ser Cys His Lys Leu Thr Val Asn Phe Ser Asp Tyr Tyr	355		360		365	
	Leu Ser Phe Asp Thr Thr Ser Lys Ser Gly Ser Asp Glu Val Glu Leu	370		375		380	
50	Asp Asp Ala Ala Gly Ser Gly Glu Leu Thr Ile Gly Leu Gly Ser Ser	385		390		395	400
55	Gly Arg Val Thr Val Val Phe Gln Tyr Ala Thr Asn Gly Gly Gly Asn	405		410		415	

EP 0 953 641 A2

Arg Tyr Val Ala Tyr Thr Val Gly Asp Ser Gly Cys Lys Thr Ile Glu
420 425 430

Ala Val Leu Leu His Gly Leu Asn Pro Gly Ala Lys Leu Val Arg Asn
435 440 445

Thr Ile Gly Asp Asn Ser Pro Gly Glu Ser Glu Leu
450 455 460

<210> 10

<211> 2278

<212> DNA

<213> Neospora caninum

<400> 10

atgggcccagt cgggtggtttt cgtcatgctt ttgtcggtaa tatttaccgc tggggcaaaa 60

acatacggag aaggtaagtc tccagctggt ttgtttgctt tgcaacaccc cccacctgga 120

gcgtctcgca actgtagatt gaagaaacta gtggacccgg ttgctgggttc ttcaggtacc 180

gtagtacatt cattggcaac agttagtcc ttttcgcata gtagcaaggc gtcgaactgt 240

tttttagtccg gatacaatcg gacgttctgc attgcgtgcg aactgctgtg aggacacctt 300

ctgatgcacg gaactgattt tctggatttg tcgggtggtt gcagcgtcgc aaccatcggc 360

ctcagcacgt tcgttacagg gggccctcga tacatggtgc caggagggtt ttaaaaaact 420

gtgcgatgac ggatattcaa aaatgtgtat tccagccaac caggtagttg caccgacaagg 480

cctgggtaga aaagaccaac aaaagctcgt atggcgggtgc tacgattcag cggcgtttct 540

ggccgaaggc gacgaaaaca atgtcctcag ctgcgtggac gactgtggcg tttcgatacc 600

gtgtcctggc ggagttgata gggataatag taccacacgct acgcgacatg atgagctttc 660

ccaattaatc aaggaaggag tagtgcgcta ttgcagtggc ttccaagcgg ctgccaacag 720

ctactgcaac aaacgatatc ctgggactgt tgcgaggaag tcgaagggtc tcggacacaa 780

ggaaccagtt aaatggagat gttacaagcc agtaaggagg agctggctag attgcattag 840

tctgccctca ccacatcgtc agcgatcgtc tcttgtgggg gataggagac atgatcctgg 900

gtcgcggaag agatgagcct ggtcctcgtc cgtgttagtg gcagcaaatt aacccacagg 960

aggtggcagg gattatttag catagcgtat gtacgttttc ggtggagggc aggagcacga 1020

gataactgta gagatccacg gcctctgtgc ctttccagtt atgttcacac agtttttacac 1080
 5 tagctgatag cattcacata cgttttacga agttcccgac aaacaccaag aggaaagtgg 1140
 gggaaatggt agatttgagg tgcgtactgt tgttgatgtg ttttaggaga gcttattatt 1200
 ttcggttttt tctgagtgcg tgagtaactg cggaacaacc tggtcctgcc ctggaggacg 1260
 10 attaggtgag ttttaagattc aggaatagca gaaatagtgc cacgaggtgc agcttcagcc 1320
 tgtaacgctg cttcttcac c actcgtatcc tggacacccc gagaaaggca tcggattggt 1380
 15 tttcaggatt taccaaaca acaatgatgc gagtcgagca gttattctgg gatttttttt 1440
 ctagaatgtg taagccagtt tcaatcgttg gctcatccgg catctttttc ctggtggcgc 1500
 tcgggtactt gcagggacag cgacaaatct agacaaaaag catttcacag atgagtcagg 1560
 20 gatttccag gcactcacct ctgtgccgaa agcatgtcca gtaggccttg tttgcctccc 1620
 gagggatcag aatcccccg cgtgtttaga tgataacggc aacgtcccag aagaggaggg 1680
 25 agggcagccc gtacaaccgc gtgacacgaa gttgcccggt gatgattcgg aaccgaccga 1740
 tgaaagtga actacacctg gtggaggtga tgatcagccg agcccaaaag aggacgggga 1800
 30 cacagactca cctgatgaag gtgaccagtc cgggggttca gagtgggtaca aacagattcc 1860
 ggaaatccgt gtcacgggtg acagcctgca agcaatgctc cacgctgggc agcagctgat 1920
 35 ggtcacctat agctctcccc aactccatgt tagtgtggga tcatgtcaca aactcacagt 1980
 gaattctcc gattattatt tgtcttttga caccacctca aagtcgggggt ccgacgaagt 2040
 ggaactggac gatgcagcgg gaagcggaga gctcacgata ggactgggaa gcagcggccg 2100
 40 tgtgactggt gtcttccagt atgccacaaa cgggtggggga aacagatatg ttgcttacac 2160
 cgtcggagat tctggatgca aaacaattga agctgttctc cttcacggcc tgaatcctgg 2220
 45 agcgaagctc gttaggaata cgataggcga taattctccg ggtgaatctg aattgtaa 2278

<210> 11

<211> 4242

<212> DNA

<213> Neospora caninum

<400> 11

55 cgggaattcg attccagccg agttcgtggt cagacgtgta cgccaccac ggtacaattt 60

attcagggga gagaaaaaga agtcgcggca aaaacataaa gctcttcggc agttcaacga 120
 5 tgaaactgca aattaatgaa atgatttaaa ctaatcccag cgcagaacgg agttgcaata 180
 accttccgac agagacgcac cggaggacct ggggaaccgat ccgaaatgag acgaggacag 240
 caacttgaga cggctcattg cgtcgcaact gtgtttgcgt aaccgctgcg agcagttccg 300
 10 ccagcccatg agtgggatgt tcgtgtgctt gggatactag gcggttcacc tgaaaggcgg 360
 tcgtcccgtt cttaagagcc gccgcgcaac agccgaagcg ctagggaccg ttggtctacc 420
 15 atcgccccat cgctcatgaa ctctagtggg gagagcgtca gctccgcaac aggtcgtgta 480
 tctggaggct acagtgagcg tcgcatttca ctcgccagta ctagcagcct tggcctttgg 540
 20 tagcgttgcg atggcctatg ccagtgcgag cgcgctaaac tactggcagt agacacacca 600
 tctggtgagc tctycctatg tctaaaacgt gaagatgagc gcgtgtgtgc ggatgacaga 660
 ggtatcaaga catctgtcag gtagaaattt tcttttaaca gttgaacaat cgtttcgtga 720
 25 ctctctggtg gtctgtctgt gtactagatg tactctttcc caagccgctc gaggaacata 780
 cgtgaagcac ggtggtactt cctgtagcaa aacatagcag gttaaaggta tgtggttcga 840
 30 aactgcagtg tgtactgtac tttggggggg ggcgcacggg tgggcacgcc catttgctag 900
 gggttcgggg aagggaaggg tgtgtggttg acggtttatc atcagagaaa ctggagtggg 960
 35 gacaagatta taatacgtca agctgcaagc cgctgtagtt ggagaaagct gtttttgagg 1020
 ggcatacttg tttgcgcgga tgatgtacgt atttcaccta aacatgttga aatacgctcg 1080
 ctgagaaacg gaggcaaaat tcaggaggaa tggggaaggg taccggtatg gtgagcacgc 1140
 40 gttgcaaaag cacaagtagg agaacacgcg acatagaaca actcggcggc catgtgtgta 1200
 aacggcatta acggatgttt ccacccttac acactctcga tgcgtgggac aatggagtcg 1260
 45 atgaaaacga tgcattggtt ggttgcatga ctgtgcgcag cacaatggcg ttcggacgag 1320
 gcaagagggg actgcacgct gcagtcactt taggcttctt tgtcctcctc gccacatcat 1380
 50 ctgtaggatt gggccaaagg tgagtcaaag catgacgtgt tttgctacgt gtaggaacag 1440
 cacgttgcgg ttcgaccact tgctcagtag ggtcatgcaa cactttgtgc tgattcaact 1500
 55 ggtgtgcagg gtgcctcgtt acccaagtgt ggagtcactc gaagaaagag ttgccgaggg 1560

tctagggcgc cgtagctccg cagcggccag tactcttcca gggagtgaca cgaacatgat 1620
 5 atcagatggt cgcgcaggca gggatgaacc aacagcgagc ccagagcatc attccgtgga 1680
 cgctccgacc acgtctgggg aaggcgaggc agatgctggg aaagtaacgc tgaggaacga 1740
 10 tgagggcctt gagggtaata tctcagccga ccatgttcta catccccctc ctgacagtga 1800
 acacgagggg ttgcaggaac cgggcacgac gcatcaggag gcgcaagaac cagacgcgag 1860
 tgaagcaatg gactcttccg cgctaccact ttccacgtcg ggtaccacat cctaacgaag 1920
 15 tcggttcaac accaggaaca gcgctgcctg ccccgatttt tagcattcca gagctctcac 1980
 cggaggaagt tgtctacgtt ttacgggttc agggatcagg cgatttcgaa attagtttcc 2040
 20 aagtaggccg ggtggtgagg cagttggaag ccatcaagag agcatacagg gaggctcacg 2100
 ggaagctaga agctgaggag ctggagtcgg aaaggggacc gacggtttcg actcggacga 2160
 aactagttga ctttatcaaa gaaaaccaga gacggctgag ggcggcgttt cagaaggtta 2220
 25 agattcagca aaagttggag gagatcgagg aactgttgca gctgtcacac gcactaaaat 2280
 ctctaggtgc ccgcctgaga ccctgccaaa aaagtaattc cccaatggag gaagagattt 2340
 30 gtcgtaagac gaaagctttg ggcgaaatgg ttgccagaa agcggaggat cttcgtcagc 2400
 atgcgtcaac tgtctcggct ctgctaggtc gcgaagctgt tgagagacag ttgcggcgtg 2460
 35 tcgacagtga acaaccctat gaacaaacag acgcccgggt tgcagccaga gcagaggaat 2520
 ttcggaaggc actggagaaa gcagcttccg gtgcgagaca attcgtgggg accacagcgg 2580
 acgaaatagt ggaggaagtg aaggaggatg ctcagtacct gcgtgatggt gcgaaagaag 2640
 40 tgttgacgaa gagccagcgc gcgctagtag acgcgtttca ggcgatcaa agggctctac 2700
 tggaggcgaa ggcaaaggag ctctagatg ccgcatcaaa ggaagctgaa gacgctcgta 2760
 45 agatcttagc ggaacagcca gcgtgattcg ccgaggacga agttggtaat gcacggtgaa 2820
 tgagggttg tcatcccaat ccccagcttg atagcgtcac gtgggttttt cgccggggaa 2880
 acgatcatta gggaggtgat gtatcgagc aaacatgggc atatcagcac cagttttttt 2940
 50 acatgtgagg gatgggatcc agtgtaggtg taagggacag ctgtctttca aatttgggct 3000
 55 tcggttgccg ctcccgttct ttcagcatat gtacaggtat gtacagtga taagtgcgtg 3060

ggccaatgtg ctctcatcaa tcatgtacag aacatatgtt ttggtcatat ctatgcagcg 3120
 5 cctgcatgag cccatgccgc tcgtgtttta cgaagccaga tgcggtgccg ccctgtccca 3180
 gctacacatg ctgtgcacgg ggaacaacgg ccatgttgga aaagtcactg tttataaat 3240
 10 gattgacaac taatgaaaaa gcactcaagc gggaaatgtt tcatgcggtc caaagagcag 3300
 gggggaaagt cactgtttta taaatgattg tgacaactat ctaatgaaaa agcactcaag 3360
 cgggaaatgt ttcatgcggt ccaaagagta gggggcgggc gtggtactga tgattaccgc 3420
 15 gtaacaatga ccacgccggc gcagatgtcg cagtgtctga gcgtttgatg ttcttttgta 3480
 tggcggaagg gtgacaaggc aaacggcgag agtcgactta cagactcacc accgggcaac 3540
 20 catcggttcc caggtcaata agctggacta ttgtcagcag atgcgatgat aacgcgtgcc 3600
 atacataaag agcgtacccg tgctagttaa agatgcgcac gcggttctgt tggcagaggt 3660
 25 cggaggcttg cctcatggag caaccgaggg ggcgcagttc tgtcttcgtg tcttccgttt 3720
 gtgtgtttga gaacgaacag atacggcgta tgtgcttgcc ttggtcacag ggagctcacc 3780
 acaaagcccg tgtagtcggg ggagtactgc tggacacagt ggcgagaata cgcgtgatca 3840
 30 atgccggcaa tagagaaatc ggcataaat tgtgtagcgg atggcgttct gtatgtcgtgta 3900
 caagcgaccc tggatcgtgt gtacccccct acgggcgggc tgccctgtga aggcaatata 3960
 35 aaatgtaatc caatgattcg ttttcatgtt acaccagata ttcttaggac gatggtactg 4020
 accatactag catctgagta gtagtctctc ggtgttcggt ggccaatcta cgactctagc 4080
 40 aatgggttcc ctctctaccc taggttccgt agtgtgggca catcacatga tgactgtcga 4140
 tccagaaatt gatacacgtg catgttctc agctatgaca attatgattg ctattcctac 4200
 45 agcagccaac cggatccgaa ttcttcgccc tatagtgaag tc 4242

<210> 12

<211> 1892

<212> DNA

<213> Neospora caninum

<220>

<221> CDS

<222> (122) .. (1381)

<400> 12

gaacaatcgt ttcgtgactc tctgggtggc tgtctgtgta ctagatgtac tctttcccaa 60

gccgctcgag gaacatacgt gaagcacggg ggtacttcct gtagcaaaac atagcagcac 120

a atg gcg ttc gga cga ggc aag agg gga ctg cac gct gca gtc atc tta 169

Met Ala Phe Gly Arg Gly Lys Arg Gly Leu His Ala Ala Val Ile Leu
1 5 10 15ggc ttc ttt gtc ctc ctc gcc aca tca tct gta gga ttg ggc caa agg 217
Gly Phe Phe Val Leu Leu Ala Thr Ser Ser Val Gly Leu Gly Gln Arg
20 25 30gtg cct cgc tac cca agt gtg gag tca ctc gaa gaa aga gtt gcc gag 265
Val Pro Arg Tyr Pro Ser Val Glu Ser Leu Glu Glu Arg Val Ala Glu
35 40 45gct cta ggg cgc cgt agc tcc gca gcg gcc agt act ctt cca ggg agt 313
Ala Leu Gly Arg Arg Ser Ser Ala Ala Ala Ser Thr Leu Pro Gly Ser
50 55 60gac acg aac atg ata tca gat ggt cgc gca ggc agg gat gaa cca aca 361
Asp Thr Asn Met Ile Ser Asp Gly Arg Ala Gly Arg Asp Glu Pro Thr
65 70 75 80gcg agc cca gag cat cat tcc gtg gac gct ccg acc acg tct ggg gaa 409
Ala Ser Pro Glu His His Ser Val Asp Ala Pro Thr Thr Ser Gly Glu
85 90 95ggc gag gca gat gct ggg aaa gta acg ctg agg aac gat gag ggc ctt 457
Gly Glu Ala Asp Ala Gly Lys Val Thr Leu Arg Asn Asp Glu Gly Leu
100 105 110gag ggt aat atc tca gcc gac cat gtt cta cat ccc cct cct gac agt 505
Glu Gly Asn Ile Ser Ala Asp His Val Leu His Pro Pro Pro Asp Ser
115 120 125gaa cac gag gtc ggt tca aca cca gga aca gcg ctg cct gcc ccg att 553
Glu His Glu Val Gly Ser Thr Pro Gly Thr Ala Leu Pro Ala Pro Ile
130 135 140ttt agc att cca gag ctc tca ccg gag gaa gtt gtc tac gtt tta cgg 601
Phe Ser Ile Pro Glu Leu Ser Pro Glu Glu Val Val Tyr Val Leu Arg
145 150 155 160gtt cag gga tca ggc gat ttc gaa att agt ttc caa gta ggc cgg gtg 649
Val Gln Gly Ser Gly Asp Phe Glu Ile Ser Phe Gln Val Gly Arg Val
165 170 175

EP 0 953 641 A2

5	gtg agg cag ttg gaa gcc atc aag aga gca tac agg gag gct cac ggg Val Arg Gln Leu Glu Ala Ile Lys Arg Ala Tyr Arg Glu Ala His Gly 180 185 190	697
10	aag cta gaa gct gag gag ctg gag tcg gaa agg gga ccg acg gtt tcg Lys Leu Glu Ala Glu Glu Leu Glu Ser Glu Arg Gly Pro Thr Val Ser 195 200 205	745
15	act cgg acg aaa cta gtt gac ttt atc aaa gaa aac cag aga cgg ctg Thr Arg Thr Lys Leu Val Asp Phe Ile Lys Glu Asn Gln Arg Arg Leu 210 215 220	793
20	agg gcg gcg ttt cag aag gtt aag att cag caa aag ttg gag gag atc Arg Ala Ala Phe Gln Lys Val Lys Ile Gln Gln Lys Leu Glu Glu Ile 225 230 235 240	841
25	gag gaa ctg ttg cag ctg tca cac gca cta aaa tct cta ggt gcc cgc Glu Glu Leu Leu Gln Leu Ser His Ala Leu Lys Ser Leu Gly Ala Arg 245 250 255	889
30	ctg aga ccc tgc caa aaa agt aat tcc cca atg gag gaa gag att tgt Leu Arg Pro Cys Gln Lys Ser Asn Ser Pro Met Glu Glu Glu Ile Cys 260 265 270	937
35	cgt aag acg aaa gct ttg ggc gaa atg gtt gcc cag aaa gcg gag gat Arg Lys Thr Lys Ala Leu Gly Glu Met Val Ala Gln Lys Ala Glu Asp 275 280 285	985
40	ctt cgt cag cat gcg tca act gtc tcg gct ctg cta ggt cgc gaa gct Leu Arg Gln His Ala Ser Thr Val Ser Ala Leu Leu Gly Arg Glu Ala 290 295 300	1033
45	gtt gag aga cag ttg cgg cgt gtc gac agt gaa caa ccc tat gaa caa Val Glu Arg Gln Leu Arg Arg Val Asp Ser Glu Gln Pro Tyr Glu Gln 305 310 315 320	1081
50	aca gac gcc ggg gtt gca gcc aga gca gag gaa ttt cgg aag gca ctg Thr Asp Ala Gly Val Ala Ala Arg Ala Glu Glu Phe Arg Lys Ala Leu 325 330 335	1129
55	gag aaa gca gct tcc ggt gcg aga caa ttc gtg ggg acc aca gcg gac Glu Lys Ala Ala Ser Gly Ala Arg Gln Phe Val Gly Thr Thr Ala Asp 340 345 350	1177
60	gaa ata gtg gag gaa gtg aag gag gat gct cag tac ctg cgt gat ggt Glu Ile Val Glu Glu Val Lys Glu Asp Ala Gln Tyr Leu Arg Asp Gly 355 360 365	1225
65	gcg aaa gaa gtg ttg acg aag agc cag cgc gcg cta gta gac gcg ttt Ala Lys Glu Val Leu Thr Lys Ser Gln Arg Ala Leu Val Asp Ala Phe 1273	

370 375 380

5 cag gcg atc caa agg gct cta ctg gag gcg aag gca aag gag ctc gta 1321
 Gln Ala Ile Gln Arg Ala Leu Leu Glu Ala Lys Ala Lys Glu Leu Val
 385 390 395 400

10 gat gcc gca tca aag gaa gct gaa gac gct cgt aag atc tta gcg gaa 1369
 Asp Ala Ala Ser Lys Glu Ala Glu Asp Ala Arg Lys Ile Leu Ala Glu
 405 410 415

15 cag cca gcg tga ttcgccgagg acgaagttgg taatgcacgg tgaatgaggg 1421
 Gln Pro Ala 420

20 ttgggtcatcc caatccccag cttgatagcg tcacgtgggt ttttcgccgg ggaaacgatc 1481
 attagggagg tgatgtatcg cagtaaacad gggcatatca gcaccagttt ttttacatgt 1541
 gagggatggg atccagtgtg ggtgtaaggg acagctgtct ttcaaatttg ggcttcgggtt 1601
 gccgctcccg ttctttcagc atatgtacag gtatgtacag tgaataagtg cgtgggcca 1661
 25 tgtgctctca tcaatcatgt acagaacata tgttttgggtc atatctatgc agcgccctgca 1721
 tgagcccatg ccgctcgtgt ttacgaagc cagatgcggt gccgccctgt cccagctaca 1781
 30 catgctgtgc acggggaaca acggccatgt tggaaaagtc actgttttat aaatgattga 1841
 caactaatga aaaagcactc aagcgggaaa tgtttcatgc ggtccaaaga g 1892

35 <210> 13
 <211> 419
 <212> PRT
 <213> Neospora caninum

40 <400> 13
 Met Ala Phe Gly Arg Gly Lys Arg Gly Leu His Ala Ala Val Ile Leu
 1 5 10 15

45 Gly Phe Phe Val Leu Leu Ala Thr Ser Ser Val Gly Leu Gly Gln Arg
 20 25 30

50 Val Pro Arg Tyr Pro Ser Val Glu Ser Leu Glu Glu Arg Val Ala Glu
 35 40 45

Ala Leu Gly Arg Arg Ser Ser Ala Ala Ala Ser Thr Leu Pro Gly Ser
 50 55 60

55 Asp Thr Asn Met Ile Ser Asp Gly Arg Ala Gly Arg Asp Glu Pro Thr

EP 0 953 641 A2

	65		70		75		80									
5	Ala	Ser	Pro	Glu	His	His	Ser	Val	Asp	Ala	Pro	Thr	Thr	Ser	Gly	Glu
					85					90					95	
	Gly	Glu	Ala	Asp	Ala	Gly	Lys	Val	Thr	Leu	Arg	Asn	Asp	Glu	Gly	Leu
10				100					105					110		
	Glu	Gly	Asn	Ile	Ser	Ala	Asp	His	Val	Leu	His	Pro	Pro	Pro	Asp	Ser
			115					120					125			
15	Glu	His	Glu	Val	Gly	Ser	Thr	Pro	Gly	Thr	Ala	Leu	Pro	Ala	Pro	Ile
		130					135					140				
	Phe	Ser	Ile	Pro	Glu	Leu	Ser	Pro	Glu	Glu	Val	Val	Tyr	Val	Leu	Arg
20	145					150					155					160
	Val	Gln	Gly	Ser	Gly	Asp	Phe	Glu	Ile	Ser	Phe	Gln	Val	Gly	Arg	Val
					165					170					175	
25	Val	Arg	Gln	Leu	Glu	Ala	Ile	Lys	Arg	Ala	Tyr	Arg	Glu	Ala	His	Gly
				180					185					190		
	Lys	Leu	Glu	Ala	Glu	Glu	Leu	Glu	Ser	Glu	Arg	Gly	Pro	Thr	Val	Ser
30			195					200					205			
	Thr	Arg	Thr	Lys	Leu	Val	Asp	Phe	Ile	Lys	Glu	Asn	Gln	Arg	Arg	Leu
		210					215					220				
35	Arg	Ala	Ala	Phe	Gln	Lys	Val	Lys	Ile	Gln	Gln	Lys	Leu	Glu	Glu	Ile
	225					230				235					240	
	Glu	Glu	Leu	Leu	Gln	Leu	Ser	His	Ala	Leu	Lys	Ser	Leu	Gly	Ala	Arg
40					245					250					255	
	Leu	Arg	Pro	Cys	Gln	Lys	Ser	Asn	Ser	Pro	Met	Glu	Glu	Glu	Ile	Cys
				260					265					270		
45	Arg	Lys	Thr	Lys	Ala	Leu	Gly	Glu	Met	Val	Ala	Gln	Lys	Ala	Glu	Asp
			275					280					285			
	Leu	Arg	Gln	His	Ala	Ser	Thr	Val	Ser	Ala	Leu	Leu	Gly	Arg	Glu	Ala
50							295					300				
	Val	Glu	Arg	Gln	Leu	Arg	Arg	Val	Asp	Ser	Glu	Gln	Pro	Tyr	Glu	Gln
	305					310					315				320	
55	Thr	Asp	Ala	Gly	Val	Ala	Ala	Arg	Ala	Glu	Glu	Phe	Arg	Lys	Ala	Leu
					325					330					335	

	Glu Lys Ala Ala Ser Gly Ala Arg Gln Phe Val Gly Thr Thr Ala Asp	
	340 345 350	
5	Glu Ile Val Glu Glu Val Lys Glu Asp Ala Gln Tyr Leu Arg Asp Gly	
	355 360 365	
10	Ala Lys Glu Val Leu Thr Lys Ser Gln Arg Ala Leu Val Asp Ala Phe	
	370 375 380	
	Gln Ala Ile Gln Arg Ala Leu Leu Glu Ala Lys Ala Lys Glu Leu Val	
	385 390 395 400	
15	Asp Ala Ala Ser Lys Glu Ala Glu Asp Ala Arg Lys Ile Leu Ala Glu	
	405 410 415	
	Gln Pro Ala	
20		
	<210> 14	
	<211> 20	
	<212> DNA	
25	<213> Neospora caninum	
	<400> 14	
	aattaaccct cactaaaggg	20
30		
	<210> 15	
	<211> 22	
	<212> DNA	
35	<213> Neospora caninum	
	<400> 15	
	gtaatacgac tcactatagg gc	22
40		
	<210> 16	
	<211> 20	
	<212> DNA	
45	<213> Neospora caninum	
	<400> 16	
	gccgcgactt ctttttctct	20
50		
	<210> 17	
	<211> 20	
	<212> DNA	
55	<213> Neospora caninum	

5 <400> 17
ctcgatcgcc tcctttactg 20

10 <210> 18
<211> 20
<212> DNA
<213> Neospora caninum

15 <400> 18
tgctagtact ggcgagtga 20

20 <210> 19
<211> 20
<212> DNA
<213> Neospora caninum

25 <400> 19
caggtttgcc acacattttt 20

30 <210> 20
<211> 21
<212> DNA
<213> Neospora caninum

35 <400> 20
atgtttcctc ctcgggcagt g 21

40 <210> 21
<211> 23
<212> DNA
<213> Neospora caninum

45 <400> 21
tcacgcgacg ccagccgcta tcg 23

50 <210> 22
<211> 20
<212> DNA
<213> Neospora caninum

55 <400> 22
gccctgacaa ttcgaccgcc 20

<210> 23

	<211> 21	
	<212> DNA	
5	<213> Neospora caninum	
	<400> 23	
	cccacaacat ccaagtcgtt c	21
10	<210> 24	
	<211> 20	
	<212> DNA	
	<213> Neospora caninum	
15	<400> 24	
	gttttgcacc atccttagtg	20
20	<210> 25	
	<211> 19	
	<212> DNA	
	<213> Neospora caninum	
25	<400> 25	
	gagagtttgc tttgcaccg	19
30	<210> 26	
	<211> 21	
	<212> DNA	
	<213> Neospora caninum	
35	<400> 26	
	ccagccgagt tcgtgttcag a	21
40	<210> 27	
	<211> 24	
	<212> DNA	
	<213> Neospora caninum	
45	<400> 27	
	caacgtggat ccgattcaag cttc	24
50	<210> 28	
	<211> 20	
	<212> DNA	
	<213> Neospora caninum	
55	<400> 28	

aaagctcttc ggcagttcaa 20

5 <210> 29
<211> 18
<212> DNA
<213> Neospora caninum

10 <400> 29
ccgcgctacc actttcca 18

15 <210> 30
<211> 18
<212> DNA
<213> Neospora caninum

20 <400> 30
gtaatacgac tcactata 18

25 <210> 31
<211> 19
<212> DNA
<213> Neospora caninum

30 <400> 31
ccgcaacgtg ctgttccta 19

35 <210> 32
<211> 18
<212> DNA
<213> Neospora caninum

40 <400> 32
catcagagaa actggagt 18

45 <210> 33
<211> 24
<212> DNA
<213> Neospora caninum

50 <400> 33
ggccaagctt gctagtactg gcga 24

55 <210> 34
<211> 31

<212> DNA

<213> *Neospora caninum*

5

<400> 34

atccaatgca tcttgctgaa tgccttaaaa g

31

10

Claims

- 15 1. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a *Neospora* GRA1 protein, said nucleotide sequence selected from the group consisting of the nucleotide sequence of the open reading frame (ORF) of SEQ ID NO: 1 from about nt 205 to about nt 777, the nucleotide sequence of the ORF of SEQ ID NO:3 from about nt 605 to about nt 1304, and the nucleotide sequence of the GRA1-encoding ORF of plasmid pRC77 (ATCC 209685).
- 20 2. The isolated polynucleotide molecule of claim 1, comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3.
- 25 3. An isolated polynucleotide molecule comprising a nucleotide sequence that is homologous to the nucleotide sequence of a polynucleotide molecule of claim 1.
4. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a polypeptide that is homologous to a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
- 30 5. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of the nucleotide sequence of the polynucleotide molecule of claim 1, 3 or 4.
- 35 6. An isolated polynucleotide molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1 from about nt 1 to about nt 204, SEQ ID NO:1 from about nt 778 to about nt 1265, SEQ ID NO:3 from about nt 1 to about nt 604, SEQ ID NO:3 from about nt 1305 to about nt 1774, and a substantial portion thereof.
- 40 7. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a *Neospora* GRA2 protein, said nucleotide sequence selected from the group consisting of the nucleotide sequence of the ORF of SEQ ID NO:4 from about nt 25 to about nt 660, and the nucleotide sequence of the GRA2-encoding ORF of plasmid pRC5 (ATCC 209686).
8. The isolated polynucleotide molecule of claim 7, comprising the nucleotide sequence of SEQ ID NO:4.
- 45 9. An isolated polynucleotide molecule comprising a nucleotide sequence that is homologous to the nucleotide sequence of a polynucleotide molecule of claim 7.
10. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a polypeptide that is homologous to a polypeptide comprising the amino acid sequence of SEQ ID NO:5.
- 50 11. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of the nucleotide sequence of the polynucleotide molecule of claim 7, 9 or 10.
- 55 12. An isolated polynucleotide molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:4 from about nt 1 to about nt 24, SEQ ID NO: 4 from about nt 661 to about nt 1031, and a substantial portion thereof.
13. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a *Neospora* SAG1 protein, said nucleotide sequence selected from the group consisting of the nucleotide sequence of the ORF of SEQ ID NO:6

from about nt 130 to about nt 1089, and the nucleotide sequence of the SAG1-encoding ORF of plasmid pRC102 (ATCC 209687).

14. The isolated polynucleotide molecule of claim 13, comprising the nucleotide sequence of SEQ ID NO:6.
15. An isolated polynucleotide molecule comprising a nucleotide sequence that is homologous to the nucleotide sequence of a polynucleotide molecule of claim 13.
16. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a polypeptide that is homologous to a polypeptide comprising the amino acid sequence of SEQ ID NO:7.
17. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of the nucleotide sequence of the polynucleotide molecule of claim 13, 15 or 16.
18. An isolated polynucleotide molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:6 from about nt 1 to about nt 129, SEQ ID NO:6 from about nt 1090 to about nt 1263, and a substantial portion thereof.
19. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a *Neospora* MIC1 protein, said nucleotide sequence selected from the group consisting of the nucleotide sequence of the ORF of SEQ ID NO:8 from about nt 138 to about nt 1520, the nucleotide sequence of the ORF of SEQ ID NO:10, and the nucleotide sequence of the MIC1-encoding ORF of plasmid pRC340 (ATCC 209688).
20. The isolated polynucleotide molecule of claim 19, comprising the nucleotide sequence of SEQ ID NO:8 or SEQ ID NO:10.
21. An isolated polynucleotide molecule comprising a nucleotide sequence that is homologous to the nucleotide sequence of a polynucleotide molecule of claim 19.
22. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a polypeptide that is homologous to a polypeptide comprising the amino acid sequence of SEQ ID NO:9.
23. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of the nucleotide sequence of the polynucleotide molecule of claim 19, 21 or 22.
24. An isolated polynucleotide molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:8 from about nt 1 to about nt 137, SEQ ID NO:8 from about nt 1521 to about nt 2069, and a substantial portion thereof.
25. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a *Neospora* MAG1 protein, said nucleotide sequence selected from the group consisting of the nucleotide sequence of the ORF of SEQ ID NO:11 from about nt 1305 to about nt 2786, the nucleotide sequence of the ORF of SEQ ID NO:12 from about nt 122 to about nt 1381, and the nucleotide sequence of the MAG1-encoding ORF of plasmid bd304 (ATCC 203413).
26. The isolated polynucleotide molecule of claim 25, comprising the nucleotide sequence of SEQ ID NO:11 or SEQ ID NO:12.
27. An isolated polynucleotide molecule comprising a nucleotide sequence that is homologous to the nucleotide sequence of a polynucleotide molecule of claim 25.
28. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a polypeptide that is homologous to a polypeptide comprising the amino acid sequence of SEQ ID NO:13.
29. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of the nucleotide sequence of the polynucleotide molecule of claim 25, 27 or 28.
30. An isolated polynucleotide molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:11 from about nt 1 to about nt 1304, SEQ ID NO:11 from about nt 2787 to about nt 4242, SEQ ID NO:12

from about nt 1 to about nt 121, SEQ ID NO:12 from about nt 1382 to about nt 1892, and a substantial portion thereof.

31. An isolated polynucleotide molecule, comprising the nucleotide sequence of SEQ ID NO:11 from about nt 127 to about nt 703.

32. An oligonucleotide molecule selected from the group consisting of SEQ ID NOS:14 to 26 and 28 to 34, and the complements thereof.

33. A recombinant vector, comprising a polynucleotide molecule: (a) comprising a nucleotide sequence encoding a *N. caninum* GRA1, GRA2, SAG1, MIC1 or MAG1 protein; (b) comprising a nucleotide sequence that is homologous to the nucleotide sequence of (a); or consisting of a nucleotide sequence that is a substantial portion of the nucleotide sequence of (a) or (b).

34. The recombinant vector of claim 33, selected from the group consisting of plasmid pRC77 (ATCC 209685); plasmid pRC5 (ATCC 209686); plasmid pRC102 (ATCC 209687); plasmid pRC340 (ATCC 209688), and plasmid bd304 (ATCC 203413).

35. The recombinant vector of claim 33, further comprising a polynucleotide molecule comprising a nucleotide sequence encoding a carrier or fusion partner such that expression of the recombinant vector results in production of a fusion protein comprising the carrier or fusion partner fused to the polypeptide encoded by the recombinant vector of claim 33.

36. A transformed host cell, comprising the recombinant vector of claim 33, 34 or 35.

37. A substantially purified or isolated polypeptide selected from the group consisting of: (a) an *N. caninum* GRA1, GRA2, SAG1, MIC1 or MAG1 protein; (b) a polypeptide having an amino acid sequence that is homologous to an *N. caninum* GRA1, GRA2, SAG1, MIC1 or MAG1 protein; (c) a polypeptide consisting of a substantial portion of an *N. caninum* GRA1, GRA2, SAG1, MIC1 or MAG1 protein, or polypeptide which is homologous thereto; (d) a fusion protein comprising the protein or polypeptide of (a), (b) or (c); and (e) an analog or derivative of the protein or polypeptide of (a), (b), (c) or (d).

38. The polypeptide of claim 37, wherein the GRA1 protein comprises the amino acid sequence of SEQ ID NO:2; the GRA2 protein comprises the amino acid sequence of SEQ ID NO:5; the SAG1 protein comprises the amino acid sequence of SEQ ID NO:7; the MIC1 protein comprises the amino acid sequence of SEQ ID NO:9; and the MAG1 protein comprises the amino acid sequence of SEQ ID NO:13.

39. An isolated antibody that specifically reacts to a *N. caninum* protein selected from the group consisting of GRA1, GRA2, SAG1, MIC1 and MAG1.

40. A genetic construct comprising a polynucleotide molecule that can be used to disable a *Neospora* gene, comprising: (a) a polynucleotide molecule having a nucleotide sequence that is otherwise the same as a nucleotide sequence encoding a GRA1, GRA2, SAG1, MIC1 or MAG1 protein from *N. caninum*, or a substantial portion of said nucleotide sequence, but which nucleotide sequence further comprises one or more disabling mutations; or (b) a polynucleotide molecule comprising a nucleotide sequence that naturally flanks *in situ* the ORF of a *Neospora* GRA1, GRA2, SAG1, MIC1, or MAG1 gene; such that transformation of a *Neospora* cell with the genetic construct of (a) or (b) results in disabling of the GRA1, GRA2, SAG1, MIC1 or MAG1 gene.

41. The genetic construct of claim 40, further comprising a selectable marker.

42. The genetic construct of claim 40, wherein the respective gene is disabled as the result of a homologous recombination event.

43. A *Neospora* cell that has been modified by transformation with the genetic construct of claim 40 such that the GRA1, GRA2, SAG1, MIC1 or MAG1 gene, or a combination thereof, has been disabled.

44. A method of preparing modified *Neospora* cells, comprising transforming *Neospora* cells with the genetic construct of claim 40, and selecting transformed cells that express a mutant phenotype selected from the group consisting of GRA1⁻, GRA2⁻, SAG⁻, MIC1⁻, and MAG⁻ as a result of said transformation.

45. A vaccine against neosporosis, comprising an immunologically effective amount of a component comprising: (a) a polypeptide of claim 37; (b) a polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide of claim 37; or (c) modified *Neospora* cells of claim 43; and a veterinarily acceptable carrier.

5 46. The vaccine of claim 45, wherein the modified *Neospora* cells are live cells.

47. The vaccine of claim 45, wherein the modified *Neospora* cells are inactivated cells.

48. The vaccine of claim 45, further comprising an adjuvant or a cytokine.

10

49. The vaccine of claim 48, wherein the adjuvant is selected from the group consisting of the RIBI adjuvant system, alum, mineral gel, an oil-in-water emulsion, a water-in-oil emulsion, Block co polymer, QS-21, SAF-M, AMPHI-GEN® adjuvant, saponin, Quil A, monophosphoryl lipid A, Avridine lipid-amine adjuvant, SEAM62, and SEAM1/2.

15

50. The vaccine of claim 45, which further comprises an immunologically effective amount of a second component that is capable of inducing a protective response against a disease or pathological condition that afflicts the mammal.

20

51. The vaccine of claim 50, wherein the second component is capable of inducing, or contributing to the induction of, a protective response against a pathogen selected from the group consisting of bovine herpes virus, bovine respiratory syncytial virus, bovine viral diarrhea virus, parainfluenza virus types I, II, or III, *Leptospira* spp., *Campylobacter* spp., *Staphylococcus aureus*, *Streptococcus agalactiae*, *Mycoplasma* spp., *Klebsiella* spp., *Salmonella* spp., rotavirus, coronavirus, rabies, *Pasteurella hemolytica*, *Pasteurella multocida*, *Clostridia* spp., *Tetanus* toxoid, *E. coli*, *Cryptosporidium* spp., *Eimeria* spp., and *Trichomonas* spp.

25

52. A method of preparing a vaccine against neosporosis, comprising combining an immunologically effective amount of: (a) a polypeptide of claim 37; (b) a polynucleotide molecule having a nucleotide sequence encoding the polypeptide of claim 37; or (c) modified *Neospora* cells of claim 43, with a veterinarily acceptable carrier.

30

53. A method of vaccinating a mammal against neosporosis, comprising administering to the mammal the vaccine of claim 45.

35

54. A kit for vaccinating a mammal against neosporosis, comprising a container comprising an immunologically effective amount of: (a) a polypeptide of claim 37; or (b) a polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide of claim 37; or (c) modified *Neospora* cells of claim 43.

55. The kit of claim 54, further comprising a second container comprising a veterinarily acceptable carrier or diluent.

40

45

50

55

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 953 641 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
13.03.2002 Bulletin 2002/11

(43) Date of publication A2:
03.11.1999 Bulletin 1999/44

(21) Application number: 99301746.6

(22) Date of filing: 09.03.1999

(51) Int Cl.7: **C12N 15/30**, **C07K 14/44**,
C07K 16/20, **C12N 5/16**,
A61K 39/002

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 26.03.1998 US 79389
15.12.1998 US 112282

(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(72) Inventors:
• **Brake, David Alan**
East Lyme, Connecticut 06333 (US)

- **Madura (née Coleman), Rebecca Anne**
Westerly, Rhode Island 02891 (US)
- **Durtschi, Becky Ann**
Ledyard, Connecticut 06339 (US)
- **Krishnan, Balakrishnan Rajendra**
East Lyme, Connecticut 06333 (US)
- **Yoder, Susan Christine**
Salem, Connecticut 06340 (US)

(74) Representative:
Simpson, Alison Elizabeth Fraser et al
Urquhart-Dykes & Lord,
30 Welbeck Street
London W1G 8ER (GB)

(54) Polynucleotide molecules encoding neospora proteins

(57) The present invention provides isolated polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1 and MAG1 proteins from *Neospora caninum*, as well as recombinant vectors, transformed host cells, and recombinantly-expressed proteins. The present invention further provides a polynucleotide molecule comprising the nucleotide se-

quence of the bidirectional *GRA1/MAG1* promoter of *N. caninum*. The present invention further provides genetic constructs based on the polynucleotide molecules of the present invention that are useful in preparing modified strains of *Neospora* cells for use in vaccines against neosporosis.

EP 0 953 641 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 99 30 1746 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	CESBRON-DELAUW M.F. ET AL.: "Molecular characterization of a 23-kilodalton major antigen secreted by Toxoplasma gondii" PROC. NATL. ACAD. SCI. USA, vol. 86, October 1989 (1989-10), pages 7537-7541, XP002168801 * the whole document *	3-6, 33-37	C12N15/30 C07K14/44 C07K16/20 C12N5/16 A61K39/002
X	WO 89 05658 A (TRANSGENE SA) 29 June 1989 (1989-06-29) * the whole document *	3-6, 33-37	
X	PARMLEY S.F. ET AL.: "Molecular characterization of a 65-kilodalton Toxoplasma gondii antigen expressed abundantly in the matrix of tissue cysts" MOL. BIOCHEM. PARASITOL., vol. 66, no. 2, August 1994 (1994-08), pages 283-296, XP001002586 * the whole document *	27-29, 33-37	
X	EP 0 431 541 A (BEHRINGWERKE AG) 12 June 1991 (1991-06-12) * compare seq 11 with p68 *	27-29, 33-37	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C12N C07K A61K
INCOMPLETE SEARCH <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>Although claim 53 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		1 October 2001	Galli, I
CATEGORY OF CITED DOCUMENTS <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (P04C07)



European Patent
Office

Application Number

EP 99 30 1746

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):

☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.

☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

☒ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

1-6, 25-31 (completely); 32-55 (partially)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 99 30 1746

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	LALLY N ET AL: "A DENSE GRANULE PROTEIN (NCDG1) GENE FROM NEOSPORA CANINUM" MOLECULAR AND BIOCHEMICAL PARASITOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 87, August 1997 (1997-08), pages 239-243, XP000982054 ISSN: 0166-6851 * the whole document *	1-6, 25-55	
A	WO 97 39009 A (US AGRICULTURE) 23 October 1997 (1997-10-23) * the whole document *	1-6, 25-55	
A	FR 2 714 074 A (PASTEUR INSTITUT ; PASTEUR INSTITUT; LILLE INST PASTEUR; INST NAT S) 23 June 1995 (1995-06-23) * the whole document *	31	TECHNICAL FIELDS SEARCHED (Int.Cl.6)

EPO FORM 1503 03.82 (P04C10)



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number

EP 99 30 1746

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-6, 25-31 and partly 32-55

An isolated polynucleotide comprising a sequence encoding a Neospora GRA1 (seq. 1-3) or MAG1 protein (seq. 11-13).

Portions and homologs thereof; corresponding oligonucleotide probes, vectors, recombinant host cells, polypeptides, antibodies, genetic constructs, mutants, vaccines and therapeutic applications.

2. Claims: 7-12 and partly 32-55

Idem as subject matter 1 but limited to GRA2 (seq. 4,5)

3. Claims: 13-18 and partly 32-55

Idem as subject matter 1 but limited to SAG1 (seq. 6,7)

4. Claims: 19-24 and partly 32-55

Idem as subject matter 1 but limited to MIC1 (seq. 8-10)

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 99 30 1746

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

01-10-2001

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 8905658	A	29-06-1989	FR	2625099 A1	30-06-1989
			EP	0346430 A1	20-12-1989
			WO	8905658 A1	29-06-1989
			JP	2502878 T	13-09-1990

EP 0431541	A	12-06-1991	DE	3940598 A1	13-06-1991
			AT	141289 T	15-08-1996
			AT	206435 T	15-10-2001
			AT	196162 T	15-09-2000
			AT	197068 T	15-11-2000
			AU	629074 B2	24-09-1992
			AU	6781990 A	13-06-1991
			CA	2031811 A1	09-06-1991
			DE	59010450 D1	19-09-1996
			DE	59010913 D1	12-10-2000
			DE	59010915 D1	23-11-2000
			DE	59010925 D1	08-11-2001
			DK	431541 T3	06-01-1997
			EP	0431541 A2	12-06-1991
			EP	0748815 A1	18-12-1996
			EP	0751147 A1	02-01-1997
			EP	0748816 A1	18-12-1996
			ES	2092483 T3	01-12-1996
			ES	2149913 T3	16-11-2000
			ES	2152357 T3	01-02-2001
			GR	3020819 T3	30-11-1996
			IE	904426 A1	19-06-1991
			JP	3085972 B2	11-09-2000
			JP	3197497 A	28-08-1991
			JP	2000308495 A	07-11-2000
			KR	215607 B1	16-08-1999
			KR	215606 B1	16-08-1999
			PT	96097 A ,B	30-09-1991
			US	6022546 A	08-02-2000
			US	6326008 B1	04-12-2001

WO 9739009	A	23-10-1997	AU	733127 B2	10-05-2001
			AU	2731297 A	07-11-1997
			CA	2251670 A1	23-10-1997
			EP	0897391 A1	24-02-1999
			WO	9739009 A1	23-10-1997

FR 2714074	A	23-06-1995	FR	2714074 A1	23-06-1995

DRM P0459

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82